Chronic Paediatric Conditions — MCQs

Q: A 6-month-old baby presents with failure to thrive, chronic diarrhea, and recurrent respiratory infections. Sweat chloride test is 70 mmol/L (normal <40). What is the most likely diagnosis?

Cystic fibrosis. ***Cystic fibrosis***- The constellation of **failure to thrive**, chronic **malabsorptive diarrhea** (due to **pancreatic insufficiency**), and recurrent **respiratory infections** (due to thick mucus) is classic for **Cystic fibrosis**.- A sweat chloride level of 70 mmol/L is diagnostic for **Cystic fibrosis** in an infant (cut-off is typically >60 mmol/L), confirming the defect in the **CFTR channel**.*Celiac disease*- While a cause of failure to thrive and chronic diarrhea, symptoms typically manifest after the introduction of **gluten** (usually after 6 months of age) and often involve abdominal distension.- It does not cause recurrent respiratory infections as a primary feature, nor is it associated with an elevated **sweat chloride** level.*Immunodeficiency*- This could explain **recurrent respiratory infections** and failure to thrive, but it typically does not cause the specific syndrome of chronic steatorrhea due to **pancreatic insufficiency**.- Immunodeficiency conditions do not result in an abnormally high **sweat chloride** test result.*Inflammatory bowel disease*- IBD rarely presents in early infancy (6 months) and usually causes features like **bloody diarrhea** and **abdominal pain** rather than the typical **steatorrhea** associated with pancreatic insufficiency.- IBD is not associated with an elevated **sweat chloride** test or recurrent sino-pulmonary infections driven by mucus accumulation.*Lactose intolerance*- This causes osmotic diarrhea and potentially failure to thrive, but the symptoms are strictly gastrointestinal and often improve when **lactose** is removed from the diet.- It does not explain the hallmark triad of pulmonary disease, malabsorption, and the pathognomonic **elevated sweat chloride**.

Q: A 13-year-old boy with type 1 diabetes for 7 years presents with intermittent episodes of abdominal bloating, early satiety, nausea, and vomiting, particularly after meals. He reports that vomiting sometimes contains food eaten several hours earlier. His HbA1c is 82 mmol/mol. On examination, he has mild epigastric tenderness and a succussion splash. Screening for coeliac disease is negative. What is the most likely diagnosis?

Gastroparesis secondary to diabetic autonomic neuropathy. ***Gastroparesis secondary to diabetic autonomic neuropathy*** - This condition is a classic complication of long-standing **Type 1 Diabetes** with poor glycemic control, leading to delayed gastric emptying due to **vagal nerve damage**.- Symptoms like **early satiety**, vomiting of food consumed hours prior, and a positive **succussion splash** indicating retained gastric contents are pathognomonic.*Diabetic ketoacidosis with gastric stasis*- While **DKA** can cause acute gastroparesis, it typically presents with acute-onset abdominal pain, **uncompensated metabolic acidosis**, and ketosis, which are not described here.- The history of intermittent postprandial symptoms over time is more indicative of a **chronic autonomic neuropathy** than an acute metabolic emergency.*Superior mesenteric artery syndrome*- This occurs when the **duodenum** is compressed between the SMA and the aorta, usually following **rapid weight loss**.- Although it presents with postprandial vomiting, it is less common in this clinical context and would not be primary suspected over **diabetic neuropathy** in a long-standing diabetic.*Helicobacter pylori-associated gastritis*- **H. pylori** commonly causes chronic epigastric pain and dyspepsia, but it does not typically lead to mechanical or functional **gastric outlet obstruction**.- The presence of a **succussion splash** strongly suggests a motility or obstructive disorder rather than simple mucosal inflammation.*Coeliac disease with false-negative serology*- While **Coeliac disease** is frequently associated with Type 1 Diabetes, it usually presents with diarrhea, malabsorption, or growth failure rather than **gastric stasis**.- Serology was negative, and the specific finding of a **succussion splash** is not a feature of Coeliac disease.

Q: An 8-year-old girl presents with frequent brief episodes where she suddenly stops what she is doing, stares blankly for 5-10 seconds, and then resumes her activity with no recollection of the event. Her teacher reports these episodes occur up to 20 times per day and are affecting her school performance. An EEG is performed. Which EEG finding would most strongly support the diagnosis of childhood absence epilepsy?

Generalized 3 Hz spike-and-wave discharges induced by hyperventilation. ***Generalized 3 Hz spike-and-wave discharges induced by hyperventilation*** - This is the pathognomonic EEG finding for **Childhood Absence Epilepsy (CAE)**, characterized by synchronous, symmetrical discharges with abrupt onset and termination. - **Hyperventilation** is a highly effective provocation technique that triggers these generalized seizures in over 90% of untreated patients. *Focal spike and wave discharges in the temporal region* - These findings are indicative of **Focal Impaired Awareness Seizures** (formerly complex partial seizures) originating in the **temporal lobe**. - Unlike absence seizures, temporal lobe seizures usually include a **post-ictal state** and last significantly longer than 10 seconds. *Hypsarrhythmia pattern with high-amplitude chaotic activity* - This chaotic EEG pattern is the hallmark of **West Syndrome** (infantile spasms), which typically presents in infants aged 4-8 months. - It consists of high-voltage, disorganized background activity and is associated with **developmental regression**. *Photoparoxysmal response with generalized polyspike-and-wave complexes* - This pattern is most commonly associated with **Juvenile Myoclonic Epilepsy (JME)** rather than childhood absence epilepsy. - JME usually presents in **adolescents** with myoclonic jerks specifically occurring upon awakening, often triggered by **photic stimulation**. *Centrotemporal spikes activated during drowsiness and sleep* - This finding is characteristic of **Benign Epilepsy with Centrotemporal Spikes (BECTS)**, also known as Benign Rolandic Epilepsy. - BECTS typically involves nocturnal seizures with **orofacial paresthesias** and drooling, rather than frequent daytime staring spells.

Q: A 5-year-old girl presents to the emergency department with a 20-minute generalized tonic-clonic seizure that has not responded to two doses of buccal midazolam given by paramedics. Intravenous access is established. Blood glucose is 5.2 mmol/L. What is the most appropriate next immediate management?

Intravenous lorazepam 0.1 mg/kg. ***Intravenous lorazepam 0.1 mg/kg*** - The child is experiencing **status epilepticus** as the seizure has lasted 20 minutes and buccal midazolam has failed. - With **IV access** established, **intravenous lorazepam** is the recommended **first-line benzodiazepine** for terminating acute seizures in the hospital setting due to its rapid action and sustained effect.*Rectal paraldehyde 0.4 ml/kg* - **Rectal paraldehyde** is a historical alternative, primarily considered only when **IV access cannot be obtained**, which is not the case here. - Its use has been largely superseded by safer and more effective **IV benzodiazepines** in modern emergency management protocols.*Intravenous phenytoin 20 mg/kg infusion* - **Phenytoin** is typically a **second or third-line agent** for **refractory status epilepticus**, used when benzodiazepines have failed. - The immediate next step after initial benzodiazepine failure and IV access establishment is another **IV benzodiazepine**, not a loading dose of phenytoin.*Intramuscular phenobarbital 20 mg/kg* - While **phenobarbital** is an antiepileptic, it is typically administered **intravenously** for status epilepticus, not intramuscularly, for rapid onset of action. - It is also generally reserved as a **third-line agent** for refractory cases, not as the immediate next step after initial benzodiazepine failure.*Intravenous levetiracetam 40 mg/kg* - **Levetiracetam** is recognized as a **third-line agent** for **refractory status epilepticus**, used after benzodiazepines and other second-line agents (like phenytoin) have failed. - The current situation requires immediate termination with a **first-line IV benzodiazepine** following initial treatment failure and established IV access.

Q: A 12-year-old girl with type 1 diabetes for 6 years presents for her annual screening appointment. She is asymptomatic. Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on two occasions three months apart. Blood pressure is 115/70 mmHg. HbA1c is 68 mmol/mol. Fundoscopy is normal. What is the most appropriate next step in management?

Optimize glycaemic control and repeat ACR in 6-12 months. ***Optimize glycaemic control and repeat ACR in 6-12 months***- An **Albumin:Creatinine Ratio (ACR)** of 3.5 mg/mmol on two occasions indicates **microalbuminuria**, representing the earliest stage of **diabetic nephropathy**.- The primary management in pediatrics is optimizing **glycaemic control** (HbA1c target 2.5 mg/mmol (males)** or **>3.5 mg/mmol (females)** is abnormal and signifies **persistent microalbuminuria**.- Ignoring this finding misses the opportunity for early intervention to prevent progression to **overt nephropathy**.*Commence ACE inhibitor therapy and repeat ACR in 3 months*- **ACE inhibitors** are typically reserved for pediatric patients with **hypertension** or those whose microalbuminuria resists glycaemic optimization.- In females of **reproductive age**, these medications require caution and reliable contraception due to potential **teratogenicity**.*Arrange renal ultrasound and refer to paediatric nephrology*- A **renal ultrasound** is not indicated for isolated microalbuminuria in the context of known **Type 1 Diabetes** without other red flags.- Referral is usually unnecessary at this stage unless there is a significant decline in **eGFR**, hematuria, or failure to respond to standard management.*Commence angiotensin receptor blocker and dietary sodium restriction*- **ARBs** are secondary to glycaemic optimization in a normotensive child and are not first-line for asymptomatic **microalbuminuria**.- While sodium restriction is generally healthy, the clinical priority is reducing the **HbA1c** of 68 mmol/mol to protective levels.

A 16-year-old girl with type 1 diabetes for 10 years attends for transition planning to adult services. Her HbA1c has been consistently between 65-72 mmol/mol over the past 2 years. Annual screening shows persistent microalbuminuria (ACR 4.8 mg/mmol) and background diabetic retinopathy with scattered microaneurysms bilaterally. She is on appropriate therapy including an ACE inhibitor. She asks about her long-term prognosis. What is the most appropriate counselling regarding her microvascular complications?

A 4-year-old boy with newly diagnosed generalized epilepsy is being commenced on sodium valproate. His mother asks about potential side effects. Which of the following monitoring investigations should be performed before starting sodium valproate and at regular intervals during treatment?

A 13-year-old boy with type 1 diabetes for 7 years presents with intermittent episodes of abdominal bloating, early satiety, nausea, and vomiting, particularly after meals. He reports that vomiting sometimes contains food eaten several hours earlier. His HbA1c is 82 mmol/mol. On examination, he has mild epigastric tenderness and a succussion splash. Screening for coeliac disease is negative. What is the most likely diagnosis?

An 8-year-old girl presents with frequent brief episodes where she suddenly stops what she is doing, stares blankly for 5-10 seconds, and then resumes her activity with no recollection of the event. Her teacher reports these episodes occur up to 20 times per day and are affecting her school performance. An EEG is performed. Which EEG finding would most strongly support the diagnosis of childhood absence epilepsy?

A 10-year-old girl with type 1 diabetes for 5 years uses insulin glargine 18 units once daily at bedtime and insulin aspart before meals. She participates in competitive gymnastics training 5 evenings per week from 5-7pm. Her mother reports that she frequently becomes hypoglycaemic during and after training sessions despite eating extra snacks. Pre-dinner glucose is usually 8-10 mmol/L. What is the most appropriate modification to her insulin regimen?

A 7-year-old boy with newly diagnosed focal epilepsy is being considered for anti-epileptic drug therapy. His seizures consist of focal motor seizures affecting his right arm with preserved awareness, occurring 2-3 times per week. MRI brain shows a small left frontal cortical dysplasia. His parents are concerned about side effects of medication. Which of the following statements regarding the decision to commence anti-epileptic drug treatment is most accurate?

A 15-year-old boy with type 1 diabetes for 9 years attends clinic with his parents. Over the past year, his HbA1c has deteriorated from 58 mmol/mol to 85 mmol/mol. He admits to frequently missing insulin doses and not checking his blood glucose. He expresses frustration about being 'different' from his peers and wanting to be 'normal'. His parents report frequent arguments at home about diabetes management. What is the most appropriate initial approach to address this situation?

A 5-year-old girl presents to the emergency department with a 20-minute generalized tonic-clonic seizure that has not responded to two doses of buccal midazolam given by paramedics. Intravenous access is established. Blood glucose is 5.2 mmol/L. What is the most appropriate next immediate management?

Q10

A 12-year-old girl with type 1 diabetes for 6 years presents for her annual screening appointment. She is asymptomatic. Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on two occasions three months apart. Blood pressure is 115/70 mmHg. HbA1c is 68 mmol/mol. Fundoscopy is normal. What is the most appropriate next step in management?

Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs

Question 1: A 6-month-old baby presents with failure to thrive, chronic diarrhea, and recurrent respiratory infections. Sweat chloride test is 70 mmol/L (normal <40). What is the most likely diagnosis?

A. Celiac disease
B. Cystic fibrosis (Correct Answer)
C. Immunodeficiency
D. Inflammatory bowel disease
E. Lactose intolerance

Explanation: ***Cystic fibrosis***- The constellation of **failure to thrive**, chronic **malabsorptive diarrhea** (due to **pancreatic insufficiency**), and recurrent **respiratory infections** (due to thick mucus) is classic for **Cystic fibrosis**.- A sweat chloride level of 70 mmol/L is diagnostic for **Cystic fibrosis** in an infant (cut-off is typically >60 mmol/L), confirming the defect in the **CFTR channel**.*Celiac disease*- While a cause of failure to thrive and chronic diarrhea, symptoms typically manifest after the introduction of **gluten** (usually after 6 months of age) and often involve abdominal distension.- It does not cause recurrent respiratory infections as a primary feature, nor is it associated with an elevated **sweat chloride** level.*Immunodeficiency*- This could explain **recurrent respiratory infections** and failure to thrive, but it typically does not cause the specific syndrome of chronic steatorrhea due to **pancreatic insufficiency**.- Immunodeficiency conditions do not result in an abnormally high **sweat chloride** test result.*Inflammatory bowel disease*- IBD rarely presents in early infancy (6 months) and usually causes features like **bloody diarrhea** and **abdominal pain** rather than the typical **steatorrhea** associated with pancreatic insufficiency.- IBD is not associated with an elevated **sweat chloride** test or recurrent sino-pulmonary infections driven by mucus accumulation.*Lactose intolerance*- This causes osmotic diarrhea and potentially failure to thrive, but the symptoms are strictly gastrointestinal and often improve when **lactose** is removed from the diet.- It does not explain the hallmark triad of pulmonary disease, malabsorption, and the pathognomonic **elevated sweat chloride**.

Question 2: A 16-year-old girl with type 1 diabetes for 10 years attends for transition planning to adult services. Her HbA1c has been consistently between 65-72 mmol/mol over the past 2 years. Annual screening shows persistent microalbuminuria (ACR 4.8 mg/mmol) and background diabetic retinopathy with scattered microaneurysms bilaterally. She is on appropriate therapy including an ACE inhibitor. She asks about her long-term prognosis. What is the most appropriate counselling regarding her microvascular complications?

A. Microalbuminuria at this stage is irreversible regardless of subsequent glycaemic control
B. With current control, progression to end-stage renal disease is inevitable within 10 years
C. Optimizing glycaemic control now can still slow progression even with established complications (Correct Answer)
D. Background retinopathy always progresses to proliferative retinopathy requiring laser therapy
E. Presence of two microvascular complications indicates imminent need for renal transplantation

Explanation: ***Optimizing glycaemic control now can still slow progression even with established complications*** - The **Diabetes Control and Complications Trial (DCCT)** and EDIC studies confirm that improving glycaemic control reduces the risk of **microvascular progression** even after complications like **microalbuminuria** or **background retinopathy** appear. - Achieving a target **HbA1c <48 mmol/mol** is critical during transition to prevent the worsening of damage through the mechanism of **metabolic memory**. *Microalbuminuria at this stage is irreversible regardless of subsequent glycaemic control* - **Microalbuminuria** (ACR 3–30 mg/mmol) is potentially **reversible** or can be stabilized with intensive glycaemic control and **ACE inhibitor** therapy. - Progression to **macroalbuminuria** is common if control remains poor, but early intervention often leads to **regression** to normoalbuminuria. *With current control, progression to end-stage renal disease is inevitable within 10 years* - While an HbA1c of 65-72 mmol/mol increases risk, **End-Stage Renal Disease (ESRD)** typically takes decades to develop, and many patients with early nephropathy remain **stable for years**. - Labelling ESRD as **inevitable** is clinically inaccurate and discouraged in transition counselling as it ignores the impact of **blood pressure** and glycaemic management. *Background retinopathy always progresses to proliferative retinopathy requiring laser therapy* - **Background retinopathy** (microaneurysms) may remain stable for long periods or even **regress** if glycaemic control and **blood pressure** are well-managed. - Progression to **proliferative diabetic retinopathy (PDR)** is not a certainty and depends heavily on the duration of **hyperglycaemia**. *Presence of two microvascular complications indicates imminent need for renal transplantation* - The presence of multiple complications indicates a **high-risk profile** requiring intensive multidisciplinary care, but does not suggest **acute organ failure**. - **Renal transplantation** is only considered for stage 5 **chronic kidney disease**, whereas this patient currently has early-stage **diabetic nephropathy**.

Question 3: A 4-year-old boy with newly diagnosed generalized epilepsy is being commenced on sodium valproate. His mother asks about potential side effects. Which of the following monitoring investigations should be performed before starting sodium valproate and at regular intervals during treatment?

A. Full blood count, renal function, and thyroid function tests
B. Liver function tests, full blood count, and serum ammonia (Correct Answer)
C. Electrocardiogram, liver function tests, and lipid profile
D. Full blood count, vitamin D levels, and bone density scan
E. Renal function, serum drug levels, and electroencephalogram

Explanation: ***Liver function tests, full blood count, and serum ammonia***- Sodium valproate carries a risk of idiosyncratic **hepatotoxicity**, making baseline and regular **Liver Function Tests (LFTs)** essential, especially during the first 6 months of therapy.- **Full blood count (FBC)** is required to monitor for **thrombocytopenia** and other blood dyscrasias, while **serum ammonia** helps detect valproate-induced **hyperammonemia** which can present as lethargy or confusion.*Full blood count, renal function, and thyroid function tests*- While FBC is necessary, valproate is not primarily excreted by the kidneys and does not typically cause **renal impairment** requiring routine monitoring.- **Thyroid function tests** are not standard for valproate; they are more relevant for medications like **lithium** or **amiodarone**.*Electrocardiogram, liver function tests, and lipid profile*- **ECG monitoring** is not routinely required for valproate, unlike drugs like **tricyclic antidepressants** or certain antipsychotics that affect the **QT interval**.- Although valproate can cause **weight gain**, a routine **lipid profile** is not a primary safety monitoring requirement compared to LFTs and hematology.*Full blood count, vitamin D levels, and bone density scan*- Long-term anticonvulsant use is linked to **reduced bone mineral density**, but **DEXA scans** are not part of the standard pre-treatment or early routine monitoring battery.- Monitoring **vitamin D** may be considered long-term, but it is less critical than monitoring for acute **liver failure** or **bone marrow suppression**.*Renal function, serum drug levels, and electroencephalogram*- Unlike phenytoin or carbamazepine, there is a poor correlation between **serum drug levels** and the therapeutic effect or toxicity of valproate, so routine monitoring is not indicated.- An **EEG** is used for diagnosis and classification of epilepsy rather than as a routine investigation to monitor for medication **side effects**.

Question 4: A 13-year-old boy with type 1 diabetes for 7 years presents with intermittent episodes of abdominal bloating, early satiety, nausea, and vomiting, particularly after meals. He reports that vomiting sometimes contains food eaten several hours earlier. His HbA1c is 82 mmol/mol. On examination, he has mild epigastric tenderness and a succussion splash. Screening for coeliac disease is negative. What is the most likely diagnosis?

A. Diabetic ketoacidosis with gastric stasis
B. Gastroparesis secondary to diabetic autonomic neuropathy (Correct Answer)
C. Superior mesenteric artery syndrome
D. Helicobacter pylori-associated gastritis
E. Coeliac disease with false-negative serology

Explanation: ***Gastroparesis secondary to diabetic autonomic neuropathy*** - This condition is a classic complication of long-standing **Type 1 Diabetes** with poor glycemic control, leading to delayed gastric emptying due to **vagal nerve damage**.- Symptoms like **early satiety**, vomiting of food consumed hours prior, and a positive **succussion splash** indicating retained gastric contents are pathognomonic.*Diabetic ketoacidosis with gastric stasis*- While **DKA** can cause acute gastroparesis, it typically presents with acute-onset abdominal pain, **uncompensated metabolic acidosis**, and ketosis, which are not described here.- The history of intermittent postprandial symptoms over time is more indicative of a **chronic autonomic neuropathy** than an acute metabolic emergency.*Superior mesenteric artery syndrome*- This occurs when the **duodenum** is compressed between the SMA and the aorta, usually following **rapid weight loss**.- Although it presents with postprandial vomiting, it is less common in this clinical context and would not be primary suspected over **diabetic neuropathy** in a long-standing diabetic.*Helicobacter pylori-associated gastritis*- **H. pylori** commonly causes chronic epigastric pain and dyspepsia, but it does not typically lead to mechanical or functional **gastric outlet obstruction**.- The presence of a **succussion splash** strongly suggests a motility or obstructive disorder rather than simple mucosal inflammation.*Coeliac disease with false-negative serology*- While **Coeliac disease** is frequently associated with Type 1 Diabetes, it usually presents with diarrhea, malabsorption, or growth failure rather than **gastric stasis**.- Serology was negative, and the specific finding of a **succussion splash** is not a feature of Coeliac disease.

Question 5: An 8-year-old girl presents with frequent brief episodes where she suddenly stops what she is doing, stares blankly for 5-10 seconds, and then resumes her activity with no recollection of the event. Her teacher reports these episodes occur up to 20 times per day and are affecting her school performance. An EEG is performed. Which EEG finding would most strongly support the diagnosis of childhood absence epilepsy?

A. Focal spike and wave discharges in the temporal region
B. Generalized 3 Hz spike-and-wave discharges induced by hyperventilation (Correct Answer)
C. Hypsarrhythmia pattern with high-amplitude chaotic activity
D. Photoparoxysmal response with generalized polyspike-and-wave complexes
E. Centrotemporal spikes activated during drowsiness and sleep

Explanation: ***Generalized 3 Hz spike-and-wave discharges induced by hyperventilation*** - This is the pathognomonic EEG finding for **Childhood Absence Epilepsy (CAE)**, characterized by synchronous, symmetrical discharges with abrupt onset and termination. - **Hyperventilation** is a highly effective provocation technique that triggers these generalized seizures in over 90% of untreated patients. *Focal spike and wave discharges in the temporal region* - These findings are indicative of **Focal Impaired Awareness Seizures** (formerly complex partial seizures) originating in the **temporal lobe**. - Unlike absence seizures, temporal lobe seizures usually include a **post-ictal state** and last significantly longer than 10 seconds. *Hypsarrhythmia pattern with high-amplitude chaotic activity* - This chaotic EEG pattern is the hallmark of **West Syndrome** (infantile spasms), which typically presents in infants aged 4-8 months. - It consists of high-voltage, disorganized background activity and is associated with **developmental regression**. *Photoparoxysmal response with generalized polyspike-and-wave complexes* - This pattern is most commonly associated with **Juvenile Myoclonic Epilepsy (JME)** rather than childhood absence epilepsy. - JME usually presents in **adolescents** with myoclonic jerks specifically occurring upon awakening, often triggered by **photic stimulation**. *Centrotemporal spikes activated during drowsiness and sleep* - This finding is characteristic of **Benign Epilepsy with Centrotemporal Spikes (BECTS)**, also known as Benign Rolandic Epilepsy. - BECTS typically involves nocturnal seizures with **orofacial paresthesias** and drooling, rather than frequent daytime staring spells.

Question 6: A 10-year-old girl with type 1 diabetes for 5 years uses insulin glargine 18 units once daily at bedtime and insulin aspart before meals. She participates in competitive gymnastics training 5 evenings per week from 5-7pm. Her mother reports that she frequently becomes hypoglycaemic during and after training sessions despite eating extra snacks. Pre-dinner glucose is usually 8-10 mmol/L. What is the most appropriate modification to her insulin regimen?

A. Increase the pre-lunch insulin aspart dose to provide better afternoon glucose control
B. Switch insulin glargine from bedtime to morning administration
C. Add metformin to reduce insulin requirements
D. Reduce the pre-lunch insulin aspart dose by 30-50% on training days (Correct Answer)
E. Split insulin glargine to twice daily administration with reduced total daily dose

Explanation: ***Reduce the pre-lunch insulin aspart dose by 30-50% on training days***- Exercise increases **insulin sensitivity** and glucose uptake by muscles, requiring less insulin to maintain euglycemia, especially during the period of physical activity.- Rapid-acting insulin administered before lunch, such as **insulin aspart**, will still have significant activity during late afternoon gymnastics, making a dose reduction crucial to prevent **exercise-induced hypoglycemia**.*Increase the pre-lunch insulin aspart dose to provide better afternoon glucose control*- Increasing the dose of **pre-lunch aspart** would heighten the risk of **hypoglycemia** during the strenuous evening gymnastics, as more insulin would be active during this period.- The reported pre-dinner glucose levels of 8-10 mmol/L are not high enough to justify an increase that would likely lead to dangerous hypoglycemia during exercise.*Switch insulin glargine from bedtime to morning administration*- Changing the timing of **basal insulin** like glargine does not directly address the peak action of **bolus insulin** (aspart) which is responsible for the hypoglycemia during late afternoon activity.- This modification could also disrupt the overall **basal insulin coverage**, potentially leading to suboptimal glycemic control at other times, including nocturnal hyperglycemia.*Add metformin to reduce insulin requirements*- **Metformin** is primarily used in **Type 2 Diabetes** or **Type 1 Diabetes** with significant insulin resistance; it is not indicated for managing acute exercise-induced hypoglycemia in a 10-year-old with uncomplicated T1DM.- Its mechanism of action doesn't directly solve the issue of excess rapid-acting insulin activity during exercise, which is the root cause of the patient's hypoglycemia.*Split insulin glargine to twice daily administration with reduced total daily dose*- While splitting the **basal insulin** dose can sometimes improve glycemic stability, it is not the most targeted intervention for hypoglycemia specifically caused by **exercise-induced increased insulin sensitivity** interacting with mealtime bolus insulin.- Reducing the total daily basal dose might compromise overall glycemic control and lead to **hyperglycemia** on non-training days or at other times.

Question 7: A 7-year-old boy with newly diagnosed focal epilepsy is being considered for anti-epileptic drug therapy. His seizures consist of focal motor seizures affecting his right arm with preserved awareness, occurring 2-3 times per week. MRI brain shows a small left frontal cortical dysplasia. His parents are concerned about side effects of medication. Which of the following statements regarding the decision to commence anti-epileptic drug treatment is most accurate?

A. Focal seizures with preserved awareness do not require anti-epileptic treatment
B. Anti-epileptic drugs should be started immediately after a single unprovoked seizure to prevent recurrence
C. The presence of a structural brain lesion increases the risk of seizure recurrence and supports starting treatment (Correct Answer)
D. Anti-epileptic drugs are contraindicated in children under 10 years due to neurodevelopmental concerns
E. Treatment should be delayed until seizures occur daily to confirm the diagnosis

Explanation: ***The presence of a structural brain lesion increases the risk of seizure recurrence and supports starting treatment*** - The identification of a **structural brain lesion**, specifically **cortical dysplasia** on MRI, significantly increases the risk of **seizure recurrence** and qualifies for a diagnosis of epilepsy, even after a single unprovoked seizure. - With seizures occurring 2-3 times per week and a high risk of recurrence due to the underlying pathology, commencing **anti-epileptic drug (AED)** therapy is medically appropriate to improve seizure control and prevent further complications. *Focal seizures with preserved awareness do not require anti-epileptic treatment* - While awareness is preserved, recurrent **focal motor seizures** (2-3 times per week) can significantly disrupt a child's life and carry a risk of **secondary generalization**. - The decision to initiate treatment is based on seizure frequency, impact on daily activities, and the presence of an underlying structural cause, rather than solely on the preservation of awareness. *Anti-epileptic drugs should be started immediately after a single unprovoked seizure to prevent recurrence* - Routine immediate initiation of **AEDs** after a single unprovoked seizure is not typically recommended unless there are specific **high-risk factors** for recurrence, such as an abnormal EEG or structural brain lesion. - In many cases, a single unprovoked seizure may not lead to further events, and the decision to treat involves carefully weighing the risk of recurrence against potential medication side effects. *Anti-epileptic drugs are contraindicated in children under 10 years due to neurodevelopmental concerns* - **AEDs** are commonly and safely prescribed for children of all ages, including those under 10, when indicated for **epilepsy management**. - Uncontrolled or frequent seizures themselves pose a substantial risk to a child's **neurodevelopment** and cognitive function, making appropriate treatment crucial despite potential side effects, which are managed by careful drug selection and monitoring. *Treatment should be delayed until seizures occur daily to confirm the diagnosis* - Delaying treatment until **daily seizures** occur is not recommended as it unnecessarily increases the risk of **status epilepticus**, injuries, and potential **long-term neurological morbidity**. - The diagnosis of epilepsy is sufficiently confirmed by recurrent seizures (2-3 times per week) in the presence of a clear **focal cortical dysplasia**, warranting earlier intervention.

Question 8: A 15-year-old boy with type 1 diabetes for 9 years attends clinic with his parents. Over the past year, his HbA1c has deteriorated from 58 mmol/mol to 85 mmol/mol. He admits to frequently missing insulin doses and not checking his blood glucose. He expresses frustration about being 'different' from his peers and wanting to be 'normal'. His parents report frequent arguments at home about diabetes management. What is the most appropriate initial approach to address this situation?

A. Arrange immediate referral to child and adolescent mental health services
B. Initiate continuous glucose monitoring to improve awareness of glucose levels
C. Explore the patient's perspective and concerns using motivational interviewing techniques (Correct Answer)
D. Inform the parents that they need to resume full responsibility for diabetes management
E. Switch to insulin pump therapy to simplify the treatment regimen

Explanation: ***Explore the patient's perspective and concerns using motivational interviewing techniques*** - The significant deterioration in **HbA1c** and poor adherence in an adolescent strongly suggest underlying **psychosocial factors**, such as the desire for autonomy and fitting in with peers. - **Motivational interviewing** is the most appropriate initial step to explore his feelings of being 'different', validate his frustrations, and collaboratively identify his own motivations for better self-management. *Arrange immediate referral to child and adolescent mental health services* - While mental health is a factor in adherence, his stated frustrations about being 'different' are common **adolescent struggles** with chronic illness, not immediate indicators for specialist **CAMHS referral** for a diagnosed disorder. - A referral might be considered if initial interventions fail or if symptoms of a severe mental health condition (e.g., clinical depression, anxiety disorder) are clearly present. *Initiate continuous glucose monitoring to improve awareness of glucose levels* - The patient's issue is not a lack of awareness of his glucose levels, but rather a lack of **motivation** and engagement with his diabetes management. - Introducing **continuous glucose monitoring (CGM)** without addressing the underlying emotional barriers may further burden him and reinforce his feeling of being 'different', potentially worsening adherence. *Inform the parents that they need to resume full responsibility for diabetes management* - Removing autonomy from a 15-year-old can exacerbate **family conflict** and lead to increased rebellion against diabetes management, as adolescents seek greater independence. - The goal is to support the adolescent in gradually assuming more responsibility, not to revert to full parental control, which can be counterproductive in this age group. *Switch to insulin pump therapy to simplify the treatment regimen* - **Insulin pump therapy** requires significant patient engagement, training, and careful self-management; it is not a 'simpler' solution for a patient who is already non-adherent. - Introducing a pump to a patient lacking motivation could increase the risk of serious complications like **diabetic ketoacidosis (DKA)** if not managed properly, as it does not address the emotional barriers.

Question 9: A 5-year-old girl presents to the emergency department with a 20-minute generalized tonic-clonic seizure that has not responded to two doses of buccal midazolam given by paramedics. Intravenous access is established. Blood glucose is 5.2 mmol/L. What is the most appropriate next immediate management?

A. Intravenous lorazepam 0.1 mg/kg (Correct Answer)
B. Rectal paraldehyde 0.4 ml/kg
C. Intravenous phenytoin 20 mg/kg infusion
D. Intramuscular phenobarbital 20 mg/kg
E. Intravenous levetiracetam 40 mg/kg

Explanation: ***Intravenous lorazepam 0.1 mg/kg*** - The child is experiencing **status epilepticus** as the seizure has lasted 20 minutes and buccal midazolam has failed. - With **IV access** established, **intravenous lorazepam** is the recommended **first-line benzodiazepine** for terminating acute seizures in the hospital setting due to its rapid action and sustained effect.*Rectal paraldehyde 0.4 ml/kg* - **Rectal paraldehyde** is a historical alternative, primarily considered only when **IV access cannot be obtained**, which is not the case here. - Its use has been largely superseded by safer and more effective **IV benzodiazepines** in modern emergency management protocols.*Intravenous phenytoin 20 mg/kg infusion* - **Phenytoin** is typically a **second or third-line agent** for **refractory status epilepticus**, used when benzodiazepines have failed. - The immediate next step after initial benzodiazepine failure and IV access establishment is another **IV benzodiazepine**, not a loading dose of phenytoin.*Intramuscular phenobarbital 20 mg/kg* - While **phenobarbital** is an antiepileptic, it is typically administered **intravenously** for status epilepticus, not intramuscularly, for rapid onset of action. - It is also generally reserved as a **third-line agent** for refractory cases, not as the immediate next step after initial benzodiazepine failure.*Intravenous levetiracetam 40 mg/kg* - **Levetiracetam** is recognized as a **third-line agent** for **refractory status epilepticus**, used after benzodiazepines and other second-line agents (like phenytoin) have failed. - The current situation requires immediate termination with a **first-line IV benzodiazepine** following initial treatment failure and established IV access.

Question 10: A 12-year-old girl with type 1 diabetes for 6 years presents for her annual screening appointment. She is asymptomatic. Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on two occasions three months apart. Blood pressure is 115/70 mmHg. HbA1c is 68 mmol/mol. Fundoscopy is normal. What is the most appropriate next step in management?

A. Reassure as this is within normal range and continue annual screening
B. Commence ACE inhibitor therapy and repeat ACR in 3 months
C. Optimize glycaemic control and repeat ACR in 6-12 months (Correct Answer)
D. Arrange renal ultrasound and refer to paediatric nephrology
E. Commence angiotensin receptor blocker and dietary sodium restriction

Explanation: ***Optimize glycaemic control and repeat ACR in 6-12 months***- An **Albumin:Creatinine Ratio (ACR)** of 3.5 mg/mmol on two occasions indicates **microalbuminuria**, representing the earliest stage of **diabetic nephropathy**.- The primary management in pediatrics is optimizing **glycaemic control** (HbA1c target <48 mmol/mol) and monitoring, rather than immediate pharmacotherapy when blood pressure is normal.*Reassure as this is within normal range and continue annual screening*- Reassurance is incorrect because an **ACR >2.5 mg/mmol (males)** or **>3.5 mg/mmol (females)** is abnormal and signifies **persistent microalbuminuria**.- Ignoring this finding misses the opportunity for early intervention to prevent progression to **overt nephropathy**.*Commence ACE inhibitor therapy and repeat ACR in 3 months*- **ACE inhibitors** are typically reserved for pediatric patients with **hypertension** or those whose microalbuminuria resists glycaemic optimization.- In females of **reproductive age**, these medications require caution and reliable contraception due to potential **teratogenicity**.*Arrange renal ultrasound and refer to paediatric nephrology*- A **renal ultrasound** is not indicated for isolated microalbuminuria in the context of known **Type 1 Diabetes** without other red flags.- Referral is usually unnecessary at this stage unless there is a significant decline in **eGFR**, hematuria, or failure to respond to standard management.*Commence angiotensin receptor blocker and dietary sodium restriction*- **ARBs** are secondary to glycaemic optimization in a normotensive child and are not first-line for asymptomatic **microalbuminuria**.- While sodium restriction is generally healthy, the clinical priority is reducing the **HbA1c** of 68 mmol/mol to protective levels.

Question 11: Which of the following is the primary mechanism by which the ketogenic diet exerts its anti-epileptic effect in children with drug-resistant epilepsy?

A. Reduction in neuronal excitability through GABA receptor upregulation
B. Inhibition of voltage-gated sodium channels in neuronal membranes
C. Metabolic shift producing ketone bodies that stabilize neuronal membranes and alter neurotransmitter levels (Correct Answer)
D. Decreased glutamate synthesis and enhanced glycine-mediated inhibition
E. Direct antagonism of NMDA receptors reducing excitatory neurotransmission

Explanation: ***Metabolic shift producing ketone bodies that stabilize neuronal membranes and alter neurotransmitter levels*** - The ketogenic diet creates a state of **ketosis**, where **ketone bodies** like beta-hydroxybutyrate become the primary fuel source, leading to **hyperpolarization** and stabilization of neurons. - It enhances **mitochondrial biogenesis** and modulates the balance of **inhibitory and excitatory neurotransmitters**, which raises the seizure threshold. *Reduction in neuronal excitability through GABA receptor upregulation* - While the diet may increase **GABA synthesis** and reduce its degradation, it does not primarily work through simple **receptor upregulation**. - This mechanism is more characteristic of pharmacological agents like **benzodiazepines** or barbiturates rather than a dietary metabolic shift. *Inhibition of voltage-gated sodium channels in neuronal membranes* - This is the primary mechanism of action for many **anti-epileptic drugs (AEDs)** such as **phenytoin** and carbamazepine. - Although the ketogenic diet has broad effects on excitability, it does not exert its main clinical effect via the direct inhibition of these specific **ion channels**. *Decreased glutamate synthesis and enhanced glycine-mediated inhibition* - While the diet does decrease **glutamate** (an excitatory neurotransmitter), the role of **glycine** is not a fundamental or primary pathway for its anti-seizure effects. - The diet is better known for its effect on the **glutamate-glutamine cycle** rather than specific glycine-mediated inhibition. *Direct antagonism of NMDA receptors reducing excitatory neurotransmission* - Direct **NMDA receptor antagonism** is a mechanism associated with drugs like **ketamine** or felbamate. - The ketogenic diet reduces the availability of excitatory substrates but is not classified as a direct **pharmacological antagonist** of the NMDA receptor.

Question 12: A 9-year-old boy with type 1 diabetes for 4 years uses a basal-bolus insulin regimen. His parents report that his morning pre-breakfast blood glucose readings are consistently high (12-15 mmol/L), despite having good control during the day. His bedtime readings are usually 6-8 mmol/L. A continuous glucose monitor shows that his glucose drops to 3.2 mmol/L at 2am then rises sharply to 14 mmol/L by 7am. What is the most appropriate adjustment to his insulin regimen?

A. Increase the evening long-acting insulin dose
B. Decrease the evening long-acting insulin dose (Correct Answer)
C. Add a bedtime snack containing complex carbohydrates
D. Increase the lunchtime rapid-acting insulin dose
E. Split the long-acting insulin to twice daily dosing

Explanation: ***Decrease the evening long-acting insulin dose***- The patient exhibits the **Somogyi phenomenon**, where **nocturnal hypoglycemia** (3.2 mmol/L at 2am) triggers a counter-regulatory hormone surge, causing **rebound hyperglycemia** by morning.- Reducing the evening **basal insulin** prevents the initial drop in glucose, thereby eliminating the subsequent hormonal spike and morning hyperglycemia.*Increase the evening long-acting insulin dose*- Increasing the dose would worsen the **nocturnal hypoglycemia** and potentially increase the severity of the rebound effect.- This intervention is appropriate for the **Dawn Phenomenon**, which lacks the dip into hypoglycemia seen here.*Add a bedtime snack containing complex carbohydrates*- While a snack might mitigate the 2am drop, it does not directly address the underlying issue of **excessive basal insulin** delivery.- Adjusting the **insulin dose** is the primary management strategy for confirmed Somogyi effects on a glucose monitor.*Increase the lunchtime rapid-acting insulin dose*- Changes to **bolus insulin** at lunch affect post-prandial readings during the afternoon and evening.- It has no clinical impact on the **overnight glucose profile** or the morning hyperglycemia observed in this case.*Split the long-acting insulin to twice daily dosing*- Splitting the dose can help with **insulin coverage gaps** but doesn't solve the issue of a too-high total relative concentration at night.- The immediate priority is **dose reduction** to ensure safety and prevent symptomatic or asymptomatic nighttime hypoglycemia.

Question 13: A 6-year-old boy with epilepsy controlled on lamotrigine presents with a 2-day history of fever, malaise, and a widespread erythematous rash. On examination, he has a maculopapular rash involving his trunk and limbs with some areas of confluence. There are oral mucosal erosions and bilateral conjunctival injection. Temperature is 38.9°C. The rash began 10 days after starting lamotrigine. What is the most appropriate immediate management?

A. Continue lamotrigine and treat symptomatically with antipyretics
B. Reduce lamotrigine dose by 50% and review in 48 hours
C. Stop lamotrigine immediately and admit for monitoring (Correct Answer)
D. Add oral antihistamines and topical corticosteroids
E. Change to carbamazepine and continue anti-epileptic treatment

Explanation: ***Stop lamotrigine immediately and admit for monitoring*** - The patient's presentation with **fever**, widespread **maculopapular rash** with confluence, **oral mucosal erosions**, and **conjunctival injection** strongly suggests a severe cutaneous adverse reaction like **Stevens-Johnson Syndrome (SJS)**. - **Lamotrigine** is a well-known culprit for SJS/TEN; immediate withdrawal of the offending drug is the most critical step to prevent progression and potential mortality, requiring inpatient monitoring. *Continue lamotrigine and treat symptomatically with antipyretics* - Continuing lamotrigine in the presence of features highly suggestive of **SJS** would be extremely dangerous, as the drug is the likely cause of the immune-mediated reaction. - Symptomatic treatment with antipyretics alone does not address the underlying **life-threatening drug hypersensitivity reaction** and risks rapid progression of the disease. *Reduce lamotrigine dose by 50% and review in 48 hours* - For a severe **idiosyncratic drug reaction** like SJS, simply reducing the dose is insufficient; even a reduced dose will continue to trigger the immune response. - Delaying definitive management (stopping the drug and admitting for aggressive supportive care) by 48 hours can lead to significant worsening of **skin detachment** and systemic complications. *Add oral antihistamines and topical corticosteroids* - Oral antihistamines and topical corticosteroids are treatments for **mild allergic rashes** or localized inflammatory conditions, not for a severe, systemic mucocutaneous reaction like SJS. - These interventions would be entirely inadequate for managing widespread **mucosal erosions** and systemic symptoms associated with SJS, failing to halt disease progression. *Change to carbamazepine and continue anti-epileptic treatment* - **Carbamazepine** is another aromatic anticonvulsant that carries a significant risk of causing **severe cutaneous adverse reactions**, including SJS/TEN, and has potential **cross-reactivity** with lamotrigine. - Switching to another high-risk drug during an acute, severe **hypersensitivity reaction** is contraindicated and could exacerbate the condition or trigger a similar reaction.

Question 14: A 14-year-old girl with type 1 diabetes for 5 years presents with bilateral pain and stiffness in her hands and feet, particularly in the mornings. On examination, she has bilateral flexion contractures at the metacarpophalangeal joints with waxy, tight skin over the dorsum of her hands. She is unable to approximate her palms together in a 'prayer sign'. Her HbA1c is 75 mmol/mol. What is the most likely diagnosis?

A. Juvenile idiopathic arthritis
B. Diabetic cheiroarthropathy (Correct Answer)
C. Dupuytren's contracture
D. Carpal tunnel syndrome
E. Systemic sclerosis

Explanation: ***Diabetic cheiroarthropathy*** - This condition, also known as **limited joint mobility syndrome**, is characterized by bilateral flexion contractures at the metacarpophalangeal joints, waxy, tight skin, and the inability to approximate palms (the **'prayer sign'**). - It is strongly associated with long-standing **Type 1 Diabetes** and poor glycemic control, evidenced by the high HbA1c, due to **non-enzymatic glycosylation of collagen**. *Juvenile idiopathic arthritis* - Typically presents with visible **joint swelling**, warmth, and effusion, which are not described in this patient's presentation. - While it causes morning stiffness, it is not specifically associated with the **waxy skin changes** or the high HbA1c levels indicative of diabetic complications. *Dupuytren's contracture* - Involves the thickening and shortening of the **palmar fascia**, leading to permanent flexion of specific fingers, most commonly the ring and little fingers. - It presents with palpable **fascial nodules** or cords, not generalized waxy skin, bilateral symmetrical stiffness involving all digits, or the 'prayer sign'. *Carpal tunnel syndrome* - Primarily presents with **paresthesia**, numbness, and pain in the **median nerve** distribution, often worsening at night. - It does not cause the **'prayer sign'** or the widespread cutaneous thickening and stiffness of the small joints described in this case. *Systemic sclerosis* - While it can feature **sclerodactyly** and tight skin, it is usually accompanied by **Raynaud’s phenomenon**, digital ulcers, and systemic organ involvement. - The strong clinical association with poorly controlled diabetes (high **HbA1c**) and the specific 'prayer sign' points more directly to diabetic cheiroarthropathy.

Question 15: A 9-year-old girl with type 1 diabetes for 3 years uses insulin glargine 16 units at bedtime and insulin aspart before meals (carbohydrate ratio 1:10). Her blood glucose readings over the past week show: fasting 4-6 mmol/L, pre-lunch 10-14 mmol/L, pre-dinner 5-7 mmol/L, bedtime 6-9 mmol/L. She eats breakfast (40g carbohydrate) at 0730 and has a mid-morning snack at school (15g carbohydrate, no insulin) at 1030. What is the most appropriate adjustment to optimize her glycaemic control?

A. Increase insulin glargine dose to 18 units at bedtime
B. Increase breakfast insulin aspart by 1-2 units to cover the elevated pre-lunch readings (Correct Answer)
C. Reduce breakfast insulin aspart by 1 unit as basal insulin is too high
D. Administer rapid-acting insulin to cover the mid-morning snack
E. Change insulin glargine from bedtime to morning administration

Explanation: ***Increase breakfast insulin aspart by 1-2 units to cover the elevated pre-lunch readings*** - The patient's **pre-lunch blood glucose** readings (10-14 mmol/L) are consistently elevated, indicating **insufficient insulin coverage** for the breakfast and mid-morning snack combined. Her **fasting glucose** is within target. - This specific post-breakfast hyperglycemia suggests the **breakfast bolus insulin (aspart)** is inadequate for the 40g breakfast and potentially the 15g mid-morning snack, making an adjustment to this dose the most direct and effective solution. *Increase insulin glargine dose to 18 units at bedtime* - The **fasting blood glucose** (4-6 mmol/L) is currently well-controlled, indicating that the **basal insulin (glargine)** dose is appropriate and not the cause of the pre-lunch hyperglycemia. - Increasing basal insulin without evidence of elevated fasting glucose could lead to **nocturnal hypoglycemia**. *Reduce breakfast insulin aspart by 1 unit as basal insulin is too high* - The current problem is **hyperglycemia** before lunch, suggesting *too little*, not too much, insulin for the morning carbohydrate intake. - Reducing the breakfast insulin aspart would further **worsen the elevated pre-lunch glucose** and is contrary to the observed pattern. *Administer rapid-acting insulin to cover the mid-morning snack* - While the 15g carbohydrate snack contributes to the pre-lunch rise, adding a separate insulin injection for such a small amount increases the **burden of treatment** and the risk of **insulin stacking** if not timed carefully with breakfast insulin. - A more practical and common approach is to adjust the **breakfast bolus** to cover the anticipated total morning carbohydrate load, including the snack. *Change insulin glargine from bedtime to morning administration* - The current bedtime administration of **insulin glargine** effectively controls overnight and **fasting glucose levels**, which are within target. - Changing the timing of basal insulin would not address the **post-breakfast insulin deficiency** and could potentially disrupt the currently stable fasting profile without benefit.

Question 16: A 16-year-old boy with type 1 diabetes for 9 years attends clinic for transition planning to adult services. His current regimen includes insulin degludec once daily and insulin aspart before meals. His HbA1c has ranged between 58-64 mmol/mol over the past year. He reports occasional missed insulin doses when out with friends and has had two episodes of severe hypoglycaemia in the past 6 months requiring assistance. He plans to attend university next year. What aspect of his diabetes management represents the highest priority to address before transition?

A. His suboptimal HbA1c levels requiring treatment intensification with insulin pump therapy
B. Recurrent severe hypoglycaemia requiring urgent review of insulin regimen and hypoglycaemia awareness (Correct Answer)
C. Need for structured education on alcohol effects and diabetes management in social situations
D. Inadequate preparation for independent self-management requiring more frequent clinic visits
E. Lack of continuous glucose monitoring technology to improve glycaemic control

Explanation: ***Recurrent severe hypoglycaemia requiring urgent review of insulin regimen and hypoglycaemia awareness***- **Severe hypoglycaemia** (requiring assistance) is a life-threatening acute complication and represents the highest **clinical risk** during the transition to independent university life.- Addressing this requires an urgent assessment of **hypoglycaemia unawareness** and a review of basal insulin doses to ensure patient safety before he leaves home.*His suboptimal HbA1c levels requiring treatment intensification with insulin pump therapy*- While his **HbA1c** (7.5-8.0%) is above the target, intensifying therapy prematurely could increase the risk of further **severe hypoglycaemic episodes**.- Safety and **glycaemic stability** must be prioritised over achieving a lower HbA1c in a patient already experiencing frequent severe lows.*Need for structured education on alcohol effects and diabetes management in social situations*- Education on **alcohol-induced hypoglycaemia** is important for university students, but it is a subset of the broader clinical priority of managing his current **hypoglycaemia risk**.- This is a preventive education strategy rather than an urgent clinical intervention for a pre-existing pattern of **neuroglycopenia**.*Inadequate preparation for independent self-management requiring more frequent clinic visits*- Frequent clinic visits do not directly resolve the physiological danger of **severe hypoglycaemia** or the underlying technical issues with his insulin regimen.- The goal of transition is to foster **autonomy** and self-efficacy; simply increasing visit frequency may hinder the development of **self-management skills**.*Lack of continuous glucose monitoring technology to improve glycaemic control*- **Continuous glucose monitoring (CGM)** is a useful tool to detect trends, but technology alone cannot replace the necessary review of **insulin dosing** and hypoglycaemia awareness.- While CGM can alert a patient to drops, the immediate priority is understanding why **third-party assistance** was required twice in a short period.

Question 17: A 6-year-old girl with childhood absence epilepsy has been on ethosuximide 250mg twice daily for 6 months with complete seizure control. Her parents report no adverse effects and she is doing well at school. Her EEG shows complete resolution of the 3 Hz spike-and-wave discharges that were present at diagnosis. Her parents ask about the long-term prognosis and treatment duration. What is the most appropriate advice regarding treatment continuation and prognosis?

A. Continue ethosuximide until age 12 then attempt withdrawal; 90% will remain seizure-free into adulthood
B. Continue ethosuximide for minimum 2 years after last seizure; 60-70% will achieve long-term remission (Correct Answer)
C. Attempt drug withdrawal now as EEG has normalized; relapse risk is less than 10% with normal EEG
D. Continue ethosuximide lifelong as childhood absence epilepsy always requires ongoing treatment
E. Switch to sodium valproate for better long-term seizure control as ethosuximide is only for initial treatment

Explanation: ***Continue ethosuximide for minimum 2 years after last seizure; 60-70% will achieve long-term remission***- Standard clinical guidelines suggest that **anti-epileptic drug (AED) withdrawal** should only be considered after a minimum of **2 years of complete seizure freedom**.- While **childhood absence epilepsy (CAE)** has an excellent prognosis, only about **60-70%** of patients achieve permanent remission, as some may transition to other seizure types like **Juvenile Myoclonic Epilepsy**.*Continue ethosuximide until age 12 then attempt withdrawal; 90% will remain seizure-free into adulthood*- Waiting until age 12 is an **arbitrary threshold**; the decision to taper is based on the duration of seizure freedom (usually 2 years) rather than a specific age.- A **90% success rate** for long-term remission is overly optimistic, as reaching adulthood seizure-free without medication occurs in roughly two-thirds of cases.*Attempt drug withdrawal now as EEG has normalized; relapse risk is less than 10% with normal EEG*- Withdrawing medication after only **6 months** is premature and carries a significantly **higher risk of relapse**, regardless of the current EEG findings.- A **normal EEG** is a positive prognostic marker, but it does not guarantee a relapse risk of less than 10% if the treatment duration was insufficient.*Continue ethosuximide lifelong as childhood absence epilepsy always requires ongoing treatment*- This is incorrect because CAE is one of the most likely epilepsy syndromes to exhibit **spontaneous resolution** during adolescence.- **Lifelong treatment** is generally reserved for syndromes like **Juvenile Myoclonic Epilepsy**, which typically require long-term AED therapy.*Switch to sodium valproate for better long-term seizure control as ethosuximide is only for initial treatment*- **Ethosuximide** is the first-line treatment for CAE and is sufficient for long-term management if it provides **complete seizure control** without side effects.- **Sodium valproate** is reserved for cases where ethosuximide fails or if the patient experiences associated **generalized tonic-clonic seizures**.

Question 18: A 4-year-old boy with type 1 diabetes is brought to the emergency department by ambulance. He was found unresponsive by his parents. Paramedics measured a blood glucose of 1.8 mmol/L and administered intramuscular glucagon 500 micrograms. On arrival, he is drowsy but responsive to voice, blood glucose is 3.2 mmol/L. He has vomited once. What is the most appropriate immediate management?

A. Administer intravenous 10% glucose bolus at 5 mL/kg followed by maintenance infusion (Correct Answer)
B. Commence intravenous 0.9% sodium chloride bolus 10 mL/kg over 30 minutes
C. Administer a second dose of intramuscular glucagon and recheck glucose in 10 minutes
D. Give oral glucose gel 1.5-2g per kg and monitor capillary glucose every 15 minutes
E. Give oral quick-acting carbohydrate (e.g., juice) once fully conscious then long-acting carbohydrate

Explanation: ***Administer intravenous 10% glucose bolus at 5 mL/kg followed by maintenance infusion***- In a child with **hypoglycemia** who is **drowsy** and has **vomited**, oral or enteral treatments are unsafe due to the high risk of **aspiration**.- Since **glucagon** works by mobilizing **glycogen stores**, its effect is transient; providing a **10% glucose bolus** followed by an infusion ensures stabilization and prevents rebound hypoglycemia.*Commence intravenous 0.9% sodium chloride bolus 10 mL/kg over 30 minutes*- This intervention is used for **circulatory collapse** or **dehydration**, but it does not contain **glucose** to correct the primary metabolic emergency.- Administering saline without glucose in this context would delay the correction of **neuroglycopenia**.*Administer a second dose of intramuscular glucagon and recheck glucose in 10 minutes*- **Glucagon** is often ineffective for repeated doses because the initial dose likely **depleted hepatic glycogen stores**.- Glucagon frequently induces **vomiting**, making continued reliance on it problematic when intravenous access is available to provide a more reliable glucose source.*Give oral glucose gel 1.5-2g per kg and monitor capillary glucose every 15 minutes*- Oral glucose gel is contraindicated in patients with an **altered level of consciousness** as they cannot protect their airway.- This patient has already **vomited**, indicating that the **gastrointestinal route** is currently unreliable and potentially hazardous.*Give oral quick-acting carbohydrate (e.g., juice) once fully conscious then long-acting carbohydrate*- While this is the protocol for **mild to moderate hypoglycemia**, this patient's current state is **severe** and necessitates faster, parenteral intervention.- Waiting for the patient to become "fully conscious" without active IV correction delays treatment for a child who is currently **symptomatically hypoglycemic** (3.2 mmol/L with drowsiness).

Question 19: An 8-year-old boy with drug-resistant focal epilepsy is being evaluated for epilepsy surgery. Video-EEG telemetry has localized his seizure focus to the left anterior temporal lobe. MRI brain shows left mesial temporal sclerosis. Neuropsychological testing reveals age-appropriate cognitive function with right hemisphere language dominance. What is the most critical investigation that must be performed before proceeding with surgical resection?

A. Functional MRI to map eloquent cortex and determine language lateralization (Correct Answer)
B. Intracranial EEG monitoring with subdural electrodes to refine seizure focus
C. Wada test (intracarotid sodium amobarbital procedure) to assess memory function
D. Repeat MRI with magnetoencephalography to confirm seizure localization
E. PET scan to identify areas of hypometabolism

Explanation: ***Functional MRI to map eloquent cortex and determine language lateralization*** - **Functional MRI (fMRI)** is crucial for **pre-surgical planning** to non-invasively map **eloquent cortex** and determine **language lateralization**, especially when the seizure focus is near critical functional areas. - Given the patient's **right hemisphere language dominance** and the seizure focus in the **left anterior temporal lobe**, fMRI is essential to precisely identify and spare language areas during resection, preventing significant postoperative deficits. *Intracranial EEG monitoring with subdural electrodes to refine seizure focus* - This is an **invasive procedure** generally considered when non-invasive studies (video-EEG, MRI) are **discordant** or insufficient for precise localization, or when the seizure focus is intimately associated with eloquent cortex. - In this case, the **video-EEG** and **MRI** findings are already **concordant** for left mesial temporal sclerosis, making functional mapping more immediately critical than further invasive localization. *Wada test (intracarotid sodium amobarbital procedure) to assess memory function* - The **Wada test** is an **invasive procedure** with associated risks, traditionally used for **language and memory lateralization** prior to epilepsy surgery. - For pediatric patients, it has largely been superseded by **non-invasive fMRI**, which provides safer and often more detailed functional mapping of language and memory regions. *Repeat MRI with magnetoencephalography to confirm seizure localization* - **Magnetoencephalography (MEG)** is valuable for localizing seizure activity, particularly in cases of **non-lesional epilepsy** or when the EEG is inconclusive. - However, this patient already has a clear structural lesion (**left mesial temporal sclerosis**) and **concordant video-EEG** localization, making further localization less critical than functional mapping for surgical safety. *PET scan to identify areas of hypometabolism* - A **PET scan (FDG-PET)** can identify areas of **interictal hypometabolism** that often correlate with the seizure onset zone, providing supportive evidence for localization. - While useful for supporting seizure focus localization, a PET scan does not provide the critical **functional mapping** information needed to protect eloquent brain regions during surgical resection.

Question 20: A 13-year-old girl with type 1 diabetes for 7 years attends for her annual review. She uses a basal-bolus regimen with good adherence. Her HbA1c is 52 mmol/mol. Urinalysis shows albumin:creatinine ratio (ACR) of 3.8 mg/mmol on two occasions 3 months apart (early morning samples). Blood pressure is 118/72 mmHg (90th centile for age, gender, and height). Serum creatinine is normal. What is the most appropriate next management step?

A. Reassure that results are within normal limits and continue annual screening
B. Arrange renal ultrasound to exclude structural abnormalities
C. Increase frequency of ACR monitoring to every 3 months and optimize glycaemic control (Correct Answer)
D. Refer to paediatric nephrology for renal biopsy
E. Commence ACE inhibitor therapy to prevent progression of diabetic nephropathy

Explanation: ***Increase frequency of ACR monitoring to every 3 months and optimize glycaemic control*** - The patient has **persistent microalbuminuria** (ACR 3.8 mg/mmol on two occasions), which is above the normal threshold and indicates the earliest stage of **diabetic nephropathy**. - In pediatric patients, the initial management focus for early diabetic nephropathy is to **intensify monitoring** of ACR and to optimize modifiable risk factors, particularly **glycaemic control** (HbA1c 52 mmol/mol, still with room for improvement) and blood pressure. *Reassure that results are within normal limits and continue annual screening* - An ACR of 3.8 mg/mmol is **abnormally elevated** and signifies early renal damage, therefore, it cannot be considered within normal limits. - Continuing only **annual screening** is insufficient when early signs of kidney involvement are present; more frequent assessment and intervention are warranted. *Arrange renal ultrasound to exclude structural abnormalities* - **Diabetic nephropathy** is a functional complication primarily affecting the microvasculature, and a **renal ultrasound** is not a standard investigation for isolated microalbuminuria in Type 1 Diabetes. - Structural abnormalities are usually investigated only if there are atypical features like **macroscopic hematuria**, rapidly declining **GFR**, or signs of urinary tract obstruction. *Refer to paediatric nephrology for renal biopsy* - A **renal biopsy** is an invasive procedure that is not warranted for the typical presentation of **early diabetic kidney disease** with normal serum creatinine and isolated microalbuminuria. - It is generally reserved for cases where the diagnosis is in doubt or there is suspicion of a **non-diabetic glomerulopathy**. *Commence ACE inhibitor therapy to prevent progression of diabetic nephropathy* - **ACE inhibitors** are typically considered for children with persistent microalbuminuria who also have **hypertension** (blood pressure >95th centile) or progressive albuminuria despite optimization of other risk factors. - This patient's blood pressure (90th centile) is not yet classified as hypertension, making the initiation of pharmacological therapy like ACE inhibitors premature as the initial step.

Question 21: A 10-year-old girl with absence epilepsy has been treated with ethosuximide 500mg daily for 8 months with good seizure control. She now presents with a 2-week history of lethargy, fever, mouth ulcers, and a non-blanching petechial rash on her legs. Blood tests reveal: Hb 68 g/L, WCC 1.8 × 10⁹/L (neutrophils 0.4 × 10⁹/L), platelets 42 × 10⁹/L. What is the most likely diagnosis and immediate management required?

A. Aplastic anaemia secondary to ethosuximide; stop drug immediately and arrange urgent haematology referral (Correct Answer)
B. Immune thrombocytopenic purpura; commence prednisolone and continue ethosuximide
C. Acute lymphoblastic leukaemia; stop ethosuximide and arrange urgent oncology assessment
D. Viral-induced bone marrow suppression; provide supportive care and continue ethosuximide
E. Ethosuximide toxicity; reduce dose by 50% and monitor blood counts weekly

Explanation: ***Aplastic anaemia secondary to ethosuximide; stop drug immediately and arrange urgent haematology referral***- The patient presents with **pancytopenia** (low Hb, WCC, and platelets), which is a rare but life-threatening idiosyncratic reaction to **ethosuximide**.- Clinical features like **lethargy** (anemia), **fever/mouth ulcers** (neutropenia), and **petechiae** (thrombocytopenia) necessitate immediate drug cessation and a **bone marrow examination**.*Immune thrombocytopenic purpura; commence prednisolone and continue ethosuximide*- **Immune thrombocytopenic purpura (ITP)** typically presents with isolated thrombocytopenia, not the **pancytopenia** seen in this patient's blood results.- Prednisolone is used for ITP, but it would not address the **bone marrow failure** caused by drug-induced suppression.*Acute lymphoblastic leukaemia; stop ethosuximide and arrange urgent oncology assessment*- While **Acute lymphoblastic leukaemia (ALL)** can cause pancytopenia and fever, the temporal relationship with **ethosuximide** makes drug-induced aplastic anemia more likely.- ALL often presents with **lymphadenopathy** or **hepatosplenomegaly**, which are not reported in this clinical scenario.*Viral-induced bone marrow suppression; provide supportive care and continue ethosuximide*- Although **viral infections** (like Parvovirus B19) can cause marrow suppression, the risk of continuing a potentially causative drug like **ethosuximide** in the face of severe pancytopenia is too high.- Supportive care alone is insufficient; the offending agent must be **discontinued** to allow for marrow recovery.*Ethosuximide toxicity; reduce dose by 50% and monitor blood counts weekly*- **Idiosyncratic reactions** like aplastic anemia are not dose-dependent; therefore, reducing the dose is inadequate and dangerous.- Severe **neutropenia** (0.4 x 10⁹/L) and thrombocytopenia represent a medical emergency that cannot be managed by simple monitoring.

Question 22: A 7-year-old boy with newly diagnosed type 1 diabetes is being commenced on insulin therapy. His diabetes team explains the different types of insulin available. His regimen will include insulin aspart with meals and insulin detemir at bedtime. The parents ask how quickly the mealtime insulin starts to work. What is the typical onset of action for insulin aspart?

A. 1-2 minutes
B. 30-60 minutes
C. 6-8 hours
D. 10-20 minutes (Correct Answer)
E. 2-4 hours

Explanation: ***10-20 minutes*** - **Insulin aspart** is a **rapid-acting insulin analogue** specifically engineered for quick absorption, with its typical onset of action occurring within **10 to 20 minutes** after subcutaneous injection. - This rapid onset allows it to cover the immediate rise in blood glucose following meals, making it ideal for **mealtime insulin** administration right before or shortly after eating. *1-2 minutes* - This onset timeframe is extremely short and does not align with the **pharmacokinetics** of any currently available subcutaneous insulin, as absorption takes longer. - Even for intravenous insulin, the metabolic effect takes longer to fully manifest compared to this duration. *30-60 minutes* - This duration is characteristic of the onset of **Regular (Soluble) human insulin**, which is a **short-acting insulin**, not a rapid-acting analogue. - Regular insulin requires administration 30-45 minutes before a meal to adequately cover post-prandial glucose excursions, which differs from rapid-acting insulins. *6-8 hours* - This timeframe is typically associated with the **duration of action** for intermediate-acting insulins (like NPH) or the **peak effect** of some longer-acting insulins. - It is far too long for the **onset of action** of any insulin, especially a mealtime insulin, which needs to act quickly. *2-4 hours* - This is the approximate onset of action for **long-acting basal insulins** such as **insulin detemir** (as mentioned in the patient's regimen) or **insulin glargine**. - These insulins provide a sustained background insulin level and are not designed for rapid control of glucose spikes associated with meals.

Question 23: What is the recommended first-line anti-epileptic drug for a 15-year-old girl newly diagnosed with juvenile myoclonic epilepsy?

A. Sodium valproate
B. Levetiracetam (Correct Answer)
C. Carbamazepine
D. Phenytoin
E. Ethosuximide

Explanation: ***Levetiracetam*** - In females of **childbearing potential**, levetiracetam is the preferred first-line agent for **Juvenile Myoclonic Epilepsy (JME)** due to a lower risk of **teratogenicity**. - It provides effective seizure control across the spectrum of seizure types in JME, including **myoclonic jerks** and generalized tonic-clonic seizures. *Sodium valproate* - While traditionally the most effective drug for JME, it is now **contraindicated** in females of childbearing age unless a strict **Pregnancy Prevention Programme** is in place. - Significant risks include **neural tube defects**, neurodevelopmental delay, and **polycystic ovary syndrome (PCOS)**. *Carbamazepine* - This drug is narrow-spectrum and can **paradoxically worsen** myoclonic and absence seizures in patients with generalized epilepsies like JME. - It is primarily indicated for **focal seizures**, and its use in JME can lead to an increase in seizure frequency. *Phenytoin* - Similar to carbamazepine, phenytoin can **exacerbate myoclonic jerks** and absence seizures in primary generalized epilepsy syndromes. - It is not recommended for JME and is associated with long-term side effects like **gingival hyperplasia** and hirsutism. *Ethosuximide* - This agent is specifically used for **absence seizures** and lacks efficacy against the **myoclonic jerks** and generalized tonic-clonic seizures characteristic of JME. - It would leave the patient at high risk for major motor seizures if used as monotherapy in this clinical scenario.

Question 24: A 14-year-old boy with type 1 diabetes for 5 years uses a basal-bolus insulin regimen. Despite regular clinic attendance, his HbA1c has been consistently between 75-82 mmol/mol over the past 18 months. His diabetes team notes he frequently misses morning blood glucose checks and often forgets his lunchtime insulin at school. During consultation, he admits feeling embarrassed about having diabetes in front of his peers and sometimes skips insulin doses to avoid attention. What is the most appropriate initial management approach to improve his glycaemic control?

A. Switch to twice-daily premixed insulin to simplify his regimen and improve compliance
B. Arrange urgent psychology referral to address his emotional wellbeing and coping strategies (Correct Answer)
C. Increase basal insulin dose by 20% to compensate for missed bolus doses
D. Commence continuous glucose monitoring and insulin pump therapy to reduce daily burden
E. Involve school nurse to administer all insulin doses during school hours

Explanation: ***Arrange urgent psychology referral to address his emotional wellbeing and coping strategies*** - The patient admits to **intentional insulin omission** due to **diabetes-related distress** and peer embarrassment, which are primary psychological barriers to management. - Addressing the **psychosocial impact** of a chronic condition during adolescence is critical to improving adherence and long-term glycemic control. *Switch to twice-daily premixed insulin to simplify his regimen and improve compliance* - While this simplifies the schedule, it offers significantly less **glycaemic flexibility** and does not address the underlying **psychological distress** regarding peer perception. - **Premixed insulin** is generally not recommended as a first-line alternative for active adolescents who require the precision of basal-bolus therapy. *Increase basal insulin dose by 20% to compensate for missed bolus doses* - Increasing **basal insulin** to cover missed bolus doses is clinically unsafe and significantly increases the risk of severe **hypoglycaemia**, especially during fasting periods or exercise. - It fails to address the behavioral issue of **missed lunchtime boluses** and avoids the root cause of the patient's non-adherence. *Commence continuous glucose monitoring and insulin pump therapy to reduce daily burden* - **Insulin pump therapy** and **CGM** can increase the visibility of the condition, potentially worsening the patient's feelings of **embarrassment** or being "different." - Advanced technology requires high levels of **engagement** and motivation, which may be absent until the patient's emotional barriers are addressed. *Involve school nurse to administer all insulin doses during school hours* - This approach may further undermine the patient's **autonomy** and increase the feeling of being singled out, potentially exacerbating his **social anxiety**. - It provides a temporary fix for dosing but does not help the adolescent develop the necessary **coping strategies** for self-management as he transitions to adulthood.

Question 25: A 5-year-old girl presents to the emergency department with her first unprovoked seizure. She had a 3-minute episode of right arm jerking that progressed to right leg involvement, with preserved consciousness throughout. After the seizure, she had weakness of the right arm and leg lasting 45 minutes before full recovery. There is no fever, and she is systemically well. Neurological examination is now normal. What investigation finding would most strongly support a diagnosis of benign epilepsy with centrotemporal spikes (benign rolandic epilepsy)?

A. MRI brain showing focal cortical dysplasia in the left frontal lobe
B. CT brain revealing left hemisphere hemiatrophy
C. EEG with hypsarrhythmia pattern
D. EEG demonstrating 3 Hz spike-and-wave discharges activated by hyperventilation
E. EEG showing centrotemporal spikes that increase in frequency during sleep (Correct Answer)

Explanation: ***EEG showing centrotemporal spikes that increase in frequency during sleep*** - The hallmark of **Benign Rolandic Epilepsy (BECTS)** is the presence of high-amplitude **centrotemporal (rolandic) spikes**, which characteristically become more frequent during **non-REM sleep**. - This patient's presentation of a **focal motor seizure** with subsequent **Todd’s paresis** (transient weakness) in a healthy 5-year-old child is classic for this self-limiting syndrome. *MRI brain showing focal cortical dysplasia in the left frontal lobe* - Findings of **focal cortical dysplasia** indicate **structural epilepsy**, which is typically associated with more refractory seizures and requires surgical consideration. - **Benign Rolandic Epilepsy** is an idiopathic syndrome where neuroimaging is characteristically **normal**. *CT brain revealing left hemisphere hemiatrophy* - **Hemiatrophy** of a cerebral hemisphere is indicative of chronic injury or syndromes like **Davidoff-Mason** or **Sturge-Weber**, not a benign epilepsy syndrome. - This child had a **normal neurological examination** after the post-ictal phase, which makes significant structural atrophy highly unlikely. *EEG with hypsarrhythmia pattern* - **Hypsarrhythmia** is the chaotic, high-voltage EEG pattern seen in **West Syndrome** (infantile spasms). - This pattern is seen in **infants** (typically 4–8 months old) and is associated with **developmental regression**, unlike the focal motor seizures seen in this 5-year-old. *EEG demonstrating 3 Hz spike-and-wave discharges activated by hyperventilation* - This EEG pattern is pathognomonic for **Childhood Absence Epilepsy**, which presents with brief **staring spells** and loss of awareness. - **Absence epilepsy** does not typically feature focal motor jerking or **post-ictal weakness (Todd's paresis)** as described in this case.

Question 26: A 12-year-old boy with type 1 diabetes for 6 years attends his annual screening appointment. He is asymptomatic. Fundoscopy reveals small red dots (microaneurysms) and tiny haemorrhages in both retinae, but no cotton wool spots, venous beading, or neovascularization. His HbA1c is 64 mmol/mol (8.0%) and blood pressure is on the 60th centile for age. What is the most appropriate classification and management plan for his retinal findings?

A. Background diabetic retinopathy; continue annual screening and optimize glycaemic control (Correct Answer)
B. Mild non-proliferative retinopathy; refer urgently to ophthalmology for panretinal photocoagulation
C. Pre-proliferative retinopathy; arrange ophthalmology review within 4 weeks
D. Proliferative retinopathy; arrange emergency same-day ophthalmology assessment
E. Non-diabetic retinal changes; investigate for bleeding disorder and continue routine screening

Explanation: ***Background diabetic retinopathy; continue annual screening and optimize glycaemic control*** - This patient presents with **microaneurysms** and **tiny haemorrhages** only, which defines the earliest stage known as **background diabetic retinopathy** (or mild non-proliferative diabetic retinopathy). - Management focuses on **optimizing glycaemic control** (as HbA1c is above target) and maintaining **annual screening**, as there are no vision-threatening features. *Mild non-proliferative retinopathy; refer urgently to ophthalmology for panretinal photocoagulation* - **Panretinal photocoagulation (PRP)** is reserved for **proliferative retinopathy** or very severe non-proliferative cases, not mild background changes. - While "mild NPDR" is a synonymous term for background retinopathy, **urgent referral** is clinically inappropriate for asymptomatic patients with these findings. *Pre-proliferative retinopathy; arrange ophthalmology review within 4 weeks* - **Pre-proliferative retinopathy** is characterized by more advanced signs such as **cotton wool spots**, **venous beading**, or intraretinal microvascular abnormalities (IRMA). - This patient lacks these features of **retinal ischaemia**, making a 4-week urgent review unnecessary at this stage. *Proliferative retinopathy; arrange emergency same-day ophthalmology assessment* - **Proliferative retinopathy** requires the presence of **neovascularization** (new vessel growth) or pre-retinal/vitreous haemorrhage. - Since these high-risk features are absent, an **emergency same-day assessment** is not indicated for this patient. *Non-diabetic retinal changes; investigate for bleeding disorder and continue routine screening* - The presence of **microaneurysms** in a patient with a 6-year history of **Type 1 Diabetes** is a classic sign of diabetic retinopathy, not a bleeding disorder. - Attributing these findings to a **bleeding disorder** would delay the necessary intensification of **diabetes management** and glycaemic optimization.

Question 27: A 9-year-old girl with a 4-year history of epilepsy controlled on sodium valproate presents for routine follow-up. Her mother reports that over the past 6 months, the girl has gained significant weight (BMI increased from 50th to 91st centile), developed increased facial hair, and has irregular periods since menarche 8 months ago. Blood tests reveal: testosterone elevated, LH:FSH ratio 3:1, fasting glucose 5.2 mmol/L, and normal thyroid function. Pelvic ultrasound shows multiple peripheral ovarian follicles bilaterally. What is the most appropriate next step in management?

A. Switch sodium valproate to levetiracetam and provide lifestyle advice (Correct Answer)
B. Commence oral contraceptive pill to regulate menstrual cycles
C. Refer to paediatric endocrinology for further investigation of hyperandrogenism
D. Reduce the dose of sodium valproate by 50% and monitor
E. Add metformin to address insulin resistance and continue valproate

Explanation: ***Switch sodium valproate to levetiracetam and provide lifestyle advice*** - **Sodium valproate** is strongly associated with **weight gain**, **hyperandrogenism**, and the development of **polycystic ovary syndrome (PCOS)**-like features in adolescent girls and women. - Replacing valproate with an alternative like **levetiracetam** is the definitive management step to reverse metabolic side effects and comply with safety guidelines for females of childbearing potential, complemented by **lifestyle advice** for weight management. *Commence oral contraceptive pill to regulate menstrual cycles* - While the **oral contraceptive pill (OCP)** can manage symptoms like irregular periods and hirsutism, it does not address the **underlying metabolic cause** triggered by valproate. - Using OCPs as a primary solution without stopping the causative medication ignores the ongoing risk of **teratogenicity** and potential worsening of **weight gain** associated with valproate. *Refer to paediatric endocrinology for further investigation of hyperandrogenism* - Referral is generally unnecessary as the clinical presentation and history of **valproate use** clearly identify the medication as the primary cause of the **PCOS-like features** (weight gain, hirsutism, elevated testosterone, LH:FSH ratio, polycystic ovaries). - Management of medication-induced hormonal changes should first involve **adjusting the epilepsy treatment** in coordination with a neurologist, rather than seeking further diagnostic investigations. *Reduce the dose of sodium valproate by 50% and monitor* - Reducing the dose is often insufficient to reverse **metabolic and endocrine side effects** fully, and it risks the loss of **seizure control** if the therapeutic threshold is not maintained. - Guidelines recommend **completely avoiding or switching** from valproate in girls and women unless no other alternative exists due to the severe **teratogenic** and endocrine risks, making a dose reduction suboptimal. *Add metformin to address insulin resistance and continue valproate* - **Metformin** may improve insulin sensitivity, but it is not the standard of care for treating **drug-induced PCOS** when a safer anticonvulsant alternative is readily available. - Continuing valproate while adding polypharmacy increases the **side effect burden** and fails to remove the primary stimulus for weight gain, hyperandrogenism, and the significant **teratogenic risk**.

Question 28: A 6-year-old boy with type 1 diabetes mellitus is being transitioned from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump therapy). His parents ask about the primary advantage of this treatment modality. What is the most important benefit of insulin pump therapy compared to multiple daily injections in children with type 1 diabetes?

A. Elimination of the need for blood glucose monitoring
B. Reduced frequency of injection site complications such as lipohypertrophy
C. More physiological insulin delivery with precise basal rate adjustments (Correct Answer)
D. Lower overall daily insulin requirements
E. Complete prevention of hypoglycaemic episodes

Explanation: ***More physiological insulin delivery with precise basal rate adjustments***- Insulin pumps allow for programmable **basal rates** that can be adjusted in very small increments to match the child's fluctuating daily needs, such as the **dawn phenomenon** or physical activity.- This modality mimics the **pancreatic secretion** of insulin more closely than long-acting injections, providing significantly more flexibility in lifestyle and meal planning.*Elimination of the need for blood glucose monitoring*- Insulin pump therapy actually necessitates **more frequent monitoring** or the use of **continuous glucose monitoring (CGM)** to ensure safety and dose accuracy.- Monitoring is critical to detect **catheter occlusions** early, which can rapidly lead to diabetic ketoacidosis due to the lack of long-acting insulin depot.*Reduced frequency of injection site complications such as lipohypertrophy*- While it reduces the number of daily punctures, the **cannula** remains in place for 2-3 days, which can still cause skin irritation or **lipohypertrophy** if sites are not rotated.- Site-related issues like **infections or abscesses** are specifically associated with continuous infusion sets if hygiene or rotation is neglected.*Lower overall daily insulin requirements*- While some patients may see a slight reduction in total units due to improved absorption, a **lower insulin dose** is not the primary clinical goal or advantage of switching to a pump.- The priority remains achieving **glycemic targets** and reducing variability rather than simply minimizing the quantity of insulin used.*Complete prevention of hypoglycaemic episodes*- While pumps can help reduce the frequency of severe events through **precise dosing**, they cannot **completely prevent** hypoglycemia caused by exercise or dosing errors.- The risk of **hypoglycemia** remains present, requiring the patient and caregivers to maintain vigilance and carry fast-acting glucose at all times.

Question 29: A 16-year-old boy with type 1 diabetes for 9 years attends for annual screening. He reports occasional paraesthesia in his feet. Monofilament testing shows reduced sensation in both feet in a stocking distribution. Ankle reflexes are absent bilaterally. Vibration sense is reduced to the level of the malleoli. HbA1c is 82 mmol/mol (9.7%). Urinalysis shows no proteinuria. What is the most appropriate initial investigation to confirm the suspected diagnosis?

A. Nerve conduction studies (Correct Answer)
B. Quantitative sensory testing
C. Skin biopsy for intraepidermal nerve fibre density
D. Sural nerve biopsy
E. MRI of lumbar spine

Explanation: ***Nerve conduction studies***- **Nerve conduction studies (NCS)** are the gold standard initial investigation to objectively confirm the diagnosis of **diabetic peripheral neuropathy**, especially large-fiber involvement indicated by absent ankle reflexes and reduced vibration sense.- They provide objective data on nerve function, allowing assessment of **nerve conduction velocity** and **amplitude**, which are typically reduced in diabetic neuropathy due to axonal loss and demyelination.*Quantitative sensory testing*- This method is primarily a **subjective test** used to quantify sensory thresholds (e.g., vibration, temperature), often employed in research settings rather than as a primary diagnostic tool for typical diabetic neuropathy.- It relies heavily on patient cooperation and perception, making it less objective and reliable than electrophysiological studies for initial confirmation of nerve damage.*Skin biopsy for intraepidermal nerve fibre density*- This investigation is specific for diagnosing **small-fiber neuropathy** by quantifying nerve fiber density in the epidermis.- It is generally considered when clinical suspicion of neuropathy is high but standard **nerve conduction studies are normal**, as small fibers are not assessed by NCS and symptoms here suggest large fiber involvement (absent reflexes).*Sural nerve biopsy*- This is an **invasive procedure** involving the removal of a nerve sample, typically reserved for atypical or rapidly progressive neuropathies where specific causes like **vasculitis**, amyloidosis, or inflammatory demyelinating conditions are suspected.- It is rarely performed for uncomplicated **diabetic peripheral neuropathy** due to its invasiveness and the typical clarity of diagnosis with less invasive methods.*MRI of lumbar spine*- An **MRI of the lumbar spine** is primarily used to investigate **spinal cord compression**, radiculopathy, or other structural pathologies affecting the spinal nerves.- The patient's symptoms (stocking distribution sensory loss, absent ankle reflexes, reduced vibration sense) are characteristic of a **generalized peripheral polyneuropathy** rather than a focal spinal issue.

Question 30: An 8-year-old boy with epilepsy presents to the emergency department with ataxia, nystagmus, and diplopia. He has been taking phenytoin for focal seizures with good control for 18 months. His mother mentions she recently increased his dose because he had a breakthrough seizure last week. Blood tests show phenytoin level of 32 mg/L (therapeutic range 10-20 mg/L), albumin 38 g/L, urea 5.2 mmol/L, creatinine 52 μmol/L. What characteristic of phenytoin pharmacokinetics most likely contributed to this presentation?

A. Linear pharmacokinetics throughout therapeutic range
B. Zero-order kinetics at higher doses (Correct Answer)
C. Extensive first-pass hepatic metabolism
D. High degree of plasma protein binding
E. Rapid renal clearance

Explanation: ***Zero-order kinetics at higher doses*** - Phenytoin exhibits **saturation kinetics**, where metabolic enzymes (CYP2C9/19) become saturated at or just above the therapeutic range, switching from first-order to **zero-order kinetics**. - This means a **fixed amount** of drug is eliminated per unit time, so small dose increases can lead to **disproportionately large increases** in plasma concentration and clinical toxicity (ataxia, nystagmus). *Linear pharmacokinetics throughout therapeutic range* - Linear or **first-order kinetics** involve elimination of a constant fraction of the drug, which would result in predictable, proportional level increases. - Phenytoin is unique because it specifically lacks **linear pharmacokinetics** at higher therapeutic concentrations, making its dosing dangerous without monitoring. *Extensive first-pass hepatic metabolism* - **First-pass metabolism** affects bioavailability (the amount of drug reaching systemic circulation) after oral administration but does not explain toxicity from a dose increase in a stable patient. - Phenytoin actually has **good oral bioavailability**, and its toxicity is driven by elimination failure due to enzyme saturation, not initial metabolism. *High degree of plasma protein binding* - While phenytoin is **90% protein-bound** to albumin, this property usually causes toxicity issues during **hypoalbuminemia** or drug displacements, which are not present here (albumin is normal). - **Protein binding** does not explain why a simple dose increase would lead to such a massive rise in serum levels compared to saturation kinetics. *Rapid renal clearance* - Phenytoin is primarily eliminated via **hepatic metabolism** to inactive metabolites, not through **rapid renal clearance**. - Only a very small percentage of phenytoin is excreted unchanged in the urine; therefore, renal function has a minimal impact on its primary clearance pathway.

Question 31: A 11-year-old boy with type 1 diabetes for 4 years uses an insulin pump delivering a total daily dose of 32 units. His basal rates are appropriately configured. He is about to eat lunch containing 60 grams of carbohydrate. His pre-lunch blood glucose is 13.2 mmol/L and his target is 6.0 mmol/L. His insulin-to-carbohydrate ratio is 1:15 and his insulin sensitivity factor is 1 unit lowers glucose by 3 mmol/L. What is the correct total bolus insulin dose?

A. 4 units
B. 6.4 units (Correct Answer)
C. 8 units
D. 10.4 units
E. 12 units

Explanation: ***6.4 units***- The total bolus dose is calculated by adding the **carbohydrate dose** (60g / 15 = **4 units**) and the **correction dose** ((13.2 mmol/L - 6.0 mmol/L) / 3 = **2.4 units**).- Summing these components (4 + 2.4) results in a total of **6.4 units**, representing the accurate insulin needed to cover both the meal and the hyperglycemia.*4 units*- This value represents only the **carbohydrate coverage** (60 / 15) without addressing the patient's elevated **pre-meal blood glucose**.- Using this dose would leave the glucose level significantly above the **target of 6.0 mmol/L**.*8 units*- This incorrect value likely stems from a calculation error in the **insulin sensitivity factor** or the **carbohydrate ratio**.- It does not follow the medical formula for combining **bolus insulin** and **correction factors** provided in the clinical data.*10.4 units*- This dose is an **overestimate** that could lead to severe **hypoglycemia** in an 11-year-old patient.- It may occur if the **total daily dose** (32 units) is incorrectly utilized in the formula instead of the specific ratios provided.*12 units*- This value is significantly higher than required and suggests a fundamental error in applying the **1:15 carbohydrate ratio**.- Routine administration of incorrect doses of this magnitude poses a high risk for **iatrogenic hypoglycemic events**.

Question 32: A 15-year-old girl with juvenile myoclonic epilepsy controlled on sodium valproate 800 mg twice daily for 3 years is seen in clinic. She has been seizure-free for 2 years. She mentions she is sexually active and wants to discuss contraception. Her weight is 68 kg and BMI is 24 kg/m². She has no other medical conditions. What is the most appropriate advice regarding contraception?

A. Combined oral contraceptive pill is safe and effective
B. Progesterone-only pill will provide adequate contraception
C. Intrauterine device is the most appropriate option (Correct Answer)
D. Depot medroxyprogesterone injection should be avoided
E. Subdermal implant (etonogestrel) is contraindicated

Explanation: ***Intrauterine device is the most appropriate option*** - **Sodium valproate** is highly **teratogenic**, causing neurodevelopmental delays and major malformations; therefore, the most reliable contraception is required for women of childbearing potential. - An **Intrauterine Device (IUD)** offers the highest efficacy (Long-Acting Reversible Contraception) and is not affected by drug-drug interactions, ensuring the **Pregnancy Prevention Programme** requirements are met. *Combined oral contraceptive pill is safe and effective* - While not pharmacologically contraindicated because valproate is not a strong **enzyme inducer**, the **typical-use failure rate** of the pill is too high given the extreme risks of valproate exposure. - Use of the COCP/POP is generally discouraged as a standalone method in patients on valproate due to the risk of **unplanned pregnancy**. *Progesterone-only pill will provide adequate contraception* - The **Progesterone-only pill (POP)** is highly user-dependent and has a higher failure rate compared to **LARC** methods like the IUD. - In the context of **valproate therapy**, methods requiring daily compliance are less suitable than long-acting options to prevent **teratogenicity**. *Depot medroxyprogesterone injection should be avoided* - This statement is incorrect as the **Depot medroxyprogesterone injection** is a reliable long-acting contraceptive that is not affected by valproate. - It is actually a recommended option for women on valproate if they prefer it over an **intrauterine device** or implant. *Subdermal implant (etonogestrel) is contraindicated* - The **subdermal implant** is not contraindicated; it is actually a highly effective **LARC** method suitable for patients on valproate. - Since valproate is not an **enzyme-inducing** anti-epileptic drug, it does not reduce the contraceptive efficacy of the etonogestrel implant.

Question 33: A 4-year-old boy with newly diagnosed type 1 diabetes is being started on insulin therapy. His weight is 16 kg. The diabetes team plans to commence a basal-bolus regimen. Using a standard starting total daily insulin dose of 0.5 units/kg/day, with 50% as basal insulin and 50% divided between three meals, what is the appropriate starting dose of rapid-acting insulin for each main meal?

A. 1.3 units (Correct Answer)
B. 2 units
C. 2.7 units
D. 4 units
E. 8 units

Explanation: ***1.3 units***- The **Total Daily Dose (TDD)** is calculated as 16 kg × 0.5 units/kg/day, equaling **8 units** of insulin per day.- The **bolus insulin** total is 50% of the TDD (4 units), which, when divided by **three meals**, results in approximately **1.3 units** per meal.*2 units*- This dose would lead to a total of 6 units of rapid-acting insulin per day (2 units × 3 meals), which exceeds the calculated **50% bolus allocation** of 4 units.- Administering 2 units per meal would disproportionately increase **prandial insulin** relative to basal insulin.*2.7 units*- This calculation incorrectly divides the **entire Total Daily Dose (8 units)** across the three meals, neglecting the crucial need for **basal insulin**.- Such a regimen would leave the patient without **long-acting insulin coverage**, leading to uncontrolled blood glucose between meals and overnight.*4 units*- This amount represents the **total daily bolus insulin** (50% of TDD) or the total daily basal insulin, not the dose for a single meal.- Administering 4 units of rapid-acting insulin at each of the three main meals would result in 12 units of bolus insulin, significantly **exceeding the TDD** of 8 units.*8 units*- This is the **Total Daily Dose (TDD)** for the patient, representing the total insulin needed over 24 hours.- Giving 8 units of rapid-acting insulin for a single meal would cause severe and potentially life-threatening **hypoglycemia**.

Question 34: A 10-year-old girl with refractory epilepsy is being evaluated for surgical intervention. MRI brain shows focal cortical dysplasia in the left frontal lobe. Video-EEG telemetry confirms seizure onset from this region, with semiology consistent with left frontal focus. Neuropsychological testing shows verbal IQ of 95 and performance IQ of 88. Functional MRI indicates language dominance in the left hemisphere. What is the most critical additional investigation before considering surgical resection?

A. Wada test (intracarotid amobarbital procedure) (Correct Answer)
B. Magnetoencephalography (MEG)
C. PET scan with fluorodeoxyglucose
D. Repeat MRI with higher resolution sequences
E. Single-photon emission computed tomography (SPECT)

Explanation: ***Wada test (intracarotid amobarbital procedure)*** - Given the **left frontal seizure focus** and confirmed **left hemisphere language dominance**, the **Wada test** is critical to precisely map **language and memory functions** relative to the planned resection area. - It assesses the functional capacity of the **contralateral (right) hemisphere**, thereby predicting the risk of **post-operative aphasia** or memory deficits by temporarily inactivating one side. *Magnetoencephalography (MEG)* - **MEG** is a non-invasive technique that localizes the **epileptogenic zone** by mapping magnetic fields produced by neuronal activity, offering high spatial resolution. - However, the **seizure focus** is already well-defined by **MRI** and **video-EEG**, and MEG does not assess the **functional risk to eloquent cortex** or the language/memory reserve. *PET scan with fluorodeoxyglucose* - **FDG-PET** is primarily used to identify areas of **interictal hypometabolism** to help localize the **epileptogenic zone**, especially in MRI-negative cases. - In this patient, the **focal cortical dysplasia** is clearly visible on MRI and confirmed by video-EEG, so further metabolic localization isn't the most critical next step for surgical planning related to language. *Repeat MRI with higher resolution sequences* - A repeat **MRI** with higher resolution aims to provide more detailed **anatomical information** about the **focal cortical dysplasia** lesion. - While useful for surgical planning, the fundamental lesion and its relationship to the seizure focus are already established, and this investigation does not address the crucial question of **functional language lateralization**. *Single-photon emission computed tomography (SPECT)* - **Ictal SPECT** is used to localize the **seizure onset zone** by detecting increased cerebral blood flow during a seizure, typically in cases where other localization methods are inconclusive. - This study is primarily a **localization tool** and does not provide the necessary **functional assessment of language and memory lateralization** vital for safely operating on a dominant frontal lobe.

Question 35: A 13-year-old boy with type 1 diabetes for 6 years is commenced on an ACE inhibitor for persistent microalbuminuria. Three months later, his blood tests show: sodium 138 mmol/L, potassium 5.8 mmol/L, urea 8.2 mmol/L, creatinine 95 μmol/L. He is asymptomatic and his blood pressure is 118/72 mmHg. ECG shows normal sinus rhythm with peaked T waves. What is the most appropriate immediate management?

A. Stop ACE inhibitor and repeat electrolytes in 1 week (Correct Answer)
B. Continue ACE inhibitor and add calcium resonium
C. Continue ACE inhibitor and repeat electrolytes in 3 months
D. Stop ACE inhibitor and arrange urgent haemodialysis
E. Stop ACE inhibitor and administer IV calcium gluconate

Explanation: ***Stop ACE inhibitor and repeat electrolytes in 1 week***- This patient has developed **moderate hyperkalaemia** (K+ 5.8 mmol/L) following the initiation of an **ACE inhibitor**, which inhibits aldosterone-mediated potassium excretion.- Given the potassium level and the presence of **peaked T waves** on ECG, the most appropriate immediate action is to **withdraw the offending agent** and monitor for resolution within a week.*Continue ACE inhibitor and add calcium resonium*- Continuing the **ACE inhibitor** would perpetuate or worsen the hyperkalaemia, posing a significant cardiac risk.- **Calcium resonium** (a potassium binder) is not the first-line treatment for drug-induced hyperkalaemia where the causative agent can be easily removed.*Continue ACE inhibitor and repeat electrolytes in 3 months*- Waiting three months to recheck electrolytes is dangerously long as **hyperkalaemia** can rapidly progress to severe cardiac arrhythmias or arrest.- Any potassium level above the normal range, especially when associated with ECG changes, warrants prompt intervention and closer monitoring.*Stop ACE inhibitor and arrange urgent haemodialysis*- **Haemodialysis** is an extreme measure reserved for **severe, refractory hyperkalaemia** (typically >6.5-7.0 mmol/L) or patients with **end-stage renal disease**.- The patient's potassium level (5.8 mmol/L) and creatinine (95 μmol/L) do not indicate the severity that would necessitate urgent dialysis.*Stop ACE inhibitor and administer IV calcium gluconate*- **IV calcium gluconate** is primarily used for **severe hyperkalaemia** (typically K+ >6.5 mmol/L) or with more pronounced cardiac toxicity (e.g., QRS widening, absent P waves) to stabilize myocardial membranes.- While peaked T waves are present, the potassium level of 5.8 mmol/L is better managed initially by **removing the precipitating factor** rather than immediate membrane stabilization.

Question 36: A 7-year-old boy with focal epilepsy has been taking carbamazepine 200 mg twice daily for 14 months with good seizure control. He now presents with a 5-day history of fever, sore throat, and lethargy. Examination reveals cervical lymphadenopathy and pharyngeal erythema. Blood tests show: Hb 68 g/L, WBC 1.8 × 10⁹/L (neutrophils 0.4 × 10⁹/L), platelets 42 × 10⁹/L. What is the most likely diagnosis?

A. Infectious mononucleosis
B. Acute lymphoblastic leukaemia
C. Carbamazepine-induced aplastic anaemia (Correct Answer)
D. Viral-induced bone marrow suppression
E. Immune thrombocytopenic purpura

Explanation: ***Carbamazepine-induced aplastic anaemia*** - **Carbamazepine** is a known cause of idiosyncratic bone marrow suppression, leading to **pancytopenia** (low Hb, WBC, and platelets) which matches the patient's blood test results. - The fever and sore throat are symptoms of severe **neutropenia** (0.4 × 10⁹/L), making the patient highly susceptible to infections. *Infectious mononucleosis* - While presenting with fever, sore throat, and **lymphadenopathy**, it typically causes **lymphocytosis** and atypical lymphocytes, not severe pancytopenia. - **Splenomegaly** is a common finding in mononucleosis, which is not mentioned in this patient's presentation. *Acute lymphoblastic leukaemia* - Can cause **pancytopenia** due to bone marrow infiltration, but often presents with a high **WBC count** due to circulating blasts. - The strong temporal association with long-term **carbamazepine therapy** makes drug-induced bone marrow failure a more direct and likely cause. *Viral-induced bone marrow suppression* - Viral infections can cause transient marrow suppression, but the severe and global **pancytopenia** (Hb 68 g/L, severe neutropenia, severe thrombocytopenia) is more consistent with severe **aplastic anaemia**. - **Carbamazepine** is a well-documented cause of severe aplastic anaemia, which would be the primary concern given the drug history. *Immune thrombocytopenic purpura* - This condition is characterized by **isolated thrombocytopenia**, often presenting with bruising or bleeding. - The patient's significant **anemia** and severe **neutropenia** exclude isolated thrombocytopenia as the diagnosis.

Question 37: A 12-year-old girl with type 1 diabetes for 5 years presents with a 6-week history of intermittent abdominal pain, bloating, and alternating constipation and diarrhoea. She has lost 2 kg in weight. Her HbA1c is 68 mmol/mol (8.4%). Examination reveals mild abdominal distension but is otherwise unremarkable. Coeliac serology shows tissue transglutaminase IgA antibody titre of 85 U/mL (normal <20) and total IgA is normal. What is the most appropriate next investigation?

A. Upper gastrointestinal endoscopy with duodenal biopsies (Correct Answer)
B. Faecal elastase measurement
C. Small bowel MRI
D. Colonoscopy with biopsies
E. Trial of gluten-free diet for 6 weeks

Explanation: ***Upper gastrointestinal endoscopy with duodenal biopsies*** - Histological confirmation is required to diagnose **Coeliac disease** in this patient, as her **tissue transglutaminase (tTG) IgA** titre is elevated but less than 10 times the upper limit of normal. - Biopsies typically reveal **villous atrophy**, **crypt hyperplasia**, and increased **intraepithelial lymphocytes**, which are necessary to confirm the diagnosis before lifelong dietary changes. *Faecal elastase measurement* - This test is used to assess **exocrine pancreatic insufficiency**, which is not the primary suspicion given the positive **tTG antibodies**. - While diabetes can have pancreatic associations, the clinical presentation and serology point specifically toward **Coeliac disease**. *Small bowel MRI* - **MRI enterography** is useful for assessing transmural inflammation in **Crohn's disease** but is not a diagnostic tool for Coeliac disease. - It cannot provide the **mucosal histology** required to identify the microscopic changes of gluten-sensitive enteropathy. *Colonoscopy with biopsies* - This procedure visualizes the large bowel and terminal ileum, whereas Coeliac disease primarily affects the **duodenum** and **proximal jejunum**. - It would be more appropriate if **Inflammatory Bowel Disease (IBD)** was the leading differential, but the serology here indicates a small bowel pathology. *Trial of gluten-free diet for 6 weeks* - A **gluten-free diet** should never be started before a definitive biopsy is performed, as it can lead to **mucosal healing** and false-negative results. - Diagnostic guidelines require the patient to remain on a **gluten-containing diet** until all diagnostic investigations are complete.

Question 38: What is the typical EEG finding characteristic of juvenile myoclonic epilepsy?

A. 3 Hz spike-and-wave discharges
B. 4-6 Hz polyspike-and-wave discharges (Correct Answer)
C. Hypsarrhythmia
D. Centrotemporal spikes
E. Periodic lateralized epileptiform discharges

Explanation: ***4-6 Hz polyspike-and-wave discharges***- This generalized pattern is the hallmark of **Juvenile Myoclonic Epilepsy (JME)** and is often precipitated by **photic stimulation** or sleep deprivation.- The pattern correlates with clinical **myoclonic jerks** that typically occur shortly after awakening in adolescent patients.*3 Hz spike-and-wave discharges*- This finding is classic for **Childhood Absence Epilepsy**, which typically presents with brief staring spells rather than myoclonic jerks.- The frequency in JME is characteristically faster (**greater than 3 Hz**) and involves multiple spikes (polyspikes).*Hypsarrhythmia*- This chaotic, high-voltage pattern with multifocal spikes is diagnostic of **West Syndrome** (infantile spasms), which occurs in infants.- It is a much more disorganized background compared to the discrete discharges seen in **JME**.*Centrotemporal spikes*- These are characteristic of **Self-limited Epilepsy with Centrotemporal Spikes** (formerly Benign Rolandic Epilepsy), which presents in childhood.- These discharges are **focal** rather than generalized and are typically activated during sleep.*Periodic lateralized epileptiform discharges*- Also known as **PLEDs**, these suggest an acute focal structural brain injury such as **herpes simplex encephalitis** or a stroke.- They represent a localized cortical irritability rather than the **idiopathic generalized epilepsy** syndrome seen in JME.

Question 39: A 5-year-old girl is brought to the emergency department having had a witnessed tonic-clonic seizure lasting 8 minutes at home. On arrival, she is still seizing. She has no previous history of epilepsy. Initial management with buccal midazolam 7.5 mg has been given by the paramedics 5 minutes ago. She is now 13 minutes into the seizure. What is the most appropriate immediate next step?

A. Administer rectal diazepam 10 mg
B. Administer intravenous lorazepam 0.1 mg/kg (Correct Answer)
C. Administer intravenous phenytoin 20 mg/kg
D. Administer intravenous phenobarbital 20 mg/kg
E. Prepare for rapid sequence intubation

Explanation: ***Administer intravenous lorazepam 0.1 mg/kg*** - According to **APLS guidelines**, if a seizure continues 5–10 minutes after a first dose of a **benzodiazepine** (like buccal midazolam), a second dose should be administered using **IV lorazepam** if access is available. - This patient is in **established status epilepticus** (seizure > 5 minutes) and requires the most effective and rapid-acting intravenous benzodiazepine to terminate the activity. *Administer rectal diazepam 10 mg* - **Rectal diazepam** is an alternative first or second-line treatment only if **intravenous access** cannot be established or in a community setting. - Since the patient is in the **Emergency Department**, intravenous access should be prioritized to deliver more reliable titration of medication. *Administer intravenous phenytoin 20 mg/kg* - **Phenytoin** is considered a **second-stage/third-line agent** used for refractory status epilepticus after two doses of benzodiazepines have failed. - Administering this now would be premature as the **benzodiazepine algorithm** has not yet been completed (only one dose given so far). *Administer intravenous phenobarbital 20 mg/kg* - **Phenobarbital** is typically reserved for **refractory status epilepticus** or specific scenarios like neonatal seizures. - It is not the immediate next step after a single failed dose of **buccal midazolam** in a 5-year-old following standard protocols. *Prepare for rapid sequence intubation* - **Rapid sequence intubation (RSI)** is indicated in the **refractory stage** of status epilepticus if the seizure lasts beyond 30-60 minutes or if there is respiratory failure. - At 13 minutes, the priority remains pharmacological termination of the seizure with **benzodiazepines** followed by anticonvulsant infusions before moving to anesthesia.

Question 40: A 14-year-old boy with type 1 diabetes for 7 years attends for routine screening. Fundoscopy reveals multiple cotton wool spots and flame haemorrhages in both eyes with venous beading and intraretinal microvascular abnormalities. Visual acuity is 6/9 bilaterally. His HbA1c is 76 mmol/mol (9.1%) and blood pressure is 138/86 mmHg. What stage of diabetic retinopathy is present?

A. Background diabetic retinopathy
B. Mild non-proliferative diabetic retinopathy
C. Moderate non-proliferative diabetic retinopathy
D. Severe non-proliferative diabetic retinopathy (Correct Answer)
E. Proliferative diabetic retinopathy

Explanation: ***Severe non-proliferative diabetic retinopathy*** - The presence of **venous beading** and **intraretinal microvascular abnormalities (IRMA)** in the fundoscopy findings are hallmarks of severe non-proliferative diabetic retinopathy. - These specific signs, along with **cotton wool spots** and **flame hemorrhages**, indicate significant retinal ischemia and fulfill the criteria of the **4-2-1 rule** for high-risk progression. *Background diabetic retinopathy* - This stage typically only includes **microaneurysms** and occasional **dot/blot hemorrhages**. - It lacks the more advanced signs of retinal ischemia such as **venous beading**, **IRMA**, or **cotton wool spots**. *Mild non-proliferative diabetic retinopathy* - Characterized by the presence of at least one **microaneurysm** and potentially some dot/blot hemorrhages. - This stage does not feature the widespread **microvascular abnormalities** or **venous beading** observed in the patient. *Moderate non-proliferative diabetic retinopathy* - This stage includes more extensive **hemorrhages** and **microaneurysms** than mild NPDR, and may have **cotton wool spots**. - However, it does not meet the specific criteria of the **4-2-1 rule**, such as **venous beading** in two or more quadrants or **IRMA** in at least one quadrant, which are present here. *Proliferative diabetic retinopathy* - The defining feature of this stage is the presence of **neovascularization** (new vessel growth) on the retina or optic disc, or **vitreous hemorrhage**. - While the patient has severe ischemia, the absence of **new vessel formation** means the disease has not yet progressed to the proliferative stage.

Question 41: A 6-year-old girl with childhood absence epilepsy has been treated with ethosuximide 250 mg twice daily for 8 months with good seizure control. Her mother reports no seizures for the past 6 months. However, the child has now developed three generalized tonic-clonic seizures over the past month. EEG shows 3 Hz spike-and-wave discharges. What is the most appropriate management?

A. Continue ethosuximide and add lamotrigine
B. Switch from ethosuximide to carbamazepine
C. Continue ethosuximide and add phenytoin
D. Switch from ethosuximide to sodium valproate (Correct Answer)
E. Increase the dose of ethosuximide

Explanation: ***Switch from ethosuximide to sodium valproate*** - **Ethosuximide** is a narrow-spectrum anticonvulsant effective only for **absence seizures** and provides no protection against **generalized tonic-clonic seizures (GTCS)**. - **Sodium valproate** is a **broad-spectrum anticonvulsant** and the drug of choice for patients presenting with both **absence seizures** and **GTCS**, as it effectively treats both seizure types. *Continue ethosuximide and add lamotrigine* - While **lamotrigine** has activity against both seizure types, **sodium valproate** is generally considered first-line for mixed absence and GTCS, prioritizing **monotherapy** over polytherapy. - Using multiple antiepileptic drugs increases the risk of **drug-drug interactions** and adverse side effects in a pediatric patient. *Switch from ethosuximide to carbamazepine* - **Carbamazepine** is contraindicated in primary generalized epilepsies, as it can **exacerbate absence seizures** and worsen the characteristic **3 Hz spike-and-wave discharges** on EEG. - It is primarily used for **focal seizures** and is unsuitable for generalized epilepsy syndromes like childhood absence epilepsy. *Continue ethosuximide and add phenytoin* - **Phenytoin**, similar to carbamazepine, can **aggravate absence seizures** and is not indicated for the management of generalized pediatric epilepsy syndromes. - It also carries a significant side-effect profile, including **gingival hyperplasia** and hirsutism, making it an unfavorable choice for a young girl. *Increase the dose of ethosuximide* - Increasing the dose of **ethosuximide** will not address the new **generalized tonic-clonic seizures**, as its mechanism of action is specific to **T-type calcium channels** relevant only to absence pathology. - The patient's absence seizures are already well-controlled; the clinical problem is the development of a **new seizure type** requiring broad-spectrum coverage.

Question 42: A 9-year-old boy with type 1 diabetes mellitus presents to clinic for his annual review. His mother reports he has been experiencing nocturnal sweating and occasional nightmares over the past 3 months. His HbA1c today is 42 mmol/mol (6.0%). His insulin regimen consists of insulin glargine 18 units once daily at bedtime and insulin aspart with meals. Blood glucose monitoring shows pre-breakfast readings between 4.2-5.8 mmol/L. What is the most appropriate initial management?

A. Reassure that nocturnal symptoms are normal at this age
B. Reduce the dose of bedtime insulin glargine
C. Increase the dose of bedtime insulin glargine
D. Perform 3am blood glucose monitoring (Correct Answer)
E. Switch from insulin glargine to NPH insulin

Explanation: ***Perform 3am blood glucose monitoring*** - The patient presents with symptoms highly suggestive of **nocturnal hypoglycemia** (sweating, nightmares) followed by a potential **Somogyi effect** (rebound glucose response). - Monitoring glucose at **3 AM** is the critical first step to differentiate between the **Somogyi effect** and the **Dawn phenomenon** before making treatment adjustments. *Reassure that nocturnal symptoms are normal at this age* - Symptoms like **nocturnal sweating** and **nightmares** in a patient with **Type 1 Diabetes** should never be dismissed as normal variation. - These are classic clinical signals of **counter-regulatory hormone** release in response to low blood sugar during sleep. *Reduce the dose of bedtime insulin glargine* - While reducing the **basal insulin** may ultimately be the treatment, it should not be done without **biochemical confirmation** of hypoglycemia. - Making dosage changes based solely on subjective symptoms without **3 AM glucose data** may lead to suboptimal glycemic control. *Increase the dose of bedtime insulin glargine* - Increasing the **insulin glargine** dose is dangerous as it would significantly worsen the risk of **severe nocturnal hypoglycemia** and potential seizures. - This action is only appropriate for the **Dawn phenomenon**, which must first be distinguished from the Somogyi effect via monitoring. *Switch from insulin glargine to NPH insulin* - **NPH insulin** has a more pronounced peak than **insulin glargine**, which often actually increases the risk of **nocturnal hypoglycemia**. - Switching to a less stable basal insulin would be counterproductive and does not address the immediate need for **diagnostic clarity**.

Question 43: An 11-year-old girl with newly diagnosed type 1 diabetes is being commenced on a basal-bolus insulin regimen. Her parents are being educated about 'sick day rules' for managing intercurrent illness. Which of the following statements represents the most important principle in sick day management?

A. Stop all insulin during illness to prevent hypoglycaemia from reduced oral intake
B. Double all insulin doses during illness due to insulin resistance
C. Continue basal insulin at usual doses and adjust rapid-acting insulin based on blood glucose and ketone monitoring (Correct Answer)
D. Switch to a sliding scale insulin regimen during any intercurrent illness
E. Reduce basal insulin by 50% and give rapid-acting insulin only if blood glucose exceeds 15 mmol/L

Explanation: ***Continue basal insulin at usual doses and adjust rapid-acting insulin based on blood glucose and ketone monitoring*** - Insulin should **never be stopped** during illness even if oral intake is reduced, as stress hormones increase insulin resistance and stimulate **ketogenesis**. - Maintaining **basal insulin** prevents metabolic decompensation, while frequent monitoring of blood glucose and **ketones** allows for safe, reactive dosing of rapid-acting insulin. *Stop all insulin during illness to prevent hypoglycaemia from reduced oral intake* - This is a dangerous misconception; stopping insulin can rapidly precipitate **Diabetic Ketoacidosis (DKA)** due to lack of suppression of fatty acid oxidation. - Regardless of food intake, the body requires **basal insulin** to manage hepatic glucose production and prevent **ketone** buildup during stress. *Double all insulin doses during illness due to insulin resistance* - Indiscriminately doubling doses creates a significant risk of **hypoglycaemia**, as insulin requirements vary widely depending on the severity and type of illness. - Dose adjustments must be tailored based on real-time **blood glucose** levels and the presence of **ketones** rather than a fixed multiplier. *Switch to a sliding scale insulin regimen during any intercurrent illness* - **Sliding scale** regimens are less effective than basal-bolus methods for maintaining stable glycemic control and are typically reserved for **inpatient settings**. - Outpatient management focuses on preserving the physiological **basal-bolus** foundation while providing supplemental "correction" doses as needed. *Reduce basal insulin by 50% and give rapid-acting insulin only if blood glucose exceeds 15 mmol/L* - Reducing basal insulin significantly increases the risk of **ketosis**, even if blood glucose levels do not appear excessively high. - Waiting until glucose reaches **15 mmol/L** is often too late to prevent metabolic distress; frequent proactive monitoring is the gold standard of **sick day management**.

Question 44: A 16-year-old girl with type 1 diabetes for 9 years presents with a 4-month history of episodic dizziness on standing, particularly in the morning. She reports her heart races when she stands up. Lying blood pressure is 105/65 mmHg with heart rate 72 bpm; after standing for 3 minutes, blood pressure is 100/68 mmHg with heart rate 110 bpm. Her HbA1c is 78 mmol/mol. Examination reveals reduced sensation to light touch in both feet in a stocking distribution. What is the most likely underlying pathophysiological mechanism for her symptoms?

A. Impaired baroreceptor sensitivity with reduced sympathetic vasoconstrictor response (Correct Answer)
B. Reduced circulating blood volume from poor glycaemic control causing dehydration
C. Adrenal insufficiency from autoimmune polyglandular syndrome
D. Postural orthostatic tachycardia syndrome (POTS) unrelated to diabetes
E. Cardiac autonomic neuropathy with impaired cardiac output on standing

Explanation: ***Impaired baroreceptor sensitivity with reduced sympathetic vasoconstrictor response*** - The patient exhibits features of **diabetic autonomic neuropathy**, where damaged nerves fail to trigger the necessary **sympathetic vasoconstriction** required to maintain blood pressure upon standing. - Reduced **baroreceptor sensitivity** leads to postural dizziness; the observed **compensatory tachycardia** (heart rate increase >38 bpm) indicates that while the vascular response is impaired, the cardiac sympathetic reflex is still partially active. *Reduced circulating blood volume from poor glycaemic control causing dehydration* - While **osmotic diuresis** from high glucose levels can cause dehydration, it usually presents with more acute systemic symptoms rather than a 4-month episodic postural pattern. - The presence of **stocking-distribution sensory loss** strongly favors a chronic neuroopathic etiology, specifically **diabetic neuropathy**, over simple volume depletion. *Adrenal insufficiency from autoimmune polyglandular syndrome* - **Adrenal insufficiency** typically presents with significant **hyponatremia**, hyperkalemia, and skin hyperpigmentation, which are not mentioned here. - In this condition, one would expect a more profound decrease in **blood pressure** and systemic fatigue rather than isolated postural symptoms alongside peripheral nerve damage. *Postural orthostatic tachycardia syndrome (POTS) unrelated to diabetes* - **POTS** is characterized by a heart rate increase of >40 bpm in adolescents without a significant drop in **blood pressure** (orthostatic hypotension). - This patient's long-standing **Type 1 Diabetes** and concurrent **peripheral neuropathy** make diabetic complications a significantly more likely cause than a primary POTS diagnosis. *Cardiac autonomic neuropathy with impaired cardiac output on standing* - **Cardiac autonomic neuropathy** usually manifests as a **fixed heart rate** or a blunt tachycardic response due to vagal and sympathetic denervation. - In this case, the heart rate increases significantly from 72 to 110 bpm, suggesting that **cardiac output** compensation is attempting to occur, despite the failure of the peripheral vasculature.

Question 45: A 4-year-old boy with epilepsy has been taking phenobarbital for 18 months following several generalized tonic-clonic seizures. His seizures are now well-controlled but his parents and nursery staff report significant behavioural changes including hyperactivity, aggression, and poor concentration affecting his development. What property of phenobarbital best explains these adverse behavioural effects?

A. Inhibition of GABA reuptake causing paradoxical excitation in children
B. Enhancement of GABAergic transmission affecting frontal lobe executive function (Correct Answer)
C. Induction of hepatic enzymes affecting neurotransmitter metabolism
D. Blockade of NMDA receptors impairing cognitive development
E. Dopamine antagonism in the prefrontal cortex

Explanation: ***Enhancement of GABAergic transmission affecting frontal lobe executive function***- Phenobarbital acts as an allosteric modulator of **GABA-A receptors**, increasing the duration of chloride channel opening to suppress seizures.- In pediatric patients, this widespread enhancement can disrupt **frontal lobe function**, leading to **paradoxical hyperactivity**, aggression, and impaired executive control.*Inhibition of GABA reuptake causing paradoxical excitation in children*- Phenobarbital enhances the **postsynaptic response** to GABA; it does not inhibit the **GAT-1 transporter** responsible for GABA reuptake.- While "paradoxical excitation" describes the clinical observation, the underlying mechanism is receptor modulation rather than **reuptake inhibition**.*Induction of hepatic enzymes affecting neurotransmitter metabolism*- Phenobarbital is a potent inducer of the **CYP450 enzyme system**, primarily affecting the metabolism of other medications and endogenous steroids.- While enzyme induction causes many **drug-drug interactions**, it is not the primary mechanism behind the **behavioral and cognitive** side effects seen in children.*Blockade of NMDA receptors impairing cognitive development*- **NMDA receptor** antagonism is more characteristic of medications like ketamine or certain effects of felbamate, rather than barbiturates.- Although high doses may have mild effects on various ion channels, the primary sedative and behavioral profile is driven by **GABAergic** rather than **glutamatergic** pathways.*Dopamine antagonism in the prefrontal cortex*- Dopamine antagonism is the hallmark mechanism of **antipsychotic medications**, not barbiturate anticonvulsants.- Phenobarbital lacks significant affinity for **D2 receptors**, and its behavioral side effects are distinct from the extrapyramidal or sedative effects of dopamine blockade.

Question 46: A 13-year-old boy with type 1 diabetes presents to the emergency department with vomiting and abdominal pain. Blood glucose is 24 mmol/L. Blood gas shows pH 7.28, bicarbonate 14 mmol/L, and blood ketones 4.2 mmol/L. He is alert and oriented. According to current DKA management guidelines for children, what is the most appropriate initial fluid resuscitation?

A. 10 ml/kg 0.9% sodium chloride bolus over 30 minutes, then maintenance fluids with potassium (Correct Answer)
B. 20 ml/kg 0.9% sodium chloride bolus rapidly over 15 minutes, then reassess
C. Start insulin infusion immediately without fluid bolus to correct hyperglycaemia
D. 10 ml/kg 0.45% sodium chloride with 5% dextrose over 1 hour
E. 20 ml/kg Hartmann's solution bolus over 30 minutes

Explanation: ***10 ml/kg 0.9% sodium chloride bolus over 30 minutes, then maintenance fluids with potassium***- This approach aligns with current DKA guidelines for children (e.g., BSPED, ISPAD), recommending a cautious **10 ml/kg 0.9% sodium chloride** bolus over 30-60 minutes for children not in **circulatory shock** (the boy is alert).- Following this initial bolus, **maintenance fluids** with **potassium supplementation** are crucial to correct dehydration, electrolyte imbalances, and prepare for insulin administration, while mitigating the risk of **cerebral oedema**.*20 ml/kg 0.9% sodium chloride bolus rapidly over 15 minutes, then reassess*- A **20 ml/kg bolus** is generally reserved for children with DKA who show clear signs of **hypovolemic shock** or profound dehydration, which is not indicated by the patient's alert and oriented state.- Rapid and large fluid boluses can cause a precipitous drop in plasma osmolality, significantly increasing the risk of **cerebral oedema**, a severe complication in paediatric DKA.*Start insulin infusion immediately without fluid bolus to correct hyperglycaemia*- **Insulin therapy** should be delayed for at least **1-2 hours** after the initiation of fluid resuscitation to allow for initial rehydration and stabilization of osmolality.- Starting insulin too early can cause a rapid decline in blood glucose and plasma osmolality, exacerbating the risk of **cerebral oedema** due to fluid shifts into brain cells.*10 ml/kg 0.45% sodium chloride with 5% dextrose over 1 hour*- Initial fluid resuscitation in DKA requires **isotonic solutions** (0.9% sodium chloride) to safely expand intravascular volume. **Hypotonic solutions** like 0.45% saline are inappropriate for initial rehydration.- **Dextrose** is typically added to IV fluids only when blood glucose levels fall to a certain threshold (e.g., <14-17 mmol/L) to prevent hypoglycemia, not during initial fluid resuscitation.*20 ml/kg Hartmann's solution bolus over 30 minutes*- While some adult DKA protocols may use balanced crystalloids, **0.9% sodium chloride** remains the standard and preferred initial fluid for volume expansion in most paediatric DKA guidelines (e.g., UK, ISPAD).- A **20 ml/kg bolus** is excessive for a child who is **alert and oriented** and not in clinical shock, and carries a higher risk of fluid overload and **cerebral oedema**.

Question 47: A 10-year-old boy with refractory epilepsy is being considered for vagus nerve stimulation (VNS) therapy. Despite trials of multiple anti-epileptic drugs, he continues to have 3-4 focal seizures with impaired awareness per week significantly impacting his quality of life. MRI brain shows no structural lesion amenable to surgical resection. His parents ask about the expected benefit of VNS. What is the most accurate statement regarding efficacy of VNS therapy in paediatric epilepsy?

A. Complete seizure freedom is achieved in approximately 60% of patients within 12 months
B. 50% or greater reduction in seizure frequency is achieved in approximately 50% of patients (Correct Answer)
C. VNS is only effective for generalized epilepsies, not focal seizures
D. Maximum benefit is seen immediately after device implantation
E. VNS works by directly suppressing epileptogenic foci through electrical inhibition

Explanation: ***50% or greater reduction in seizure frequency is achieved in approximately 50% of patients*** - This describes the typical efficacy of VNS therapy, often referred to as the **"50-50 rule"**, which means approximately half of patients experience at least a 50% reduction in seizure frequency. - This level of reduction, while not complete freedom, significantly improves **quality of life** and reduces seizure burden in patients with **drug-resistant epilepsy**. *Complete seizure freedom is achieved in approximately 60% of patients within 12 months* - **Complete seizure freedom** with VNS is rare, occurring in only a small minority of patients (typically less than 10%). - A 60% rate of seizure freedom is more aligned with outcomes from successful **resective epilepsy surgery**, not VNS. *VNS is only effective for generalized epilepsies, not focal seizures* - VNS is **FDA-approved and effective for both focal and generalized epilepsy syndromes**, particularly in cases of **drug-resistant epilepsy**. - This patient presents with **focal seizures**, for which VNS is a recognized treatment option when surgical resection is not feasible. *Maximum benefit is seen immediately after device implantation* - The efficacy of VNS typically **increases over time**, with clinical improvements often observed gradually over several months to years (up to 12-24 months). - This **delayed response** is characteristic of its neuromodulatory mechanism, which involves long-term changes in brain activity rather than immediate suppression. *VNS works by directly suppressing epileptogenic foci through electrical inhibition* - VNS modulates brain activity via **vagal afferents** to the **nucleus tractus solitarius**, influencing widespread thalamocortical networks. - It does not directly target or electrically inhibit specific **epileptogenic foci**, but rather exerts a broader neuromodulatory effect on seizure networks.

Question 48: A 15-year-old girl with type 1 diabetes for 8 years attends for routine screening. She is found to have background diabetic retinopathy with several microaneurysms and dot haemorrhages in both eyes but no other features. Her HbA1c is 68 mmol/mol and blood pressure is 118/72 mmHg. Visual acuity is normal at 6/6 bilaterally. What is the most appropriate management plan for her retinopathy?

A. Urgent referral to ophthalmology for laser photocoagulation
B. Commence anti-VEGF intravitreal injections
C. Optimize glycaemic and blood pressure control with continued annual screening (Correct Answer)
D. Increase screening frequency to 6-monthly intervals
E. Start fenofibrate therapy to slow retinopathy progression

Explanation: ***Optimize glycaemic and blood pressure control with continued annual screening*** - The patient has **background diabetic retinopathy** (R1), indicated by **microaneurysms** and **dot haemorrhages** with normal visual acuity, signifying no maculopathy or proliferative changes. - At this stage, the primary management is to **optimize glycaemic control** (HbA1c 68 mmol/mol is elevated) and **blood pressure** to prevent progression, with **annual screening** being appropriate. *Urgent referral to ophthalmology for laser photocoagulation* - **Laser photocoagulation** is reserved for advanced stages like **proliferative diabetic retinopathy** (neovascularization) or significant macular edema. - This patient has **background retinopathy** without maculopathy or proliferative features, which does not warrant urgent laser treatment. *Commence anti-VEGF intravitreal injections* - **Anti-VEGF intravitreal injections** are indicated for **diabetic macular oedema** or advanced proliferative retinopathy. - The patient's **normal visual acuity (6/6)** and absence of other severe features rule out significant macular edema or active proliferation requiring anti-VEGF. *Increase screening frequency to 6-monthly intervals* - **Increased screening frequency** to 6-monthly intervals is usually recommended for **pre-proliferative retinopathy** (R2), which includes features like cotton wool spots or venous beading. - For mild **background diabetic retinopathy** (R1) without maculopathy, **annual screening** is the standard recommendation. *Start fenofibrate therapy to slow retinopathy progression* - **Fenofibrate therapy** has been studied for slowing retinopathy progression in adults but is **not a standard treatment** in paediatric populations for diabetic retinopathy. - The primary management for this patient remains **tight glycaemic and blood pressure control**, rather than initiating fenofibrate.

Question 49: A 7-year-old girl presents with episodes witnessed by her teacher where she suddenly stops talking, stares blankly for about 10 seconds with subtle eye blinking, then immediately continues her previous activity with no awareness of the episode. These occur multiple times daily. An EEG is performed showing generalized 3 Hz spike-and-wave discharges with hyperventilation provocation testing reproducing a typical episode. What underlying mechanism explains why hyperventilation provokes these seizures?

A. Hyperventilation induces anxiety which triggers absence seizures through stress hormones
B. Hyperventilation causes cerebral hypoxia triggering neuronal hyperexcitability
C. Reduced cerebral blood flow from hypocapnia lowers seizure threshold in susceptible individuals (Correct Answer)
D. Alkalosis from hyperventilation directly depolarizes thalamocortical neurons
E. Increased oxygen delivery enhances metabolic activity in epileptogenic foci

Explanation: ***Reduced cerebral blood flow from hypocapnia lowers seizure threshold in susceptible individuals***- Hyperventilation leads to **hypocapnia** (low CO2), which causes potent **cerebral vasoconstriction** and a subsequent reduction in **cerebral blood flow**.- This physiological shift affects the **thalamocortical circuits**, facilitating the characteristic **3 Hz spike-and-wave discharges** seen in childhood absence epilepsy.*Hyperventilation induces anxiety which triggers absence seizures through stress hormones*- Absence seizures are **neurological events** triggered by physiological changes, not primarily by psychological stress or corticosteroids.- While stress can be a non-specific trigger for many seizure types, it is not the mechanism behind **hyperventilation provocation** tests.*Hyperventilation causes cerebral hypoxia triggering neuronal hyperexcitability*- Hyperventilation actually maintains or slightly increases **arterial oxygen** levels; there is no systemic **hypoxia** involved.- The seizure is triggered by the **metabolic shift** and vasoconstriction related to carbon dioxide levels, not a lack of oxygen delivery.*Alkalosis from hyperventilation directly depolarizes thalamocortical neurons*- Respiratory **alkalosis** does occur during hyperventilation, but it primarily affects ionized **calcium levels**, which can increase excitability but is not the primary mechanism for absence induction.- The classic provocation in absence epilepsy is more specifically linked to the **vascular and metabolic response** to low CO2 rather than direct pH-induced depolarization.*Increased oxygen delivery enhances metabolic activity in epileptogenic foci*- Hyperventilation actually results in **decreased oxygen delivery** to the brain because vasoconstriction reduces the total volume of blood reaching the tissue.- Absence seizures involve **generalized** thalamocortical networks rather than localized **epileptogenic foci** seen in focal epilepsies.

Question 50: A 12-year-old boy with type 1 diabetes for 5 years presents to clinic. His HbA1c has risen from 58 mmol/mol to 74 mmol/mol over the past 6 months despite no reported changes in his insulin regimen or diet. His parents mention he has become more self-conscious about injecting insulin at school and with friends. He appears withdrawn during the consultation. What is the most important factor to explore in this clinical scenario?

A. Presence of coeliac disease affecting insulin absorption
B. Development of insulin antibodies causing resistance
C. Psychosocial factors including diabetes burnout and adherence issues (Correct Answer)
D. Progression to insulin resistance associated with puberty
E. Malabsorption syndrome reducing carbohydrate intake

Explanation: ***Psychosocial factors including diabetes burnout and adherence issues*** - The patient's parents report he has become more **self-conscious** about injecting insulin and he appears **withdrawn**, strongly suggesting underlying psychological distress and potential **non-adherence** to his insulin regimen. - Adolescence is a common period for **diabetes burnout**, where peer pressure and the desire for normalcy can lead to omitted insulin doses, directly resulting in a rise in **HbA1c**. *Presence of coeliac disease affecting insulin absorption* - While **coeliac disease** is associated with Type 1 Diabetes, it typically causes **malabsorption**, leading to **hypoglycemia** due to reduced carbohydrate absorption, rather than persistent hyperglycemia and rising **HbA1c**. - This diagnosis does not explain the patient's specific **psychological distress** or social anxiety related to insulin injections. *Development of insulin antibodies causing resistance* - Clinically significant **insulin antibody development** causing resistance is extremely rare with modern **recombinant insulin analogues** and is an unlikely cause for the rise in **HbA1c**. - This would also not account for the patient's observed **behavioral changes**, such as self-consciousness and withdrawal. *Progression to insulin resistance associated with puberty* - **Pubertal insulin resistance** is a physiological phenomenon due to hormonal changes, leading to an increased insulin requirement, but it does not explain the **behavioral changes** (self-consciousness, withdrawal) described in the patient. - While it could contribute to difficulty in glycemic control, the psychosocial elements are a more direct and pressing factor given the clinical presentation. *Malabsorption syndrome reducing carbohydrate intake* - A **malabsorption syndrome** would typically result in **hypoglycemia** and often weight loss due to inadequate nutrient absorption, which is contrary to a rising **HbA1c** that indicates chronic hyperglycemia. - The patient's social and emotional symptoms are not consistent with a primary **malabsorption** issue.

Question 51: An 8-year-old girl with epilepsy has been taking sodium valproate for 2 years with excellent seizure control. Her parents bring her to clinic reporting that she has gained 8 kg in weight over the past year, developed increased facial hair, and her scalp hair has become noticeably thinner. Blood tests show normal liver function and full blood count. What is the most appropriate management approach?

A. Continue sodium valproate and reassure that these are minor side effects
B. Switch to levetiracetam and discuss that it has fewer metabolic side effects (Correct Answer)
C. Reduce the dose of sodium valproate by 50%
D. Add metformin to address the weight gain
E. Switch to carbamazepine which has a better side effect profile

Explanation: ***Switch to levetiracetam and discuss that it has fewer metabolic side effects***- The patient is experiencing significant **metabolic and cosmetic side effects** of sodium valproate, including **weight gain**, **hirsutism**, and **alopecia** (hair thinning), which necessitate a change in therapy.- **Levetiracetam** is a suitable alternative as it provides broad-spectrum efficacy with a significantly better side effect profile regarding **weight** and **hormonal balance**, preserving seizure control.*Continue sodium valproate and reassure that these are minor side effects*- These side effects are not "minor" as they can significantly impact the patient's **quality of life**, lead to **PCOS-like symptoms**, and reduce **adherence** to treatment.- Ignoring significant weight gain, hirsutism, and hair thinning can have long-term **metabolic and psychosocial consequences** for an 8-year-old girl.*Reduce the dose of sodium valproate by 50%*- Reducing the dose by 50% risks **breakthrough seizures** and loss of excellent seizure control, which is not an acceptable compromise given the availability of alternative AEDs.- Many of valproate's metabolic side effects are not strictly dose-dependent, and a partial reduction may not adequately resolve the **hirsutism** and **weight gain**.*Add metformin to address the weight gain*- Adding **metformin** introduces further polypharmacy and potential **gastrointestinal side effects**, without directly addressing the underlying cause of the valproate-induced metabolic and cosmetic issues.- The primary management strategy for drug-induced adverse effects, especially when significant, is to replace the offending drug rather than treating its **symptoms with additional medications**.*Switch to carbamazepine which has a better side effect profile*- **Carbamazepine** is less suitable for generalized epilepsy as it can worsen some seizure types, and it has its own set of side effects, including **enzyme induction** and potential **weight gain**.- **Levetiracetam** is preferred over carbamazepine in this scenario due to its broader spectrum of activity and superior metabolic and cosmetic side effect profile.

Question 52: What is the recommended target HbA1c for children and young people with type 1 diabetes according to NICE guidelines?

A. 42 mmol/mol (6.0%) or lower
B. 48 mmol/mol (6.5%) or lower (Correct Answer)
C. 53 mmol/mol (7.0%) or lower
D. 58 mmol/mol (7.5%) or lower
E. 64 mmol/mol (8.0%) or lower

Explanation: ***48 mmol/mol (6.5%) or lower***- **NICE guidelines** state that the target HbA1c for children and young people with **Type 1 Diabetes** should be 48 mmol/mol (6.5%) or lower to reduce long-term **vascular complications**.- This level is chosen to achieve optimal **glycaemic control** without significantly increasing the risk of severe **hypoglycaemia**.*42 mmol/mol (6.0%) or lower*- This value represents a **non-diabetic** HbA1c range and is generally considered too difficult to maintain for pediatric patients.- Aiming for this level significantly increases the clinical risk of frequent and severe **hypoglycaemic episodes**.*53 mmol/mol (7.0%) or lower*- While this used to be a common target, modern guidelines have lowered the threshold to improve **long-term outcomes** and minimize **microvascular damage**.- This target may only be acceptable if the child has frequent **hypoglycaemic unawareness** or other specific clinical contraindications.*58 mmol/mol (7.5%) or lower*- This was once the standard target for young children to avoid the neurocognitive effects of **hypoglycaemia**.- Subsequent evidence has shown that better health outcomes are achieved with the lower **48 mmol/mol** target without undue harm.*64 mmol/mol (8.0%) or lower*- This level is considered suboptimal and is associated with a significantly increased risk of **retinopathy**, **nephropathy**, and **neuropathy**.- Targets this high are discouraged unless there are severe **psychosocial factors** or comorbidities preventing safer control.

Question 53: A 5-year-old boy with newly diagnosed epilepsy presents to the emergency department with a continuous tonic-clonic seizure lasting 35 minutes. He has received two doses of buccal midazolam (10 mg) by paramedics 10 minutes apart without effect, and one dose of intravenous lorazepam (0.1 mg/kg) 8 minutes ago which also failed to terminate the seizure. Intravenous access is secure. What is the most appropriate next pharmacological intervention?

A. Give a second dose of intravenous lorazepam 0.1 mg/kg
B. Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes (Correct Answer)
C. Give intravenous diazepam 0.25 mg/kg as bolus
D. Commence intravenous midazolam infusion 0.15 mg/kg/hour
E. Give rectal paraldehyde 0.4 ml/kg mixed with equal volume of olive oil

Explanation: ***Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes*** - This patient is in **refractory status epilepticus**, having failed initial management with **benzodiazepines**; standard protocols dictate moving to a second-line **antiepileptic drug (AED)** if seizures persist after two doses. - **Phenytoin** (20 mg/kg) or **levetiracetam** are the preferred second-line agents to terminate prolonged seizures when **intravenous access** is established. *Give a second dose of intravenous lorazepam 0.1 mg/kg* - Current guidelines recommend a maximum of **two doses** of benzodiazepines (including pre-hospital buccal midazolam) to avoid **respiratory depression** and because further doses are unlikely to stop the seizure. - This child has already received three benzodiazepine treatments (two buccal, one IV), making further doses inappropriate and delaying **definitive seizure control**. *Give intravenous diazepam 0.25 mg/kg as bolus* - **Diazepam** is another benzodiazepine; switching to a different drug in the same class after several failed attempts is not recommended and increases the risk of **sedation and apnea**. - Management should prioritize a long-acting **loading dose** of an AED like phenytoin rather than repeated short-acting boluses. *Commence intravenous midazolam infusion 0.15 mg/kg/hour* - Continuous **midazolam infusions** are reserved for **third-line management** (refractory status) usually requiring intensive care monitoring and intubation. - It is only indicated after second-line agents like **phenytoin**, **phenobarbital**, or **levetiracetam** have failed to terminate the seizure. *Give rectal paraldehyde 0.4 ml/kg mixed with equal volume of olive oil* - **Rectal paraldehyde** is a historical rescue medication rarely used in modern emergency departments when **intravenous access** is already secured. - It is less effective and more difficult to administer compared to **intravenous phenytoin** or **levetiracetam** in an acute hospital setting.

Question 54: A 14-year-old girl with type 1 diabetes for 6 years presents for annual screening. She is on a basal-bolus regimen with good glycaemic control (HbA1c 52 mmol/mol). Screening reveals an albumin:creatinine ratio (ACR) of 3.5 mg/mmol on a random urine sample. She is asymptomatic and has normal blood pressure. What is the most appropriate next step in management?

A. Start an ACE inhibitor immediately
B. Repeat ACR on two further early morning samples within 3-6 months (Correct Answer)
C. Refer urgently to paediatric nephrology
D. Increase insulin doses to improve glycaemic control further
E. Arrange a renal ultrasound scan

Explanation: ***Repeat ACR on two further early morning samples within 3-6 months*** - A single elevated **Albumin:Creatinine Ratio (ACR)** is insufficient for a diagnosis of **microalbuminuria** because transient increases can be caused by exercise, infection, or menstruation. - Guidelines require two out of three **early morning urine samples** to be abnormal over a 3-6 month period to confirm persistent microalbuminuria in diabetic patients. *Start an ACE inhibitor immediately* - **ACE inhibitors** are only indicated once persistent microalbuminuria is confirmed or if the patient develops **hypertension**. - Initiating therapy based on one random sample is premature as the elevation may be **transient** and reversible without medication. *Refer urgently to paediatric nephrology* - Urgent referral is not indicated for an isolated, asymptomatic finding of **microalbuminuria** in a patient with **Stage 1 (Grade 1)** nephropathy screening. - Management initially occurs in the diabetic clinic; referral is reserved for **declining GFR**, hematuria, or failure to respond to standard therapy. *Increase insulin doses to improve glycaemic control further* - The patient's **HbA1c (52 mmol/mol)** is already at a good target level, and aggressive intensification could increase the risk of **hypoglycaemia**. - While glycemic control is vital, the immediate priority for this screening result is to **confirm persistence** of the albuminuria through serial testing. *Arrange a renal ultrasound scan* - A **renal ultrasound** is not part of the standard screening protocol for **diabetic nephropathy**, which is a functional and histological diagnosis rather than structural. - Imaging is typically reserved for cases where there is diagnostic doubt, such as suspected **obstructive uropathy** or atypical kidney size.

Question 55: A 6-year-old boy with a history of three afebrile generalized tonic-clonic seizures over the past 6 months undergoes an EEG. The EEG shows 3 Hz spike-and-wave discharges on a normal background. His parents report he sometimes has brief episodes of staring with eyelid fluttering that last 5-10 seconds. Neurological examination is normal. What is the most likely diagnosis?

A. Juvenile myoclonic epilepsy
B. Childhood absence epilepsy (Correct Answer)
C. Benign rolandic epilepsy
D. Lennox-Gastaut syndrome
E. Panayiotopoulos syndrome

Explanation: ***Childhood absence epilepsy*** - The classic EEG finding of **3 Hz spike-and-wave discharges** on a normal background is pathognomonic for this condition. - Clinical presentation involving **brief staring spells** with **eyelid fluttering** lasting 5-10 seconds and age-appropriate onset (6 years) aligns with typical absence seizures, which can occasionally be associated with **generalized tonic-clonic seizures**. *Juvenile myoclonic epilepsy* - This typically presents in **adolescence** (ages 12-18) rather than early childhood and is characterized by early morning **myoclonic jerks**. - The EEG for this condition would more likely show **4-6 Hz polyspike-and-wave** discharges rather than the classic 3 Hz pattern. *Benign rolandic epilepsy* - Also known as benign epilepsy with centrotemporal spikes (BECTS), it usually presents with **focal seizures** involving the face, oropharynx, or drooling, often during sleep. - The EEG diagnostic hallmark is **centrotemporal spikes** rather than generalized spike-and-wave discharges. *Lennox-Gastaut syndrome* - This is severe childhood epilepsy characterized by a triad of multiple seizure types, **intellectual disability**, and an abnormal EEG pattern. - Expect an EEG showing **slow spike-and-wave discharges** (usually <2.5 Hz) and a background that is typically abnormal/slowed. *Panayiotopoulos syndrome* - A benign focal epilepsy presenting with **autonomic symptoms** like vomiting, pallor, or sweating, often during sleep. - The EEG shows focal **occipital spikes** or multifocal spikes, which contrasts with the generalized discharges seen in this patient.

Question 56: A 9-year-old girl with type 1 diabetes for 4 years attends clinic with her parents. She uses a basal-bolus insulin regimen with insulin detemir twice daily and insulin aspart with meals. Her mother reports that she has been experiencing episodes of unusual behaviour in the early morning, including confusion and aggression, which resolve after eating breakfast. Her evening blood glucose readings are typically 8-10 mmol/L. What is the most appropriate management strategy?

A. Increase the evening dose of insulin detemir
B. Switch to insulin glargine once daily at bedtime
C. Reduce the evening dose of insulin detemir (Correct Answer)
D. Add a bedtime snack containing complex carbohydrates
E. Increase the dinner-time dose of insulin aspart

Explanation: ***Reduce the evening dose of insulin detemir***- The child's early morning confusion and aggression resolving after breakfast are classic symptoms of **nocturnal hypoglycaemia**, indicating that the basal insulin dose is too high.- Reducing the evening dose of **insulin detemir**, which provides overnight basal coverage, directly addresses the underlying cause of the low blood glucose episodes.*Increase the evening dose of insulin detemir*- This strategy would **exacerbate nocturnal hypoglycaemia**, leading to more frequent or severe episodes of low blood sugar during the night.- Administering more **basal insulin** when a patient is already experiencing hypoglycaemia is an inappropriate and potentially dangerous intervention.*Switch to insulin glargine once daily at bedtime*- While insulin glargine is a long-acting insulin, simply switching formulations without adjusting the **total basal insulin dose** will not necessarily resolve the hypoglycaemic episodes.- The primary issue is the **excessive basal effect** overnight, not the specific type of long-acting insulin used.*Add a bedtime snack containing complex carbohydrates*- A bedtime snack might temporarily prevent early nocturnal hypoglycaemia, but it fails to address the fundamental problem of **over-insulinization**.- This approach can lead to **unwanted weight gain** and might only shift the timing of hypoglycaemia or cause rebound hyperglycaemia.*Increase the dinner-time dose of insulin aspart*- Increasing the dose of **insulin aspart**, a rapid-acting insulin, would primarily lower post-dinner blood glucose levels, potentially leading to **hypoglycaemia earlier in the night**.- The early morning symptoms point to an issue with the **basal insulin** effect, not the prandial insulin for dinner.

Question 57: A 16-year-old girl with juvenile myoclonic epilepsy controlled on levetiracetam presents with deteriorating school performance and social withdrawal over 6 months. Her parents report increased irritability and episodes where she cries without obvious reason. She has been seizure-free for 2 years. On direct questioning, she admits to feeling low most days but denies suicidal ideation. What is the most appropriate management approach considering her epilepsy and mental health?

A. Recognize depression as a potential adverse effect of levetiracetam; consider switching to lamotrigine and commence SSRI therapy with monitoring (Correct Answer)
B. Diagnose adjustment disorder related to chronic illness; refer for cognitive behavioural therapy without changing anti-epileptic medication
C. Interpret symptoms as typical adolescent behaviour; provide reassurance and routine follow-up in 6 months
D. Add sodium valproate for mood stabilization while continuing levetiracetam
E. Stop levetiracetam immediately and observe for symptom resolution before starting alternative anti-epileptic drug

Explanation: ***Recognize depression as a potential adverse effect of levetiracetam; consider switching to lamotrigine and commence SSRI therapy with monitoring***- **Levetiracetam** is well-known for causing **behavioral adverse effects** such as irritability and depression in up to 15% of patients, which matches this patient's clinical presentation.- **Lamotrigine** is an effective alternative for **Juvenile Myoclonic Epilepsy (JME)** and possesses **mood-stabilizing properties**, while **SSRIs** are safe and do not significantly lower the **seizure threshold**.*Diagnose adjustment disorder related to chronic illness; refer for cognitive behavioural therapy without changing anti-epileptic medication*- While **CBT** is a valuable supportive therapy, failing to address the **iatrogenic cause** (levetiracetam) ignores the primary trigger for the mood change.- **Adjustment disorder** is less likely given the 6-month duration and the strong temporal association with potential drug-induced side effects.*Interpret symptoms as typical adolescent behaviour; provide reassurance and routine follow-up in 6 months*- **Functional impairment**, such as deteriorating school performance and social withdrawal, indicates a pathological state rather than normal adolescent development.- A 6-month delay in follow-up is dangerous as it ignores the risk of **clinical depression** progression and potential **suicidal ideation** development.*Add sodium valproate for mood stabilization while continuing levetiracetam*- **Sodium valproate** is strictly contraindicated for females of **childbearing potential** unless no other alternative exists due to its high risk of **teratogenicity**.- Continuing levetiracetam while adding a second drug fails to remove the most likely cause of the **psychiatric symptoms** and increases the drug burden.*Stop levetiracetam immediately and observe for symptom resolution before starting alternative anti-epileptic drug*- **Abrupt withdrawal** of an anti-epileptic drug carries a high risk of **rebound seizures** or **status epilepticus**.- Management of a seizure-free patient requires a careful **cross-tapering** strategy where the new drug is introduced before the old one is completely withdrawn.

Question 58: An 11-year-old boy with type 1 diabetes presents with his third episode of severe hypoglycaemia requiring third-party assistance in 6 months. His parents report he no longer experiences warning symptoms before hypoglycaemic episodes. His average blood glucose from his meter is 7.8 mmol/L with significant variability. HbA1c is 54 mmol/mol. What is the most appropriate strategy to restore hypoglycaemia awareness?

A. Meticulous avoidance of hypoglycaemia by accepting higher glucose targets (>7 mmol/L) for 3-6 months (Correct Answer)
B. Increase frequency of blood glucose monitoring to 10-12 times daily
C. Switch from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump)
D. Reduce total daily insulin dose by 20% immediately
E. Prescribe continuous glucose monitoring with predictive low glucose alerts

Explanation: ***Meticulous avoidance of hypoglycaemia by accepting higher glucose targets (>7 mmol/L) for 3-6 months*** - The most effective strategy to restore **hypoglycemia awareness** is a sustained period of meticulous avoidance of all hypoglycemic episodes, allowing the body's **counter-regulatory hormone** responses to reset. - Accepting temporarily higher **glucose targets** (e.g., >7 mmol/L) creates a buffer zone, preventing the brain from repeatedly adapting to low glucose and thus re-sensitizing the autonomic warning symptoms. *Increase frequency of blood glucose monitoring to 10-12 times daily* - While increased monitoring helps in detecting **hypoglycaemia** more promptly, it does not directly restore the blunted physiological **autonomic warning symptoms** which are crucial for awareness. - It serves as a detection tool but does not address the underlying desensitization of the body's response to low glucose. *Switch from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump)* - An **insulin pump** can offer more precise insulin delivery and potentially reduce glucose variability, which may help reduce the frequency of hypoglycaemia. - However, the mode of insulin delivery itself does not directly restore **hypoglycaemia awareness**; rather, the critical factor is a sustained period of avoiding low blood glucose levels. *Reduce total daily insulin dose by 20% immediately* - An immediate and arbitrary reduction of the **total daily insulin dose** by 20% can lead to uncontrolled **hyperglycaemia** and is not a nuanced approach to restore awareness. - The goal is careful titration and adjustment of insulin to prevent lows, not a blanket reduction that might compromise overall glycemic control without guaranteeing awareness restoration. *Prescribe continuous glucose monitoring with predictive low glucose alerts* - **Continuous Glucose Monitoring (CGM)** with alerts is an excellent safety tool to prevent severe hypoglycaemic episodes by providing external warnings. - While CGM helps in preventing future lows, it acts as an external aid and does not physiologically

Question 59: A 6-year-old girl with epilepsy has been taking sodium valproate for 18 months with good seizure control. Her mother reports that she has recently noticed increased bruising and two episodes of epistaxis. Blood tests show: Haemoglobin 118 g/L, White cell count 6.8 × 10⁹/L, Platelets 185 × 10⁹/L, PT 13 seconds (normal range 11-14), APTT 38 seconds (normal range 26-34). What is the most likely explanation for these findings?

A. Valproate-induced thrombocytopenia and platelet dysfunction
B. Valproate-induced inhibition of von Willebrand factor synthesis (Correct Answer)
C. Acquired haemophilia due to factor VIII inhibitor development
D. Vitamin K deficiency secondary to enzyme induction
E. Immune thrombocytopenic purpura as an autoimmune comorbidity

Explanation: ***Valproate-induced inhibition of von Willebrand factor synthesis*** - **Sodium valproate** can cause an acquired **von Willebrand syndrome** by reducing **von Willebrand factor (vWF)** levels and activity, which leads to impaired platelet adhesion. - This deficiency results in a prolonged **APTT** because **vWF** stabilizes **Factor VIII**, explaining the mucocutaneous bleeding (bruising, epistaxis) with a normal platelet count and PT. *Valproate-induced thrombocytopenia and platelet dysfunction* - While valproate can induce **thrombocytopenia**, the patient's **platelet count** of 185 × 10⁹/L is within the normal range, ruling out significant thrombocytopenia. - **Platelet dysfunction** would typically present with a normal **APTT**, whereas this patient has a significantly **prolonged APTT** of 38 seconds. *Acquired haemophilia due to factor VIII inhibitor development* - **Acquired haemophilia** is extremely rare in children and is not a recognized side effect of **sodium valproate** therapy. - This condition usually causes more severe, spontaneous **haematomas** or deep tissue bleeding, rather than just mucocutaneous symptoms. *Vitamin K deficiency secondary to enzyme induction* - **Sodium valproate** is an **enzyme inhibitor**, not an inducer, so it would not cause **vitamin K deficiency** through increased metabolism of clotting factors. - **Vitamin K deficiency** primarily prolongs the **Prothrombin Time (PT)**, which is normal (13 seconds) in this patient, while the APTT is prolonged. *Immune thrombocytopenic purpura as an autoimmune comorbidity* - **Immune thrombocytopenic purpura (ITP)** is characterized by a significantly low **platelet count**, usually below 100 × 10⁹/L, which contradicts this patient's normal platelet count. - In **ITP**, **coagulation times** (PT and APTT) are typically **normal**, which is inconsistent with the prolonged APTT seen here.

Question 60: A 13-year-old boy with type 1 diabetes for 7 years presents for his annual complication screening. Urinalysis shows albumin:creatinine ratio (ACR) of 3.5 mg/mmol on an early morning sample. Two further early morning samples over the next 3 months show ACR values of 3.8 mg/mmol and 4.1 mg/mmol. His blood pressure is 118/72 mmHg (95th percentile for age). HbA1c is 71 mmol/mol. eGFR is normal. What is the most appropriate initial management for his kidney disease?

A. Commence ACE inhibitor therapy and intensify glycaemic control measures (Correct Answer)
B. Intensify glycaemic control and arrange repeat screening in 12 months
C. Refer to paediatric nephrology for kidney biopsy
D. Commence angiotensin receptor blocker and strict low-protein diet
E. Check for urinary tract infection and repeat testing when infection is excluded

Explanation: ***Commence ACE inhibitor therapy and intensify glycaemic control measures***- The patient has confirmed **persistent moderately increased albuminuria** (ACR 3.5-4.1 mg/mmol over 3 months), which is the earliest sign of **diabetic kidney disease** in Type 1 Diabetes.- **ACE inhibitors** are the first-line pharmacological intervention to provide **renoprotection** by reducing intraglomerular pressure, especially given his high-normal blood pressure (95th percentile), and intensifying **glycaemic control** (HbA1c 71 mmol/mol) is crucial to slow disease progression.*Intensify glycaemic control and arrange repeat screening in 12 months*- While **glycaemic control** is vital for preventing diabetic complications, simply arranging repeat screening in 12 months is insufficient for established **moderately increased albuminuria**.- Delaying the initiation of **renoprotective therapy** (like ACE inhibitors) increases the risk of progression to overt **macroalbuminuria** and further kidney damage.*Refer to paediatric nephrology for kidney biopsy*- A **kidney biopsy** is not indicated at this stage as the presentation with long-standing Type 1 Diabetes and persistent albuminuria is classic for **diabetic nephropathy**.- Biopsy is typically reserved for atypical features such as rapid decline in **eGFR**, presence of **haematuria**, or albuminuria without typical diabetic retinopathy.*Commence angiotensin receptor blocker and strict low-protein diet*- While **angiotensin receptor blockers (ARBs)** are an alternative to ACE inhibitors, they are usually reserved for patients intolerant to ACE inhibitors rather than initial therapy.- A **strict low-protein diet** is not recommended for children with early diabetic nephropathy as it can negatively impact their growth and development.*Check for urinary tract infection and repeat testing when infection is excluded*- The diagnosis of **persistent moderately increased albuminuria** has already been confirmed by three separate early morning samples over three months.- This consistent finding makes a transient cause like a **urinary tract infection (UTI)** highly unlikely, as UTIs cause temporary, not chronic, elevations in ACR.

Question 61: A 4-year-old boy presents to the emergency department with a focal seizure involving right-sided facial twitching that has been ongoing for 35 minutes. He remains conscious but unable to speak. There is no fever. He has no previous history of seizures. What is the most appropriate immediate management?

A. Buccal midazolam 5 mg or intravenous lorazepam 0.1 mg/kg (Correct Answer)
B. Intravenous phenytoin loading dose 20 mg/kg over 20 minutes
C. Intravenous levetiracetam 40 mg/kg over 5 minutes
D. Rectal diazepam 5 mg and observe
E. Obtain urgent CT head before administering any anti-epileptic medication

Explanation: ***Buccal midazolam 5 mg or intravenous lorazepam 0.1 mg/kg*** - This patient is in **status epilepticus** (seizure lasting >5 minutes, or in this case, >30 minutes), which necessitates immediate first-line treatment with **benzodiazepines**. - **Buccal midazolam** (5 mg for ages 1–5 years) or **IV lorazepam** (0.1 mg/kg) are the recommended agents for rapid termination of status epilepticus in children due to their quick onset of action. *Intravenous phenytoin loading dose 20 mg/kg over 20 minutes* - **Phenytoin** is a **second-line** anti-epileptic drug for status epilepticus, used only if initial benzodiazepine treatment fails. - Its administration requires slower infusion rates and **cardiac monitoring**, making it unsuitable for the immediate, rapid termination required in the first few minutes of status epilepticus. *Intravenous levetiracetam 40 mg/kg over 5 minutes* - **Levetiracetam** is an alternative **second-line** agent for status epilepticus, similar to phenytoin or valproate, and is not indicated as the initial first-line treatment. - The immediate priority in status epilepticus is to administer a **benzodiazepine** to stop the seizure before considering non-benzodiazepine anticonvulsants. *Rectal diazepam 5 mg and observe* - While **rectal diazepam** can be used in emergency seizure management, **buccal midazolam** is generally preferred in most settings for its ease of administration and social acceptability. - Given the **35-minute duration** of the seizure, observation alone is inappropriate; active and aggressive treatment to terminate the seizure is critical to prevent neuronal damage. *Obtain urgent CT head before administering any anti-epileptic medication* - In a patient with **status epilepticus**, the absolute priority is **seizure termination** to prevent brain injury and systemic complications. - While **neuroimaging** is important for identifying the underlying cause, delaying life-saving anti-epileptic treatment to obtain a CT head is contraindicated.

Question 62: A 10-year-old girl with type 1 diabetes for 4 years presents with a 6-week history of intermittent abdominal pain, loose stools, and failure to gain weight. She has lost 2 kg. Her HbA1c has improved from 65 to 52 mmol/mol without changes to her insulin regimen. On examination, she appears pale and has angular stomatitis. What is the most likely diagnosis?

A. Coeliac disease (Correct Answer)
B. Improved glycaemic control with reduced caloric loss
C. Diabetic gastroparesis
D. Inflammatory bowel disease
E. Exocrine pancreatic insufficiency

Explanation: ***Coeliac disease*** - Type 1 diabetes and **coeliac disease** share a strong genetic association (**HLA-DQ2/DQ8**), making this a common comorbidity, especially in children with diabetes. - The symptoms of **abdominal pain**, **loose stools**, **weight loss**, and **failure to thrive**, combined with **pallor** and **angular stomatitis** (due to nutrient deficiencies) and a **paradoxical improvement in HbA1c** (due to carbohydrate malabsorption), are highly indicative of coeliac disease. *Improved glycaemic control with reduced caloric loss* - While HbA1c has improved, this is not due to true improved glycaemic control, as evidenced by the concurrent **weight loss**, **abdominal pain**, and signs of **malnutrition**. - Genuine improved glycaemic control without insulin changes would stem from active dietary or lifestyle management, not from a pathological process causing nutrient malabsorption. *Diabetic gastroparesis* - **Diabetic gastroparesis** primarily causes symptoms like **nausea**, **vomiting**, **early satiety**, and **bloating** due to delayed gastric emptying, not typically loose stools or significant weight loss from malabsorption. - It is also a complication of **long-standing diabetes** and is less common in a child with only a 4-year history of the disease. *Inflammatory bowel disease* - While **inflammatory bowel disease** (IBD) can cause abdominal pain, weight loss, and loose stools, it does not typically lead to the specific **paradoxical decrease in HbA1c** through carbohydrate malabsorption. - Symptoms often include **bloody stools**, perianal disease, or distinct extra-intestinal manifestations, which are not described in this case. *Exocrine pancreatic insufficiency* - Although **exocrine pancreatic insufficiency** can cause malabsorption, **steatorrhea**, and weight loss, it is a far **less common** cause of these symptoms in Type 1 diabetes patients compared to coeliac disease. - It also wouldn't typically present with the specific constellation of symptoms, including the **paradoxical HbA1c improvement** and the particular micronutrient deficiencies suggested by angular stomatitis, as clearly as coeliac disease in this context.

Question 63: A 15-year-old girl with juvenile myoclonic epilepsy has been well-controlled on sodium valproate for 2 years. She now presents requesting advice about contraception as she is sexually active. Liver function tests and full blood count are normal. She has no plans for pregnancy. What is the most appropriate management regarding her anti-epileptic medication?

A. Continue valproate but ensure effective contraception and comprehensive counselling about teratogenic risks with pregnancy prevention programme (Correct Answer)
B. Switch immediately to levetiracetam as it has a better safety profile in women of childbearing potential
C. Continue valproate without changes as she has no immediate pregnancy plans
D. Switch to lamotrigine gradually, though risk of seizure recurrence is significant in juvenile myoclonic epilepsy
E. Add folic acid 5mg daily and continue valproate unchanged

Explanation: ***Continue valproate but ensure effective contraception and comprehensive counselling about teratogenic risks with pregnancy prevention programme*** - **Sodium valproate** is the most effective treatment for **Juvenile Myoclonic Epilepsy (JME)**, and given she is well-controlled, continuing it is appropriate, provided robust measures are in place to prevent pregnancy. - The **Pregnancy Prevention Programme (PPP)** for valproate mandates **effective contraception** and comprehensive **counselling on teratogenic risks** (e.g., neural tube defects, developmental delay) for all females of childbearing potential, along with annual risk acknowledgement. *Switch immediately to levetiracetam as it has a better safety profile in women of childbearing potential* - While **levetiracetam** is safer in pregnancy, an immediate switch from a well-controlled regimen risks **seizure recurrence** or exacerbation, which could be dangerous. - **JME** is particularly responsive to valproate, and switching should be a carefully planned, gradual process, if at all, considering the patient's well-being and seizure control. *Continue valproate without changes as she has no immediate pregnancy plans* - This approach is unsafe and contrary to guidelines, as it exposes the patient to significant risks of **unplanned pregnancy** and severe **teratogenic effects** associated with valproate. - The absence of immediate pregnancy plans does not negate the need for active **risk management** and adherence to the **Pregnancy Prevention Programme (PPP)** for valproate. *Switch to lamotrigine gradually, though risk of seizure recurrence is significant in juvenile myoclonic epilepsy* - **Lamotrigine** can sometimes **exacerbate myoclonic seizures** in patients with **Juvenile Myoclonic Epilepsy (JME)**, making it a less suitable alternative for this specific syndrome. - While gradual switching is generally preferred for AEDs, selecting an agent known to worsen the patient's specific epilepsy type is inappropriate. *Add folic acid 5mg daily and continue valproate unchanged* - While **high-dose folic acid (5mg)** is crucial for women on valproate to reduce the risk of **neural tube defects**, it does not mitigate the broader **neurodevelopmental risks** (e.g., cognitive impairment) associated with valproate exposure. - Folic acid supplementation alone is insufficient and does not fulfill the comprehensive requirements of the **Pregnancy Prevention Programme (PPP)**, which includes robust contraception and counselling.

Question 64: A 12-year-old boy with type 1 diabetes for 5 years attends for routine screening. He is asymptomatic but fundoscopy reveals multiple microaneurysms and scattered dot-and-blot haemorrhages in both eyes, with no macular involvement or cotton wool spots. His HbA1c is 68 mmol/mol. What grade of diabetic retinopathy does this represent and what is the most appropriate management?

A. Mild non-proliferative diabetic retinopathy; continue annual screening and optimize glycaemic control (Correct Answer)
B. Moderate non-proliferative diabetic retinopathy; refer to ophthalmology for 6-monthly review
C. Severe non-proliferative diabetic retinopathy; urgent ophthalmology referral for consideration of laser therapy
D. Proliferative diabetic retinopathy; immediate ophthalmology referral for panretinal photocoagulation
E. Diabetic maculopathy; urgent ophthalmology referral for consideration of intravitreal therapy

Explanation: ***Mild non-proliferative diabetic retinopathy; continue annual screening and optimize glycaemic control***- This stage is characterized by the presence of at least one **microaneurysm** and potentially scattered **dot-and-blot haemorrhages**, but lacks features of more advanced disease like **cotton wool spots** or macular involvement.- Management involves **optimizing glycaemic control** (reducing HbA1c to target) and blood pressure, with standard **annual digital retinal screening** if no maculopathy is present.*Moderate non-proliferative diabetic retinopathy; refer to ophthalmology for 6-monthly review*- **Moderate NPDR** typically shows more extensive haemorrhages (>20 in each quadrant) or the presence of **cotton wool spots** and venous beading in one quadrant.- This patient's description of "scattered" lesions without cotton wool spots fits the mild category, requiring standard annual review rather than a **6-monthly ophthalmic follow-up**.*Severe non-proliferative diabetic retinopathy; urgent ophthalmology referral for consideration of laser therapy*- **Severe NPDR** is diagnosed using the **4-2-1 rule**: extensive haemorrhages in 4 quadrants, venous beading in 2, or **IRMA** (intraretinal microvascular abnormalities) in 1, none of which are described here.- This stage carries a high risk of progression to proliferative disease and requires **urgent specialist referral**, but not based on these asymptomatic findings.*Proliferative diabetic retinopathy; immediate ophthalmology referral for panretinal photocoagulation*- **Proliferative retinopathy (PDR)** is defined by the presence of **neovascularization** (new vessel growth) at the disc or elsewhere, or vitreous haemorrhage, none of which are noted on fundoscopy.- Since no new vessels or significant ischaemic features were noted, **panretinal photocoagulation** is not indicated at this time.*Diabetic maculopathy; urgent ophthalmology referral for consideration of intravitreal therapy*- **Maculopathy** is specifically defined by the presence of lesions (exudates, haemorrhages, or oedema) within the **macular area**, which would impact central vision.- The scenario explicitly states there is **no macular involvement**, making this diagnosis and the need for **anti-VEGF intravitreal therapy** incorrect.

Question 65: An 8-year-old boy with focal epilepsy has been seizure-free for 30 months on lamotrigine monotherapy. His parents enquire about discontinuing anti-epileptic medication. According to current guidelines, what factor would most strongly support continuing treatment rather than attempting withdrawal at this time?

A. Presence of persistent epileptiform discharges on EEG (Correct Answer)
B. Family history of epilepsy in a first-degree relative
C. Age at onset of first seizure being under 2 years
D. Previous failure of initial anti-epileptic drug requiring switch to lamotrigine
E. History of three seizures before achieving control

Explanation: ***Presence of persistent epileptiform discharges on EEG***- A **persistent epileptiform EEG** is one of the strongest predictors of seizure recurrence, doubling the risk compared to children with a normal EEG prior to withdrawal.- Most guidelines recommend performing a **repeat EEG** before discontinuing medication to help stratify the risk of relapse after a period of seizure freedom.*Family history of epilepsy in a first-degree relative*- While **genetic predisposition** is a factor in epilepsy etiology, it is not a primary contraindication for attempting drug withdrawal after sustained seizure freedom.- Clinical status and **EEG findings** carry much more weight in predicting successful withdrawal than a family history of the condition.*Age at onset of first seizure being under 2 years*- Very early onset may sometimes be associated with **symptomatic etiologies**, but age under 2 years is not a definitive barrier to withdrawal if the child is now stable and seizure-free.- Conversely, **older age at onset** (adolescence) is often viewed as a higher risk factor for lifelong epilepsy compared to childhood-onset epilepsy.*Previous failure of initial anti-epileptic drug requiring switch to lamotrigine*- Switching medications due to **side effects** doesn't preclude withdrawal; only **refractory epilepsy** (failure to control seizures) significantly increases the risk of recurrence.- Since the patient is currently well-controlled on **monotherapy**, the history of a drug switch is less concerning than active epileptiform activity on EEG.*History of three seizures before achieving control*- A **low number of total seizures** (such as three) before achieving remission is actually a favorable prognostic indicator for successful medication withdrawal.- High seizure frequency before control or a long duration before reaching **seizure-free status** would be more indicative of the need to continue treatment.

Question 66: A 5-year-old girl with newly diagnosed type 1 diabetes is being discharged from hospital. Her parents are being educated about sick day management. She develops gastroenteritis with vomiting and reduced oral intake. Her blood glucose is 15.2 mmol/L and ketones are 1.8 mmol/L. What is the most appropriate immediate management advice?

A. Continue usual insulin doses, encourage frequent small amounts of fluid, and check blood glucose and ketones 2-hourly (Correct Answer)
B. Reduce insulin dose by 50%, encourage clear fluids only, and check blood glucose 4-hourly
C. Omit insulin until she is eating normally again and monitor blood glucose 6-hourly
D. Give an additional correction dose of rapid-acting insulin and withhold all food until vomiting settles
E. Present immediately to emergency department for intravenous fluid therapy

Explanation: ***Continue usual insulin doses, encourage frequent small amounts of fluid, and check blood glucose and ketones 2-hourly*** - During illness, **insulin requirements** often increase due to stress hormones, making it crucial to continue usual basal insulin to prevent **diabetic ketoacidosis (DKA)**. - Frequent monitoring of **blood glucose and ketones** (every 2 hours) is vital during sick days to guide further management, including potential correction doses, and detect worsening metabolic state early. *Reduce insulin dose by 50%, encourage clear fluids only, and check blood glucose 4-hourly* - Reducing insulin doses in a child with **hyperglycemia (15.2 mmol/L)** and **ketosis (1.8 mmol/L)** is dangerous and will accelerate the progression to DKA. - **4-hourly monitoring** is insufficient for a sick child with type 1 diabetes, especially with vomiting and elevated ketones, as rapid metabolic changes can occur. *Omit insulin until she is eating normally again and monitor blood glucose 6-hourly* - **Never omit insulin** in type 1 diabetes, even with reduced oral intake, as this is a direct pathway to severe **DKA** due to the body's absolute insulin deficiency. - Monitoring **blood glucose 6-hourly** during illness is too infrequent and delays critical intervention for rapidly deteriorating metabolic status. *Give an additional correction dose of rapid-acting insulin and withhold all food until vomiting settles* - While a correction dose might be needed, **withholding all food** and fluids for an extended period in a vomiting child increases the risk of dehydration and can worsen ketosis by not providing glucose substrate. - The priority is to provide **small, frequent sips of carbohydrate-containing fluids** to maintain hydration and provide energy, even if the child is vomiting. *Present immediately to emergency department for intravenous fluid therapy* - Although concerning, her ketone level of **1.8 mmol/L** indicates moderate ketosis, which can often be managed at home initially with vigilant monitoring and oral fluids, before it progresses to severe DKA (typically >3.0 mmol/L). - Immediate emergency department presentation is typically warranted for signs of **established DKA** such as deep, rapid breathing (Kussmaul's), severe abdominal pain, persistent vomiting despite oral rehydration attempts, or altered consciousness.

Question 67: A 14-year-old girl with type 1 diabetes for 6 years presents with a 3-month history of delayed gastric emptying symptoms including early satiety, bloating, and postprandial nausea. Her HbA1c is 75 mmol/mol with significant glucose variability. Examination reveals no abdominal masses. Coeliac screening is negative. What investigation would best confirm the suspected diagnosis?

A. Gastric emptying scintigraphy (Correct Answer)
B. Oesophagogastroduodenoscopy with biopsy
C. Abdominal ultrasound
D. Hydrogen breath test
E. Autonomic function testing

Explanation: ***Gastric emptying scintigraphy***- This is the **gold standard** for diagnosing **diabetic gastroparesis** by measuring the rate at which a radiolabelled solid meal leaves the stomach over a 4-hour period.- Retention of more than **10% of the meal at 4 hours** confirms delayed gastric emptying in a patient with autonomic complications of Type 1 Diabetes.*Oesophagogastroduodenoscopy with biopsy*- Primarily used to exclude **mechanical obstruction**, peptic ulcers, or **coeliac disease**, but it cannot objectively measure gastric motility.- While used as a first-line test to rule out structural issues, it will typically show a **normal gastric lumen** in cases of functional gastroparesis.*Abdominal ultrasound*- Useful for detecting **gallstones** or pyloric stenosis, but it is not sensitive or specific enough to diagnose **gastroparesis**.- It provides anatomical mapping rather than the functional **dynamic assessment** required to evaluate gastric transit time.*Hydrogen breath test*- This test is specifically used to diagnose **Small Intestinal Bacterial Overgrowth (SIBO)** or **carbohydrate malabsorption** (e.g., lactose intolerance).- While SIBO can coexist with gastroparesis due to stasis, the test does not provide information on the **rate of stomach emptying**.*Autonomic function testing*- Used to assess **cardiovascular autonomic neuropathy** (e.g., heart rate variability), which shares a common pathology with gastroparesis.- While it confirms generalized **autonomic dysfunction**, it does not provide the **organ-specific data** needed to confirm a diagnosis of gastroparesis.

Question 68: A 7-year-old boy presents with episodic events described by his teacher. During class, he suddenly becomes unresponsive for approximately 10 seconds, stares blankly, and exhibits subtle eyelid fluttering. He immediately resumes his previous activity with no post-ictal confusion. These episodes occur 5-10 times daily. An EEG shows bilateral synchronous 3 Hz spike-and-wave discharges. What is the expected response to hyperventilation during EEG testing in this condition?

A. Provocation of typical absence seizures with 3 Hz spike-and-wave activity (Correct Answer)
B. Development of focal sharp waves in the temporal region
C. Appearance of hypsarrhythmia pattern
D. No significant change in EEG pattern
E. Emergence of polyspike-and-wave complexes at 4-6 Hz

Explanation: ***Provocation of typical absence seizures with 3 Hz spike-and-wave activity*** - **Hyperventilation** is a potent and classic precipitating factor for **childhood absence epilepsy (CAE)**, consistently inducing both the clinical staring spells and the characteristic **3 Hz spike-and-wave** discharges on EEG. - This physiological maneuver induces **hypocapnia** and subsequent **cerebral vasoconstriction**, which increases neuronal excitability and lowers the seizure threshold in genetically predisposed individuals with CAE. *Development of focal sharp waves in the temporal region* - **Focal sharp waves** localized to the temporal region are indicative of **focal epilepsy**, such as **temporal lobe epilepsy (TLE)**, not generalized absence epilepsy. - **Childhood absence epilepsy** is a **generalized epilepsy** syndrome, meaning EEG abnormalities are bilateral and synchronous, reflecting widespread cortical involvement rather than a localized origin. *Appearance of hypsarrhythmia pattern* - The **hypsarrhythmia** pattern on EEG is a hallmark of **West syndrome (infantile spasms)**, characterized by chaotic, high-amplitude slow waves and multifocal spikes. - West syndrome typically affects infants (under 1 year) and presents with specific infantile spasms and developmental regression, distinct from the clinical presentation and age of this 7-year-old with absence seizures. *No significant change in EEG pattern* - **Hyperventilation** is highly effective in activating absence seizures, provoking the characteristic EEG changes in a high percentage (around 90%) of untreated patients with **childhood absence epilepsy**. - A lack of any change in the EEG pattern during hyperventilation would argue strongly against a diagnosis of **absence epilepsy** and would prompt consideration of alternative conditions. *Emergence of polyspike-and-wave complexes at 4-6 Hz* - **Polyspike-and-wave complexes**, particularly at a faster frequency like 4-6 Hz, are the characteristic EEG findings associated with **Juvenile Myoclonic Epilepsy (JME)**. - While JME can include absence seizures, they are usually accompanied by prominent **myoclonic jerks**, typically upon awakening, and present in an older age group (adolescence) than the patient described.

Question 69: A 9-year-old boy with type 1 diabetes for 3 years attends his annual review. His blood tests show HbA1c of 58 mmol/mol. His mother reports that he has been experiencing morning hyperglycaemia despite good control during the day. His bedtime glucose readings are typically 6-8 mmol/L, but morning fasting glucose is 12-14 mmol/L. What phenomenon best explains his morning hyperglycaemia?

A. Dawn phenomenon (Correct Answer)
B. Somogyi effect
C. Insulin resistance syndrome
D. Dietary non-compliance
E. Insufficient total daily insulin dose

Explanation: ***Dawn phenomenon***- The **Dawn phenomenon** occurs due to a natural surge in **counter-regulatory hormones** like **growth hormone** and **cortisol** in the early morning, which triggers hepatic glucose production.- It is characterized by **morning hyperglycemia** despite normal or near-normal blood glucose levels at bedtime and the absence of **nocturnal hypoglycemia**.*Somogyi effect*- This describes **rebound hyperglycemia** in the morning as a response to an undetected episode of **hypoglycemia** during the night (around 2-3 AM).- Differentiating this from the dawn phenomenon requires measuring glucose in the middle of the night; the Somogyi effect would show **low midnight glucose**, whereas dawn phenomenon would show normal or high levels.*Insulin resistance syndrome*- This refers to a systemic condition where tissues have a **diminished response** to insulin, typically associated with **Type 2 Diabetes** and obesity, not specifically isolated morning spikes.- While it can coexist with Type 1 Diabetes (Double Diabetes), it does not explain the specific **circadian pattern** of glucose rise seen in this boy.*Dietary non-compliance*- This involves inconsistent carbohydrate intake or failure to bolus for meals, which usually results in **post-prandial spikes** throughout the day rather than just a fasting morning rise.- The scenario states the patient has **good control during the day** and normal bedtime readings, which makes nocturnal dietary issues unlikely.*Insufficient total daily insulin dose*- If the total daily insulin dose were insufficient, one would expect the **HbA1c** to be significantly higher and glucose levels to be elevated **consistently throughout the day**.- Since the patient has **good daytime control** and normal bedtime readings (6-8 mmol/L), the basal-bolus balance is generally appropriate, pointing away from a global insulin deficiency.

Question 70: A 6-year-old girl with type 1 diabetes mellitus is being started on insulin therapy. Her parents ask about the onset of action of different insulin preparations. What is the approximate onset of action of insulin aspart?

A. 5-15 minutes (Correct Answer)
B. 30-60 minutes
C. 1-2 hours
D. 2-4 hours
E. 4-6 hours

Explanation: ***5-15 minutes*** - **Insulin aspart** is a **rapid-acting** insulin analogue designed for **prandial** (mealtime) control, allowing for administration immediately before or even after eating. - Its rapid onset is due to a structural modification that prevents hexamer formation, allowing for faster absorption into the bloodstream compared to regular insulin. *30-60 minutes* - This is the typical onset of action for **Regular insulin**, which is classified as a **short-acting** insulin. - Because of this delay, Regular insulin must be administered at least **30 minutes before** a meal to match the postprandial glucose spike. *1-2 hours* - This onset of action is characteristic of **NPH (Neutral Protamine Hagedorn)**, which is an **intermediate-acting** insulin. - NPH is often used to provide basal coverage or twice-daily dosing but is not suitable for immediate mealtime glycemic control. *2-4 hours* - This time frame corresponds to the onset of **long-acting** insulin analogues such as **insulin glargine** (U-100) or **detemir**. - These insulins are used to provide stable **basal levels** of insulin throughout the day and night rather than responding to food intake. *4-6 hours* - This delay is significantly longer than any bolus or standard basal insulin, occasionally seen with very-long-acting formulations like **degludec** reaching steady states. - Using an insulin with this onset for mealtime coverage would lead to severe **post-meal hyperglycemia** followed by late-onset hypoglycemia.

Question 71: A 16-year-old boy with type 1 diabetes for 8 years presents for routine review. His HbA1c has been suboptimal at 75-82 mmol/mol over the past year despite multiple clinic appointments. He admits to frequently missing insulin doses and not checking his blood glucose regularly. He expresses frustration with diabetes management and feeling "different" from his peers. His growth and development are normal and there are no acute complications. What is the most appropriate initial approach to improve his diabetes management?

A. Refer to child and adolescent mental health services for assessment of depression
B. Switch to insulin pump therapy to simplify his insulin regimen
C. Arrange urgent admission for intensive diabetes education and supervised insulin administration
D. Explore his feelings about diabetes and collaborate on mutually agreed realistic goals (Correct Answer)
E. Prescribe continuous glucose monitoring to reduce the burden of finger-prick testing

Explanation: ***Explore his feelings about diabetes and collaborate on mutually agreed realistic goals***- This adolescent is experiencing **diabetes burnout** and psychosocial stress, common during this developmental stage; building a **therapeutic alliance** through empathetic communication is the essential first step.- Using **motivational interviewing** to explore his frustrations and set collaborative, incremental goals significantly improves **treatment adherence** and self-management in this age group.*Refer to child and adolescent mental health services for assessment of depression*- While **depression** is more prevalent in teens with chronic illness, the primary issue described is **diabetes-related distress** and non-adherence, rather than clear diagnostic features of a clinical mood disorder.- Initial psychosocial support for diabetes burnout should ideally be provided by the **diabetes multidisciplinary team** before a specialist mental health referral is considered.*Switch to insulin pump therapy to simplify his insulin regimen*- Successful **insulin pump therapy** requires high levels of engagement, including frequent carbohydrate counting and active management, which the patient is currently struggling with.- Introducing complex **technology** without addressing underlying motivation and non-adherence often leads to increased frustration and **poor glycemic control**, potentially increasing risks like DKA.*Arrange urgent admission for intensive diabetes education and supervised insulin administration*- Urgent admission is reserved for **acute medical complications** like DKA or severe illness, not for suboptimal HbA1c in an otherwise stable patient.- Forcible supervision can be **counterproductive** in adolescents, potentially damaging their developing sense of autonomy and increasing their resistance to long-term diabetes management.*Prescribe continuous glucose monitoring to reduce the burden of finger-prick testing*- While **continuous glucose monitoring (CGM)** can reduce the physical burden of testing, it still requires the patient to actively use the data to adjust insulin, which is unlikely if he is already **missing doses**.- Technology is an important adjunct, but it cannot replace the foundational need to address the patient's **psychological barriers** and motivation to engage with their diabetes care.

Question 72: A 11-year-old boy with refractory focal epilepsy is being evaluated for possible epilepsy surgery. He has tried four different antiepileptic drugs without adequate seizure control and experiences 2-3 seizures per week affecting his school attendance and quality of life. Video-EEG telemetry has identified a consistent seizure focus in the right frontal lobe. MRI brain shows focal cortical dysplasia in the same region. Neuropsychological testing shows age-appropriate cognitive function. Which additional investigation is most critical in determining his suitability for surgical resection?

A. Functional MRI to map eloquent cortex in relation to the dysplastic area (Correct Answer)
B. Positron emission tomography (PET) scan to assess metabolic activity
C. Single photon emission computed tomography (SPECT) during seizure
D. Genetic testing for epilepsy gene mutations
E. Repeat MRI with higher resolution 3T protocol

Explanation: ***Functional MRI to map eloquent cortex in relation to the dysplastic area*** - Since the seizure focus is already localized to the **right frontal lobe** via EEG and MRI, the priority shifts to determining the safety of resection relative to **eloquent cortex** (e.g., motor or language areas). - **fMRI** provides vital information on whether surgical removal of the **focal cortical dysplasia** can be achieved without causing permanent neurological or motor deficits. *Positron emission tomography (PET) scan to assess metabolic activity* - **PET scans** are primarily used to identify areas of **interictal hypometabolism** when structural MRI is normal or discordant with EEG. - In this case, the **seizure focus** is already well-defined by both MRI and EEG, making metabolic mapping less critical than functional mapping. *Single photon emission computed tomography (SPECT) during seizure* - **Ictal SPECT** is used to localize the seizure generator by measuring **regional cerebral blood flow** during an ictus, which is helpful in non-lesional cases. - Because a **structural lesion** (focal cortical dysplasia) has already been identified and correlates with the EEG, SPECT is not the most critical next step. *Genetic testing for epilepsy gene mutations* - **Genetic testing** can identify specific syndromes or etiologies, which may help predict pharmacological response or long-term prognosis. - While useful for diagnosis and counseling, it does not provide the **anatomical or functional mapping** required to determine the surgical feasibility of resecting a known lesion. *Repeat MRI with higher resolution 3T protocol* - A **3T MRI** is superior for detecting subtle **focal cortical dysplasia**, but the lesion in this patient has already been successfully identified. - Further high-resolution imaging will not address the primary surgical concern regarding the proximity of the **epileptogenic zone** to critical functional brain regions.

Question 73: A 4-year-old boy with newly diagnosed type 1 diabetes is being commenced on insulin therapy. His parents ask about the rationale for using rapid-acting insulin analogues (such as insulin aspart or lispro) rather than regular soluble human insulin for mealtime boluses. What is the primary pharmacokinetic advantage of rapid-acting insulin analogues in paediatric diabetes management?

A. They have a longer duration of action allowing less frequent dosing
B. They have more predictable absorption and reduced risk of late hypoglycaemia (Correct Answer)
C. They do not require injection and can be administered orally
D. They are more potent requiring lower doses per unit of carbohydrate
E. They do not require refrigeration improving storage convenience

Explanation: ***They have more predictable absorption and reduced risk of late hypoglycaemia*** - Rapid-acting analogues (insulin aspart, lispro) have a **faster onset** and **peak action** that more closely matches post-meal glucose absorption, leading to improved glycemic control. - Their **shorter duration of action** minimizes the risk of **postprandial late hypoglycaemia**, which is crucial in children with often unpredictable eating schedules and physical activity. *They have a longer duration of action allowing less frequent dosing* - Rapid-acting insulin analogues actually have a **shorter duration of action** (typically 3-5 hours) compared to regular human insulin (6-8 hours). - This pharmacokinetic property makes them ideal for mealtime coverage, while **long-acting basal insulins** are used for less frequent dosing to cover basal needs. *They do not require injection and can be administered orally* - Insulin, being a **protein hormone**, would be inactivated and digested by **gastrointestinal enzymes** if administered orally. - All currently available insulin preparations for **Type 1 diabetes** necessitate **subcutaneous injection** or continuous infusion via a pump. *They are more potent requiring lower doses per unit of carbohydrate* - Rapid-acting insulin analogues have a **similar biological potency** per unit as regular human insulin when it comes to lowering blood glucose. - Their primary advantage is their **pharmacokinetic profile** (speed of action and duration), not an inherently higher potency that would lead to lower dose requirements. *They do not require refrigeration improving storage convenience* - Like all insulin preparations, rapid-acting analogues **require refrigeration** for long-term storage to maintain their stability and efficacy. - While in use, they can be kept at **room temperature** for a limited time (usually 28 days), which is similar to the storage requirements for regular human insulin and not a unique advantage.

Question 74: A 15-year-old girl with juvenile myoclonic epilepsy has been well-controlled on sodium valproate 800 mg twice daily for 3 years. She attends clinic with her mother requesting information about future pregnancy planning. She is not currently sexually active. Understanding the teratogenic risks, which counseling point regarding valproate and pregnancy is most accurate?

A. Folic acid supplementation at standard doses (400 micrograms daily) eliminates the risk of neural tube defects
B. The risk of major congenital malformations with valproate exposure is approximately 10% (Correct Answer)
C. Valproate can be safely continued if conception is avoided during periods of high seizure frequency
D. Switching to lamotrigine before any pregnancy is planned eliminates all teratogenic risk
E. Developmental disorders in offspring occur only when major malformations are present

Explanation: ***The risk of major congenital malformations with valproate exposure is approximately 10%***- **Sodium valproate** carries the highest risk among antiepileptic drugs, with malformations occurring in about **10%** of pregnancies compared to 2–3% in the general population.- This high rate of **teratogenicity** is a primary reason for the strict regulations regarding its use in females of childbearing potential.*Folic acid supplementation at standard doses (400 micrograms daily) eliminates the risk of neural tube defects*- High-dose **folic acid (5 mg daily)** is required for women on antiepileptics, but it only **reduces** rather than eliminates the risk of **neural tube defects**.- Valproate-associated risks extend beyond neural tube defects to include **cardiac anomalies** and orofacial clefts which folic acid does not fully prevent.*Valproate can be safely continued if conception is avoided during periods of high seizure frequency*- The risk of **malformations** is associated with valproate exposure during the **first trimester** (organogenesis), regardless of seizure frequency at the time of conception.- Current **MHRA guidance** mandates that valproate must not be used in women of childbearing potential unless a **Pregnancy Prevention Programme** is in place.*Switching to lamotrigine before any pregnancy is planned eliminates all teratogenic risk*- While **lamotrigine** has a lower risk profile (2–3%), no antiepileptic drug is considered to have **zero teratogenic risk**.- Switching must be balanced against the risk of **seizure recurrence**, particularly as **Juvenile Myoclonic Epilepsy** often responds poorly to drugs other than valproate.*Developmental disorders in offspring occur only when major malformations are present*- Valproate exposure is associated with **neurodevelopmental delay** in 30–40% of children, which can occur **independently** of physical malformations.- These issues include a lower **IQ**, delays in walking and talking, and increased risks of **Autism Spectrum Disorder** or ADHD.

Question 75: A 10-year-old girl with type 1 diabetes for 3 years attends for annual screening. She is asymptomatic and examination is unremarkable. Screening blood tests show: HbA1c 56 mmol/mol (7.3%), serum creatinine 48 µmol/L, total cholesterol 4.2 mmol/L. Two consecutive early morning urine samples show albumin:creatinine ratios of 3.2 mg/mmol and 3.5 mg/mmol (normal <3.0 mg/mmol). Blood pressure is 108/68 mmHg (75th centile for age, sex and height). What is the most appropriate management?

A. Commence ACE inhibitor therapy to prevent progression of nephropathy
B. Repeat albumin:creatinine ratio in 3-6 months and review glycaemic control (Correct Answer)
C. Arrange urgent paediatric nephrology referral for renal biopsy
D. Commence statin therapy to reduce cardiovascular risk
E. Increase frequency of HbA1c monitoring to every 2 months

Explanation: ***Repeat albumin:creatinine ratio in 3-6 months and review glycaemic control*** - The presence of two elevated **albumin:creatinine ratio (ACR)** samples suggests **microalbuminuria**, an early sign of **diabetic nephropathy**. However, in children, microalbuminuria can be **transient** due to various factors like illness or exercise, and requires confirmation with further testing. - Her **HbA1c** of 7.3% indicates suboptimal **glycaemic control** (target typically <6.5% for children with type 1 diabetes). Optimizing glucose control is the cornerstone of preventing progression of diabetic complications, including nephropathy, and should be pursued before considering pharmacotherapy. *Commence ACE inhibitor therapy to prevent progression of nephropathy* - **ACE inhibitors** are typically considered for **persistent microalbuminuria** (defined as three out of three positive samples over 3-6 months) or established hypertension, which is not the case here given her normal blood pressure and only two positive ACRs. - Initiating an ACE inhibitor in a 10-year-old with only two samples suggesting microalbuminuria, without optimizing **glycaemic control** first, is premature. *Arrange urgent paediatric nephrology referral for renal biopsy* - **Renal biopsy** is an invasive procedure and is generally reserved for cases of **atypical kidney disease** presentation, such as rapidly declining **GFR**, significant **haematuria**, or proteinuria that is severe or unresponsive to standard management, which are not present here. - In a patient with established **type 1 diabetes** and early microalbuminuria, the findings are consistent with the natural progression of **diabetic kidney disease**, making a biopsy unnecessary at this stage. *Commence statin therapy to reduce cardiovascular risk* - This patient's **total cholesterol** level of 4.2 mmol/L is within an acceptable range for a child and does not warrant **statin therapy** at this age. Statin use in children is generally reserved for severe dyslipidaemia or specific genetic conditions. - While **cardiovascular risk** is a concern in type 1 diabetes, the primary intervention at this stage is **glycaemic control** and blood pressure management, not lipid-lowering medication. *Increase frequency of HbA1c monitoring to every 2 months* - Standard monitoring for **HbA1c** in type 1 diabetes is typically every 3 months, which provides sufficient data to assess **glycaemic control** and adjust treatment plans effectively. - While the HbA1c is elevated, simply increasing the **frequency of monitoring** without implementing changes to the **diabetes management plan** (e.g., insulin regimen, diet, exercise) will not improve her glycaemic control or address the emerging microalbuminuria.

Question 76: A 7-year-old girl with epilepsy has been taking lamotrigine monotherapy for focal seizures with good control for 2 years. She now presents with a 3-day history of widespread erythematous rash involving her trunk and limbs, fever of 38.5°C, and oral mucosal ulceration. She was started on co-trimoxazole for a urinary tract infection 5 days ago. Examination reveals tender bilateral cervical lymphadenopathy and facial oedema. Blood tests show: WBC 12.5 × 10⁹/L with 15% eosinophils, ALT 180 IU/L, AST 165 IU/L. What is the most appropriate immediate management?

A. Discontinue lamotrigine immediately and admit for monitoring and supportive care (Correct Answer)
B. Continue lamotrigine but discontinue co-trimoxazole and prescribe oral prednisolone
C. Reduce lamotrigine dose by 50% and start oral antihistamines for the rash
D. Discontinue both medications and commence alternative antiepileptic drug immediately
E. Continue both medications and start intravenous immunoglobulin therapy

Explanation: ***Discontinue lamotrigine immediately and admit for monitoring and supportive care***- The patient's presentation with **widespread erythematous rash**, **fever**, **oral mucosal ulceration**, **lymphadenopathy**, **facial oedema**, **eosinophilia** (15%), and **elevated liver enzymes** is highly suggestive of **DRESS syndrome** (Drug Reaction with Eosinophilia and Systemic Symptoms). - **Lamotrigine** is a well-known cause of DRESS syndrome, and immediate cessation of the suspected offending drug is the most critical initial step to prevent progression to multi-organ failure and reduce mortality. Admission is essential for comprehensive monitoring and supportive care. *Continue lamotrigine but discontinue co-trimoxazole and prescribe oral prednisolone* - Continuing **lamotrigine** is highly dangerous as it is a potent trigger for **severe cutaneous adverse reactions** (SCARs) like DRESS syndrome; its continued administration could worsen the life-threatening systemic reaction. - While co-trimoxazole can also cause DRESS, the long-term use of lamotrigine and its known interaction with co-trimoxazole (which can increase lamotrigine levels) makes lamotrigine a strong suspect. Discontinuing only co-trimoxazole while keeping the primary culprit would be insufficient. *Reduce lamotrigine dose by 50% and start oral antihistamines for the rash* - A **dose reduction** of the offending drug is inadequate for managing a severe hypersensitivity reaction like DRESS; complete and immediate withdrawal is necessary to halt the immune-mediated damage. - **Oral antihistamines** only provide symptomatic relief for pruritus and do not address the underlying systemic inflammation, organ involvement, or the progression of the DRESS syndrome. *Discontinue both medications and commence alternative antiepileptic drug immediately* - While discontinuing both suspected drugs is appropriate, immediately initiating a new **antiepileptic drug** during an acute DRESS episode carries a significant risk of inducing a cross-reactive hypersensitivity reaction or complicating the clinical picture. - The immediate priority is the stabilization of the patient and management of the DRESS syndrome; alternative seizure control strategies should be considered cautiously and tailored after the acute reaction is under control. *Continue both medications and start intravenous immunoglobulin therapy* - Continuing **lamotrigine** and **co-trimoxazole** in the presence of DRESS syndrome is contraindicated as it perpetuates the immune response and organ damage. - While **intravenous immunoglobulin (IVIG)** can be used in some severe SCARs like toxic epidermal necrolysis, it is not established as a primary or sole treatment for DRESS syndrome, and it does not replace the crucial need to withdraw the offending medication.

Question 77: A 13-year-old boy with type 1 diabetes for 5 years presents to clinic for routine review. His recent HbA1c is 68 mmol/mol (8.4%), which is higher than his previous values of 55-58 mmol/mol. His blood glucose diary shows unexplained hyperglycaemia in the late afternoon and evening despite apparently good adherence to his insulin regimen. He is Tanner stage 4 puberty. His weight is on the 50th centile and has remained stable. What is the most likely explanation for the deteriorating glycaemic control?

A. Insulin omission or reduction to avoid weight gain
B. Development of insulin antibodies reducing insulin efficacy
C. Physiological insulin resistance associated with puberty (Correct Answer)
D. Lipohypertrophy at injection sites reducing insulin absorption
E. Undiagnosed coeliac disease affecting carbohydrate absorption

Explanation: ***Physiological insulin resistance associated with puberty*** - During **mid-to-late puberty (Tanner stages 3-4)**, increased secretion of **growth hormone** and **sex steroids** naturally induces **insulin resistance**. - This physiological change explains the patient's **deteriorating glycemic control** (higher HbA1c, unexplained late afternoon/evening hyperglycemia) despite good adherence, often necessitating a **20-50% increase in insulin dosage**. *Insulin omission or reduction to avoid weight gain* - While **insulin omission (diabulimia)** is a concern in adolescents with type 1 diabetes, the patient's **stable weight on the 50th centile** makes this explanation less likely. - Deliberate insulin reduction often leads to more significant and variable **hyperglycemia** or recurrent **diabetic ketoacidosis**, not just a gradual rise in HbA1c. *Development of insulin antibodies reducing insulin efficacy* - Clinically significant **insulin antibodies** are exceedingly rare with modern **recombinant human insulin analogues** and typically manifest as very severe and erratic insulin resistance. - The presented scenario of a gradual, explainable deterioration during a specific physiological stage (puberty) does not align with the characteristics of insulin antibody-mediated resistance. *Lipohypertrophy at injection sites reducing insulin absorption* - **Lipohypertrophy** can indeed cause erratic and unpredictable insulin absorption, leading to **hyperglycemia** or **hypoglycemia**. - However, the patient's specific age and **Tanner stage 4** point more strongly towards a systemic physiological cause rather than a localized injection site issue. *Undiagnosed coeliac disease affecting carbohydrate absorption* - **Coeliac disease** is a common comorbidity with Type 1 Diabetes, but it typically causes **malabsorption**, leading to **unexplained hypoglycemia** or *improved* glycemic control if carbohydrate intake is poorly absorbed. - Furthermore, **weight loss** or **failure to thrive** would be expected, which contradicts this patient's **stable weight on the 50th centile** and *worsening hyperglycemia*.

Question 78: An 8-year-old boy with focal epilepsy has been taking carbamazepine for 18 months with complete seizure control. His mother brings him to clinic concerned about behavioral changes. Over the past 3 months, his teacher has reported poor concentration, irritability, and deteriorating academic performance. He has also had two unexplained falls without loss of consciousness. His carbamazepine level is within the therapeutic range. What is the most likely explanation for these symptoms?

A. Subclinical seizure activity despite therapeutic drug levels
B. Carbamazepine-induced hyponatraemia affecting cognitive function (Correct Answer)
C. Development of attention deficit hyperactivity disorder
D. Behavioral side effects of carbamazepine
E. Progression of underlying neurological condition

Explanation: ***Carbamazepine-induced hyponatraemia affecting cognitive function*** - **Carbamazepine** can cause **SIADH**, leading to **hyponatraemia** which presents insidiously with **irritability**, poor concentration, and **deteriorating academic performance**. - The unexplained falls may indicate **ataxia** or gait instability resulting from low sodium levels rather than seizure activity. *Subclinical seizure activity despite therapeutic drug levels* - While possible, the history of **complete seizure control** for 18 months makes new subclinical activity less likely than a metabolic side effect. - **Subclinical seizures** typically wouldn't explain the acute onset of **unexplained falls** as the primary motor symptom in this context. *Development of attention deficit hyperactivity disorder* - **ADHD** usually presents with long-standing patterns of inattention and does not explain the **physical falls** described. - The sudden decline in academic performance and behavior after 18 months of stability suggests an **acquired medical cause** rather than a primary psychiatric disorder. *Behavioral side effects of carbamazepine* - While **carbamazepine** can cause irritability, these effects usually appear near the **initiation of therapy** rather than after 18 months of good tolerance. - Behavioral side effects alone do not account for the **neurological signs** such as unexplained falls. *Progression of underlying neurological condition* - Progression typically manifests as **breakthrough seizures** or specific **focal neurological deficits** rather than generalized cognitive decline. - The clinical stability prior to these symptoms makes a **drug-induced metabolic complication** a more probable and reversible explanation.

Question 79: A 12-year-old girl with type 1 diabetes for 4 years is being reviewed in clinic. She uses an insulin pump (continuous subcutaneous insulin infusion) with good diabetes control. Her HbA1c is 52 mmol/mol (6.9%). She is going on a school sports trip involving 3 hours of moderate-intensity hiking daily for 5 days. She asks for advice about managing her diabetes during this activity. What is the most appropriate strategy to prevent hypoglycaemia during these activities?

A. Set a temporary basal rate reduction of 20-30% starting 1-2 hours before exercise (Correct Answer)
B. Discontinue the insulin pump during all physical activities and give subcutaneous rapid-acting insulin before meals
C. Increase carbohydrate intake to 30g per hour during exercise without adjusting basal insulin
D. Switch from pump therapy to multiple daily injections for the duration of the trip
E. Give 50% of usual bolus doses and reduce basal rate by 50% throughout the 5 days

Explanation: ***Set a temporary basal rate reduction of 20-30% starting 1-2 hours before exercise***- **Moderate-intensity exercise** increases insulin sensitivity, raising the risk of **hypoglycaemia**. Reducing the **basal rate** 1-2 hours prior allows existing insulin to wane and the lower dose to take effect, preventing a drop in blood glucose.- This is a well-established and flexible strategy for **insulin pump users** during **prolonged physical activity**, allowing for proactive management of glucose levels.*Discontinue the insulin pump during all physical activities and give subcutaneous rapid-acting insulin before meals*- Disconnecting the pump for 3 hours removes all **basal insulin**, which is essential for preventing **hyperglycaemia** and **ketosis**, even during exercise.- Relying solely on mealtime boluses would lead to uncontrolled glucose levels, as the body still requires continuous background insulin.*Increase carbohydrate intake to 30g per hour during exercise without adjusting basal insulin*- While additional **carbohydrates** are often needed, consuming them without reducing **insulin** can lead to **hyperglycaemia** and excessive caloric intake.- The safest approach for managing **prolonged activity** combines appropriate carbohydrate supplementation with a **reduction in insulin dosage**.*Switch from pump therapy to multiple daily injections for the duration of the trip*- Switching to **multiple daily injections (MDI)** from a pump removes the **precision** and **flexibility** of continuous insulin delivery.- This change is unnecessary and could lead to **unstable glycaemic control** due to different insulin kinetics and a lack of familiarity with the new regimen during a trip.*Give 50% of usual bolus doses and reduce basal rate by 50% throughout the 5 days*- A drastic **50% reduction** in both basal and bolus insulin across *all 5 days* is likely excessive for periods of rest or lower activity.- Such a broad reduction risks **hyperglycaemia** and potentially **diabetic ketoacidosis (DKA)** during non-exercise periods, making it an unsafe and imprecise strategy.

Question 80: A 5-year-old girl is brought to the paediatric neurology clinic following three witnessed episodes over 2 months. During these episodes, she suddenly stops playing, stares blankly for approximately 8-10 seconds with subtle eye fluttering, then immediately resumes her previous activity with no post-ictal confusion. Her development is normal and there are no abnormal findings on neurological examination. Her EEG shows 3 Hz spike-and-wave discharges during hyperventilation. What is the most important prognostic factor regarding seizure remission in this condition?

A. Age at onset of seizures (Correct Answer)
B. Frequency of seizures before treatment initiation
C. Duration of each individual seizure episode
D. Presence of photoparoxysmal response on EEG
E. Family history of epilepsy

Explanation: ***Age at onset of seizures*** - For **Childhood Absence Epilepsy (CAE)**, an earlier age of onset (typically between 4 and 8 years) is the most significant **positive prognostic factor** for achieving **seizure remission**. - Most children who present within this age range are likely to outgrow the condition by **adolescence**. *Frequency of seizures before treatment initiation* - While a high frequency of absence seizures can impact a child's daily life and learning, it does not reliably predict the likelihood of **long-term remission** in CAE. - Many children with frequent daily episodes achieve excellent control and eventual remission with appropriate **antiepileptic medication**. *Duration of each individual seizure episode* - Typical absence seizures are brief (5-10 seconds); slight variations in duration do not significantly alter the **prognostic outcome** for remission. - Significantly longer or **atypical absence seizures** (which have different clinical and EEG characteristics) carry a different, generally less favorable prognosis. *Presence of photoparoxysmal response on EEG* - A **photoparoxysmal response** is an EEG finding typically associated with certain **idiopathic generalized epilepsies**, such as Juvenile Myoclonic Epilepsy, rather than being a primary prognostic factor for typical CAE remission. - Its presence is not considered the most important factor in predicting the likelihood of outgrowing **Childhood Absence Epilepsy**. *Family history of epilepsy* - While CAE often has a **genetic predisposition**, the presence of a family history of epilepsy does not stand as the most important prognostic factor for **seizure remission** in an individual child. - The specific clinical presentation and characteristic **EEG findings (3 Hz spike-and-wave)** are more critical for predicting remission than family history alone.

Question 81: Which biochemical feature is the defining diagnostic criterion that distinguishes diabetic ketoacidosis from hyperosmolar hyperglycaemic state in children with type 1 diabetes mellitus?

A. Blood glucose concentration greater than 30 mmol/L
B. Serum osmolality greater than 320 mOsmol/kg
C. Presence of significant ketonaemia or ketonuria (Correct Answer)
D. Serum bicarbonate less than 15 mmol/L
E. pH less than 7.3

Explanation: ***Presence of significant ketonaemia or ketonuria*** - The hallmark of **Diabetic Ketoacidosis (DKA)** is the accumulation of ketone bodies resulting from **absolute insulin deficiency**, which leads to unrestrained **lipolysis**. - In contrast, **Hyperosmolar Hyperglycaemic State (HHS)** is characterized by a relative insulin deficiency sufficient to prevent **ketogenesis**, making the presence of high ketones the primary differentiator. *Blood glucose concentration greater than 30 mmol/L* - While extreme **hyperglycaemia** (>33.3 mmol/L) is a core feature of **HHS**, glucose levels in **DKA** can also be significantly elevated. - High blood glucose alone cannot distinguish between the two states as both involve **osmotic diuresis** and varying degrees of glucose elevation. *Serum osmolality greater than 320 mOsmol/kg* - Severe **hyperosmolality** is the defining trait of **HHS**, but mild elevations in osmolality can still occur in patients with **DKA**. - This parameter measures solute concentration and does not address the underlying **pathophysiological process** of ketone production unique to DKA. *Serum bicarbonate less than 15 mmol/L* - Low **bicarbonate** levels indicate **metabolic acidosis**, which is typical of **DKA** but is a consequence of ketone production rather than the specific diagnostic threshold. - In some cases of **HHS**, bicarbonate can be mildly reduced due to dehydration or lactic acidosis, making it less specific than direct ketone measurement. *pH less than 7.3* - A **pH less than 7.3** confirms **acidemia**, which is required for a diagnosis of **DKA**, but it is secondary to the accumulation of organic acids (ketones). - Like bicarbonate, **pH** is a measure of the severity of acidosis rather than the unique biochemical marker that identifies the metabolic pathway of **ketogenesis**.

Question 82: A 14-year-old boy with type 1 diabetes mellitus for 6 years attends the emergency department with a 2-day history of vomiting and abdominal pain. He has continued his insulin but has been unable to eat. Observations: temperature 37.8°C, heart rate 115 bpm, blood pressure 105/65 mmHg, respiratory rate 28/min with deep sighing respiration, capillary refill time 3 seconds. Capillary blood glucose is 18.2 mmol/L. Urinalysis shows 3+ ketones and 2+ glucose. What is the single most important immediate investigation to guide management?

A. Serum electrolytes, urea, creatinine and bicarbonate (Correct Answer)
B. Blood cultures and full blood count
C. Serum amylase and lipase
D. Chest radiograph
E. Abdominal ultrasound

Explanation: ***Serum electrolytes, urea, creatinine and bicarbonate*** - Confirmation of **Diabetic Ketoacidosis (DKA)** severity relies on assessing **bicarbonate** levels and pH, with a low bicarbonate being a key diagnostic criterion for metabolic acidosis. - Monitoring **electrolytes**, especially **potassium**, is crucial to guide fluid and insulin therapy, as DKA patients often have a total body potassium deficit, and managing it prevents life-threatening arrhythmias. *Blood cultures and full blood count* - While **infection** can precipitate DKA, these tests do not directly confirm the metabolic diagnosis or dictate the immediate fluid and insulin management strategy. - An elevated **white cell count** can be a stress response in DKA and is not always indicative of an underlying bacterial infection requiring immediate antimicrobial therapy. *Serum amylase and lipase* - **Abdominal pain** is a common symptom in DKA, often related to metabolic acidosis and gastric stasis, and typically resolves with DKA treatment. - Though DKA can cause mild elevations in **amylase**, these tests are not immediately essential unless there is a strong clinical suspicion of co-existing **acute pancreatitis** after initial stabilization. *Chest radiograph* - The **deep sighing respirations** (Kussmaul breathing) are a compensatory mechanism for the metabolic acidosis, not an indication of primary lung pathology requiring immediate imaging. - A chest X-ray would only be considered if there were specific clinical signs or symptoms suggesting a respiratory infection, such as **pneumonia**, as a potential trigger for DKA. *Abdominal ultrasound* - Abdominal pain in DKA is usually **functional** and non-surgical, meaning it's rarely due to an anatomical issue requiring immediate imaging. - This investigation is generally reserved for cases where abdominal pain persists despite correction of **metabolic derangements** and adequate rehydration.

Question 83: A 9-year-old boy with epilepsy has been taking sodium valproate 600 mg twice daily for juvenile myoclonic epilepsy for the past 3 years with good seizure control. At his routine clinic appointment, his weight has increased from the 75th to the 98th centile over the past year, and examination reveals mild tremor of his hands. Blood tests show: serum sodium 139 mmol/L, potassium 4.2 mmol/L, ALT 58 IU/L (normal 10-40), AST 52 IU/L (normal 10-40), ammonia 65 µmol/L (normal 11-32). What is the most appropriate next step in management?

A. Continue current dose and repeat liver function tests in 1 month
B. Discontinue valproate immediately and commence levetiracetam
C. Reduce valproate dose to 400 mg twice daily and monitor symptoms
D. Check serum valproate level and consider dose reduction if therapeutic (Correct Answer)
E. Add topiramate as adjunctive therapy to facilitate valproate withdrawal

Explanation: ***Check serum valproate level and consider dose reduction if therapeutic*** - The patient exhibits several **dose-related side effects of sodium valproate**, including **weight gain**, **fine tremor**, and **hyperammonemia** (elevated ammonia, 65 µmol/L). - Checking **serum valproate levels** is crucial to guide a safe dose adjustment, allowing mitigation of side effects while aiming to maintain **seizure control**, especially given his 3 years of seizure-freedom. *Continue current dose and repeat liver function tests in 1 month* - Continuing the current dose ignores significant clinical signs of **drug toxicity**, such as **tremor** and rapid **weight gain**, which require active management. - While transaminases are mildly elevated, the symptomatic presentation combined with **hyperammonemia** necessitates a more immediate and proactive intervention than just observation. *Discontinue valproate immediately and commence levetiracetam* - **Abrupt withdrawal** of an effective anti-epileptic drug like valproate carries a high risk of **seizure exacerbation** or **status epilepticus**. - Switching to a new drug should be a gradual process if necessary, and valproate remains a first-line treatment for **juvenile myoclonic epilepsy (JME)**. *Reduce valproate dose to 400 mg twice daily and monitor symptoms* - An **empirical dose reduction** without knowing the current **serum valproate level** risks reducing the drug below its therapeutic range, potentially leading to **seizure recurrence**. - **Therapeutic drug monitoring** provides objective data to guide dose adjustments, ensuring efficacy is maintained while managing side effects. *Add topiramate as adjunctive therapy to facilitate valproate withdrawal* - **Topiramate** can actually exacerbate **valproate-induced hyperammonemia**, making it an unsuitable choice, especially when the primary goal is to manage existing toxicity. - Introducing **polypharmacy** is generally avoided if monotherapy can be optimized, and direct dose adjustment of valproate is the initial appropriate step for managing its side effects.

Question 84: A 6-year-old girl with type 1 diabetes mellitus attends the paediatric diabetes clinic for routine follow-up. She was diagnosed 18 months ago and uses a basal-bolus insulin regimen. Her mother reports that she has been experiencing episodes of sweating, tremor, and irritability before breakfast on several occasions over the past 2 weeks. Blood glucose monitoring shows readings of 3.4 mmol/L and 3.6 mmol/L at these times. What is the most appropriate initial management step?

A. Reduce the evening long-acting insulin dose (Correct Answer)
B. Increase the evening long-acting insulin dose
C. Add a bedtime snack containing complex carbohydrates
D. Switch from basal-bolus to mixed insulin twice daily
E. Arrange urgent continuous glucose monitoring

Explanation: ***Reduce the evening long-acting insulin dose*** - The patient is experiencing recurrent **pre-breakfast hypoglycemia**, evidenced by readings <4 mmol/L and **autonomic symptoms** (sweating, tremors), which indicates an excess of **basal insulin** overnight. - Reducing the **evening long-acting insulin** is the standard adjustment to ensure glucose levels remain within the target range during the night and early morning hours. *Increase the evening long-acting insulin dose* - This action would dangerously lower overnight blood glucose levels even further, increasing the risk of **severe hypoglycemia** or seizures. - It is contraindicated when the patient is already showing **low glucose readings** and symptoms upon waking. *Add a bedtime snack containing complex carbohydrates* - While a bedtime snack might provide a temporary glucose buffer, it serves as a compensatory mechanism rather than addressing the **underlying cause** of insulin excess. - Relying on snacks can lead to **unnecessary weight gain** and may result in suboptimal glycemic control compared to adjusting the insulin dose. *Switch from basal-bolus to mixed insulin twice daily* - **Basal-bolus regimens** generally offer superior glycemic control and flexibility compared to **mixed insulin**, which is more prone to causing hypoglycemic peaks. - Switching the entire regimen is unnecessary when a simple **dose titration** of the current regimen is likely to resolve the issue. *Arrange urgent continuous glucose monitoring* - While **CGM** is a valuable tool for tracking trends, the diagnosis of fasting hypoglycemia is already clinically clear from the **SMBG (Self-Monitoring of Blood Glucose)** readings and symptoms. - Clinical management should be prioritized by adjusting the insulin dose first rather than delaying action for **urgent monitoring** setup.

Question 85: A 16-year-old boy with type 1 diabetes for 7 years presents for transition planning to adult services. His current HbA1c is 72 mmol/mol. He admits to frequently missing insulin doses and not checking blood glucose regularly. He expresses anxiety about managing his diabetes independently and feels overwhelmed by the responsibility. According to best practice guidelines for transition, which approach is most appropriate?

A. Transfer to adult services immediately as he is now 16 years old
B. Continue in paediatric services until he demonstrates better diabetes control
C. Arrange joint paediatric-adult clinic appointments with a structured transition plan (Correct Answer)
D. Refer to psychology services and delay transition until mental health improves
E. Transfer to adult services but arrange frequent review appointments initially

Explanation: ***Arrange joint paediatric-adult clinic appointments with a structured transition plan*** - Transition is a **gradual process**, not a single event, and **joint clinics** facilitate continuity of care and relationship building with the new adult team. - A **structured transition plan** addresses the patient's anxiety and poor self-management by providing a safety net and clear milestones during the shift to adult services. *Transfer to adult services immediately as he is now 16 years old* - **Immediate transfer** based solely on age is linked to poor clinical outcomes, including **deteriorating glycaemic control** and disengagement from care. - Abruptly moving a patient who is already **anxious** and struggling with self-care increases the risk of **diabetic ketoacidosis (DKA)** and loss to follow-up. *Continue in paediatric services until he demonstrates better diabetes control* - **Delaying transition** solely based on glycaemic control is ineffective, as the move to adult services is often the catalyst needed for maturing **self-management skills**. - Paediatric services are not designed for long-term care of older adolescents, and **prolonged stay** may foster unhealthy dependency rather than independence. *Refer to psychology services and delay transition until mental health improves* - While **psychological support** is crucial for managing diabetes-related anxiety, it should be integrated into the transition process rather than used as a reason to **postpone** it. - Delaying the process can exacerbate the patient's feelings of being overwhelmed; transition teams should include **multidisciplinary support** including psychologists. *Transfer to adult services but arrange frequent review appointments initially* - Transferring without a **joint handover** period lacks the necessary bridge between paediatric and adult care models, which differ significantly in **autonomy expectations**. - Frequent reviews in adult services alone do not address the **emotional transition** or the need for a familiar paediatric presence to boost the patient's confidence.

Question 86: A 9-year-old boy with drug-resistant epilepsy is being commenced on the ketogenic diet as adjunctive therapy. His seizures are characterized by daily focal impaired awareness seizures despite trials of three appropriate anti-epileptic medications. Before initiating the diet, baseline investigations reveal: random glucose 5.2 mmol/L, bicarbonate 24 mmol/L, urine ketones negative. Which metabolic parameter requires closest monitoring during the first 2 weeks after starting the ketogenic diet?

A. Serum lipid profile for hypercholesterolaemia
B. Blood glucose for hypoglycaemia
C. Serum bicarbonate for metabolic acidosis (Correct Answer)
D. Serum calcium for hypocalcaemia
E. Liver transaminases for hepatotoxicity

Explanation: ***Serum bicarbonate for metabolic acidosis*** - The ketogenic diet involves the production of **beta-hydroxybutyrate** and **acetoacetate**, which are organic acids that can lead to **metabolic acidosis** during the initiation phase. - **Serum bicarbonate** must be monitored closely in the first 2 weeks to ensure the patient does not develop clinically significant **ketoacidosis**, especially as the body adapts to fat-based metabolism. *Serum lipid profile for hypercholesterolaemia* - While a high-fat diet can lead to **hyperlipidaemia**, these changes typically manifest as a **long-term complication** rather than an acute risk in the first 14 days. - Routine monitoring of **cholesterol and triglycerides** is usually scheduled at 3-month intervals rather than the acute initiation window. *Blood glucose for hypoglycaemia* - Although **hypoglycaemia** can occur during the transition to ketosis, it is usually a transient risk managed in the **first 48–72 hours**. - Compared to the persistent risk of developing acidosis during the first few weeks, sustained glucose monitoring is less critical than **bicarbonate** surveillance after the initial few days. *Serum calcium for hypocalcaemia* - Long-term use of the ketogenic diet is associated with **osteopenia** and **kidney stones**, requiring **calcium and vitamin D** monitoring. - These mineral disturbances are **chronic side effects** and do not represent a primary acute metabolic concern within the first 2 weeks of therapy. *Liver transaminases for hepatotoxicity* - **Hepatotoxicity** is a rare complication and is more commonly associated with concurrent use of **valproate** rather than the diet itself. - While baseline and periodic **liver function tests** are performed, they are not the most critical metabolic parameter to track for acute diet-induced instability.

Question 87: A 15-year-old girl with type 1 diabetes for 9 years attends for routine screening. She is asymptomatic. Fundoscopy performed by the ophthalmologist reveals several microaneurysms and dot haemorrhages in both eyes, but no cotton wool spots, venous changes, or new vessel formation. Visual acuity is normal at 6/6 bilaterally. What is the most appropriate classification and management of her retinopathy?

A. No diabetic retinopathy; continue annual screening
B. Background diabetic retinopathy; continue annual screening (Correct Answer)
C. Pre-proliferative diabetic retinopathy; increase screening to 6-monthly
D. Proliferative diabetic retinopathy; refer for laser photocoagulation
E. Diabetic maculopathy; refer for optical coherence tomography

Explanation: ***Background diabetic retinopathy; continue annual screening*** - The presence of **microaneurysms** and **dot haemorrhages** in the absence of more severe signs (like cotton wool spots or new vessel formation) is characteristic of **background (non-proliferative) diabetic retinopathy**. - At this stage, the standard management involves continued **annual screening** to monitor progression, alongside optimization of **glycaemic control** and blood pressure. *No diabetic retinopathy; continue annual screening* - This classification is incorrect because the presence of **microaneurysms** and **dot haemorrhages** indicates the earliest signs of diabetic retinal damage. - A diagnosis of "No diabetic retinopathy" would mean a completely normal fundoscopic examination without any vascular changes. *Pre-proliferative diabetic retinopathy; increase screening to 6-monthly* - **Pre-proliferative retinopathy** is characterized by more severe signs such as **cotton wool spots**, venous beading, or intraretinal microvascular abnormalities (IRMA), which are explicitly absent in this patient. - Without these features, increasing screening frequency to **6-monthly** is not yet indicated. *Proliferative diabetic retinopathy; refer for laser photocoagulation* - **Proliferative diabetic retinopathy** is defined by the presence of **neovascularization** (new blood vessel formation) or vitreous/preretinal haemorrhage. - The patient has no new vessel formation, therefore, immediate referral for **laser photocoagulation** is not required. *Diabetic maculopathy; refer for optical coherence tomography* - **Diabetic maculopathy** involves oedema or exudates affecting the **macular area**, which typically leads to a reduction in **visual acuity**. - This patient has normal **visual acuity (6/6)** and no reported macular oedema or exudates, making this diagnosis unlikely.

Question 88: A 8-year-old girl with epilepsy controlled on sodium valproate 400 mg twice daily for 2 years presents with a 3-month history of tremor affecting her hands. The tremor is present at rest and worsens with intentional movements. Her seizures remain well controlled with no episodes in the past 18 months. Examination confirms a coarse tremor of both hands but is otherwise normal. Valproate level is within therapeutic range. What is the most appropriate management?

A. Continue valproate and add propranolol for tremor
B. Reduce valproate dose and monitor seizure control
C. Switch to levetiracetam as monotherapy
D. Add lamotrigine and gradually withdraw valproate (Correct Answer)
E. Reassure that tremor will resolve and continue current treatment

Explanation: ***Add lamotrigine and gradually withdraw valproate*** - **Valproate-induced tremor** is a common dose-related side effect; given the patient's age and sex, switching to a safer alternative like **lamotrigine** is appropriate to avoid long-term side effects such as **teratogenicity** and **metabolic issues**. - The standard management for changing anti-epileptic drugs in a stable patient is **cross-titration**, which involves adding the new drug and reaching a therapeutic dose before gradually tapering the offending agent to prevent **seizure recurrence**. *Continue valproate and add propranolol for tremor* - Adding a second medication to treat a side effect increases the **pill burden** and the risk of further side effects from the **beta-blocker**. - This approach does not address the underlying **valproate toxicity** or other long-term risks associated with valproate use in a young female. *Reduce valproate dose and monitor seizure control* - While reducing the dose may diminish the **tremor**, it often fails to eliminate it completely and places the patient at a higher risk of **breakthrough seizures**. - Since the patient has been seizure-free for 18 months, maintaining optimal control while transitioning to an agent without a **tremor-related profile** is preferred. *Switch to levetiracetam as monotherapy* - An abrupt switch or rapid substitution to **levetiracetam** carries a significant risk of **status epilepticus** or pharmacological instability. - While levetiracetam is a valid alternative, the **cross-tapering** method with a drug like lamotrigine is typically safer for ensuring continuous seizure suppression. *Reassure that tremor will resolve and continue current treatment* - **Valproate-induced tremors** are generally not self-limiting and persist as long as the medication remains at the current therapeutic dosage. - Ignoring the tremor can significantly impair functionality, such as **fine motor tasks** or school performance, and is not an appropriate clinical response.

Question 89: A 12-year-old boy with type 1 diabetes for 4 years presents for routine review. His recent capillary blood glucose readings show: pre-breakfast 6.5-8.0 mmol/L, pre-lunch 4.5-6.0 mmol/L, pre-evening meal 8.5-11.0 mmol/L, bedtime 5.5-7.0 mmol/L. His HbA1c is 64 mmol/mol. He takes insulin aspart before meals and insulin detemir at bedtime. Which modification to his insulin regimen would best address the pre-evening meal hyperglycaemia?

A. Increase the breakfast insulin aspart dose
B. Increase the lunchtime insulin aspart dose (Correct Answer)
C. Increase the evening insulin detemir dose
D. Add a second dose of insulin detemir in the morning
E. Change from insulin detemir to insulin glargine

Explanation: ***Increase the lunchtime insulin aspart dose***- The **pre-evening meal hyperglycemia** (8.5–11.0 mmol/L) indicates that the rapid-acting insulin given at lunch was insufficient to cover the carbohydrates consumed, leading to elevated glucose levels later in the afternoon.- Since **insulin aspart** is a rapid-acting analogue, increasing its **lunchtime dose** will provide better coverage for the lunch meal and the subsequent post-prandial period, effectively lowering blood glucose before the evening meal.*Increase the breakfast insulin aspart dose*- Increasing this dose would primarily affect **post-breakfast** and **pre-lunch** blood glucose levels.- The **pre-lunch** readings are already within the target range (4.5–6.0 mmol/L), so increasing this dose risks **hypoglycemia** during the late morning.*Increase the evening insulin detemir dose*- **Insulin detemir** is a long-acting basal insulin given at bedtime, primarily controlling **fasting (pre-breakfast)** glucose levels.- The **pre-breakfast** readings (6.5–8.0 mmol/L) and bedtime readings are not the primary issue, so increasing this dose would risk **nocturnal hypoglycemia** without directly addressing the pre-evening meal hyperglycemia.*Add a second dose of insulin detemir in the morning*- Adding a morning basal dose would provide additional long-acting insulin, but the specific pattern points to a **prandial insulin deficit** at lunch.- Adjusting the rapid-acting insulin dose for a specific meal-related hyperglycemia is generally the most direct and appropriate first-line strategy.*Change from insulin detemir to insulin glargine*- Both **insulin detemir** and **insulin glargine** are long-acting basal insulins, with similar profiles.- Switching basal insulin types is typically considered for issues like frequent **nocturnal hypoglycemia**, significant **glucose variability**, or insufficient duration of action, not for targeted pre-meal hyperglycemia from a specific bolus deficiency.

Question 90: A 10-year-old girl with refractory focal epilepsy is being evaluated for potential epilepsy surgery. Video-EEG telemetry has identified a clear seizure focus in the right anterior temporal region. MRI brain shows right mesial temporal sclerosis. Neuropsychological testing reveals normal cognitive function. Which additional investigation is most important before proceeding with surgical evaluation?

A. Functional MRI to assess language lateralization (Correct Answer)
B. Repeat EEG after sleep deprivation
C. PET scan to identify areas of hypometabolism
D. Single-photon emission computed tomography (SPECT)
E. Genetic testing for epilepsy gene mutations

Explanation: ***Functional MRI to assess language lateralization*** - Before **temporal lobe surgery**, it is critical to determine **language dominance** to minimize the risk of post-operative deficits, especially if surgical margins are close to eloquent areas. - **fMRI** provides a non-invasive alternative to the **Wada test** for assessing both language and memory lateralization in pediatric surgical candidates. *Repeat EEG after sleep deprivation* - The seizure focus has already been clearly identified in the **right anterior temporal region** through **video-EEG telemetry**, making repeat baseline studies redundant. - **Sleep deprivation** is typically used to increase the yield of interictal discharges in patients with non-diagnostic initial studies, which is not the case here. *PET scan to identify areas of hypometabolism* - **FDG-PET** is most useful when the **MRI is normal** or when there is discordance between EEG and imaging findings. - Since the MRI clearly shows **mesial temporal sclerosis** and matches the EEG focus, PET scan wouldn't change the management plan. *Single-photon emission computed tomography (SPECT)* - **Ictal SPECT** is used to localize the seizure onset zone by detecting focal hyperperfusion but is reserved for **MRI-negative cases** or discordant data. - In this patient, the **MRI and EEG are concordant**, so additional localization studies are not the priority over functional mapping. *Genetic testing for epilepsy gene mutations* - **Genetic testing** is indicated for specific syndromes or when there is no structural cause found; however, this patient has a clear **structural lesion** (**mesial temporal sclerosis**). - Identification of a mutation would not alter the surgical necessity or the pre-surgical mapping requirements for a **symptomatic focal epilepsy**.

Question 91: A 11-year-old boy with type 1 diabetes is brought to the emergency department with vomiting, abdominal pain, and lethargy. Capillary blood glucose is 28.5 mmol/L. Urinalysis shows 3+ ketones. Blood gas analysis reveals: pH 7.15, pCO2 2.8 kPa, bicarbonate 8 mmol/L, base excess -18. He weighs 35 kg. According to current DKA management guidelines, what is the most appropriate initial fluid bolus?

A. 0.9% sodium chloride 350 mL over 60 minutes (Correct Answer)
B. 0.9% sodium chloride 700 mL over 15 minutes
C. 0.45% sodium chloride with 5% dextrose 350 mL over 60 minutes
D. 0.9% sodium chloride 175 mL over 30 minutes
E. Hartmann's solution 350 mL over 30 minutes

Explanation: ***0.9% sodium chloride 350 mL over 60 minutes***- According to **BSPED guidelines**, children in **Diabetic Ketoacidosis (DKA)** should receive an initial fluid bolus of **10 mL/kg** (350 mL for a 35 kg child) of **0.9% sodium chloride**.- The bolus must be administered slowly over **60 minutes** to reduce the risk of **cerebral oedema**, unless the patient is in clinical **shock**.*0.9% sodium chloride 700 mL over 15 minutes*- This dose corresponds to **20 mL/kg** and is given too rapidly; high volumes and rapid infusion are major risk factors for **cerebral oedema** in children.- Rapid boluses over 15 minutes are reserved only for patients in **hypovolaemic shock** with signs of circulatory collapse.*0.45% sodium chloride with 5% dextrose 350 mL over 60 minutes*- **Hypotonic solutions** and **dextrose** should not be used for the initial fluid resuscitation bolus in DKA.- Dextrose is only added to the maintenance fluids once the blood glucose levels fall below **14 mmol/L**.*0.9% sodium chloride 175 mL over 30 minutes*- This represents a weight-based dose of **5 mL/kg**, which is lower than the recommended initial bolus of **10 mL/kg** for DKA management.- While caution is needed, **10 mL/kg** is the standard protocol to begin correcting dehydration before starting fixed-rate **insulin infusion**.*Hartmann's solution 350 mL over 30 minutes*- Although Hartmann's is a balanced crystalloid, **0.9% sodium chloride** is the preferred and standard recommended fluid for the initial bolus in paediatric **DKA protocols**.- The infusion rate of **30 minutes** is twice as fast as the recommended **60-minute duration** intended to prevent rapid osmotic shifts.

Question 92: A 5-year-old boy with newly diagnosed childhood absence epilepsy is being considered for treatment. He experiences 15-20 absence seizures daily, each lasting 5-10 seconds, significantly impacting his schooling. His neurological examination is normal and EEG shows classical 3 Hz spike-and-wave discharges. His mother is concerned about medication side effects. Which aspect of his condition makes treatment most strongly indicated at this time?

A. The high frequency of seizures affecting educational development (Correct Answer)
B. The risk of progression to generalized tonic-clonic seizures
C. The need to prevent cognitive decline from repeated seizures
D. The requirement for treatment before starting school activities
E. The potential for spontaneous remission being low without treatment

Explanation: ***The high frequency of seizures affecting educational development***- In **childhood absence epilepsy (CAE)**, treatment is primarily indicated when the frequent seizures result in **functional impairment**, significantly disrupting **learning and educational progress**.- Experiencing 15-20 daily seizures, each causing a brief **loss of awareness**, means the child is missing critical instructional periods, directly impeding his **academic performance**.*The risk of progression to generalized tonic-clonic seizures*- While a minority of children with CAE may eventually develop **generalized tonic-clonic seizures (GTCS)**, this potential future risk is not the most immediate or primary indication for starting treatment.- The decision to initiate medication is more strongly driven by the **current impact** of the absence seizures on the child's daily life and schooling.*The need to prevent cognitive decline from repeated seizures*- Absence seizures, even if frequent, are generally not associated with **progressive cognitive decline** or permanent brain damage over time.- Treatment aims to improve **attention and focus** by reducing seizure frequency, thereby enhancing learning and participation, rather than preventing a decline in innate **cognitive abilities**.*The requirement for treatment before starting school activities*- Treatment for CAE is indicated when seizures are **symptomatic** and interfere with a child's **development and daily functioning**, not merely as a prerequisite for school activities.- Children with very infrequent or mild absence seizures might not require immediate **pharmacological intervention** to participate in school.*The potential for spontaneous remission being low without treatment*- This statement is **incorrect**; a substantial proportion (approximately **70-80%**) of children with CAE achieve **spontaneous remission** by adolescence, often irrespective of early treatment.- Medication is used to manage acute symptoms and improve **quality of life** during the active phase of the disorder, not to fundamentally alter the long-term **natural history** or likelihood of remission.

Question 93: A 13-year-old girl with type 1 diabetes for 5 years presents to clinic. She uses an insulin pump (continuous subcutaneous insulin infusion). Over the past 3 months, her HbA1c has risen from 58 mmol/mol to 75 mmol/mol. Her insulin pump download shows frequent meal boluses being administered but basal rates appear unchanged from 3 months ago. She has grown 4 cm and gained 3 kg during this period. Which factor is most likely contributing to her deteriorating glycaemic control?

A. Development of insulin pump malfunction
B. Inadequate basal insulin rates for increased body mass (Correct Answer)
C. Coeliac disease affecting insulin absorption
D. Deliberate insulin omission (diabulimia)
E. Development of insulin antibodies

Explanation: ***Inadequate basal insulin rates for increased body mass***- During **puberty** and periods of rapid **growth** (4 cm and 3 kg in 3 months), total daily insulin requirements significantly increase due to the effects of **growth hormone** and sex hormones on insulin sensitivity.- The pump download confirms **unchanged basal rates** despite increasing body mass, indicating that the baseline insulin supply is no longer sufficient to maintain **glycemic control**.*Development of insulin pump malfunction*- **Pump malfunction** or infusion site failure typically leads to **acute hyperglycemia** and a high risk of **diabetic ketoacidosis (DKA)** rather than a gradual 3-month rise in HbA1c.- Frequent meal boluses being recorded in the download suggests the device is operational and being utilized by the patient.*Coeliac disease affecting insulin absorption*- **Coeliac disease** reduces the absorption of **carbohydrates** from the gut, which typically results in unexplained **hypoglycemia** and a decrease in insulin requirements.- It does not affect the absorption of **subcutaneous insulin**, but rather the metabolic demand for it based on nutrient intake.*Deliberate insulin omission (diabulimia)*- The pump download shows that **frequent meal boluses** are still being administered, which argues against systemic, deliberate **insulin omission** for weight control.- Patients with **diabulimia** often show a pattern of missed boluses and weight loss, whereas this patient has **gained weight** and is actively using the pump.*Development of insulin antibodies*- The development of clinically significant **insulin antibodies** is extremely rare with the use of modern **recombinant insulin analogues**.- This would not be the primary suspicion in a growing adolescent compared to the physiological demand for **dose titration** during puberty.

Question 94: A 7-year-old girl with focal epilepsy has been taking carbamazepine 200 mg twice daily for 18 months with good seizure control. She now presents with progressive unsteadiness, double vision, and drowsiness over the past week. Examination reveals horizontal nystagmus and ataxia. Her mother reports no recent illness or medication changes. Blood tests show: carbamazepine level 58 micromol/L (therapeutic range 20-50 micromol/L), sodium 128 mmol/L, normal renal and liver function. What is the most appropriate immediate management?

A. Reduce carbamazepine dose and monitor symptoms (Correct Answer)
B. Stop carbamazepine immediately and start levetiracetam
C. Continue current dose and treat with fluid restriction
D. Add sodium valproate to improve seizure control
E. Perform urgent brain MRI to exclude posterior fossa pathology

Explanation: ***Reduce carbamazepine dose and monitor symptoms*** - The patient presents with classic signs of **carbamazepine toxicity**, including **ataxia**, **nystagmus**, **diplopia**, and drowsiness, supported by a serum level of 58 micromol/L (above the therapeutic range). - A dose reduction is the most appropriate immediate step to alleviate these symptoms and manage the associated **SIADH-induced hyponatremia** (128 mmol/L) without risking the withdrawal seizures associated with abrupt discontinuation. *Stop carbamazepine immediately and start levetiracetam* - Abruptly stopping an anticonvulsant after long-term use, especially in a patient with previously well-controlled epilepsy, carries a significant risk of precipitating **status epilepticus** or breakthrough seizures. - While toxicity is evident, the drug should be **tapered** or its dose reduced rather than stopped suddenly, unless there is a life-threatening allergic reaction like Stevens-Johnson syndrome. *Continue current dose and treat with fluid restriction* - Continuing the current dose directly ignores the primary cause of the patient's symptoms, which is **dose-dependent toxicity** confirmed by the elevated serum drug levels. - While fluid restriction is a treatment for **hyponatremia**, it does not address the neurological symptoms caused by the **toxic concentration** of carbamazepine itself. *Add sodium valproate to improve seizure control* - The patient previously had **good seizure control**, indicating that adding another antiepileptic drug is unnecessary and could increase the risk of **drug-drug interactions** and further side effects. - Sodium valproate can inhibit the metabolism of certain drugs, which could potentially worsen the existing **carbamazepine toxicity**. *Perform urgent brain MRI to exclude posterior fossa pathology* - Although neurological symptoms like ataxia and nystagmus can be indicative of posterior fossa pathology, the presence of an **elevated carbamazepine level** and characteristic signs of drug toxicity provide a clear medical explanation for the symptoms. - An **urgent brain MRI** is not the initial most appropriate step when a clear pharmacological cause for the symptoms has been identified.

Question 95: What is the mechanism of action of insulin glargine in the management of type 1 diabetes mellitus?

A. It stimulates endogenous insulin production from pancreatic beta cells
B. It increases peripheral glucose uptake and decreases hepatic glucose production (Correct Answer)
C. It delays gastric emptying and reduces postprandial glucose excursions
D. It inhibits renal glucose reabsorption leading to glycosuria
E. It enhances insulin receptor sensitivity in target tissues

Explanation: ***It increases peripheral glucose uptake and decreases hepatic glucose production***- Like all insulin molecules, **insulin glargine** binds to insulin receptors to facilitate **glucose transport** into muscle and adipose tissue.- It provides a steady **basal level** of insulin, which suppresses **gluconeogenesis** and glycogenolysis in the liver to maintain stable fasting blood glucose.*It stimulates endogenous insulin production from pancreatic beta cells*- This describes the mechanism of **sulfonylureas**; in **Type 1 Diabetes**, beta cells are destroyed, making this mechanism ineffective.- **Insulin glargine** is an exogenous replacement and does not produce native insulin from the pancreas.*It delays gastric emptying and reduces postprandial glucose excursions*- This is the mechanism associated with **GLP-1 receptor agonists** and **amylin analogs** (like pramlintide).- **Insulin glargine** is a long-acting basal insulin and is not primarily intended to manage sudden **postprandial spikes**.*It inhibits renal glucose reabsorption leading to glycosuria*- This mechanism is specific to **SGLT2 inhibitors** (gliflozins), which work in the **proximal convoluted tubule** of the kidney.- Insulin does not promote the excretion of glucose in urine; it promotes the **utilization and storage** of glucose.*It enhances insulin receptor sensitivity in target tissues*- This describes the action of **insulin sensitizers** such as **metformin** or thiazolidinediones (TZDs).- While insulin glargine binds to receptors, its primary effect is direct **metabolic signaling** rather than increasing the sensitivity of those receptors to existing insulin.

Question 96: A 14-year-old boy with type 1 diabetes for 6 years attends for his annual review. His HbA1c is 68 mmol/mol (8.4%). Screening blood tests reveal: total cholesterol 5.8 mmol/L, HDL 1.1 mmol/L, LDL 3.9 mmol/L, triglycerides 1.8 mmol/L, TSH 8.2 mU/L (normal 0.5-5.0), free T4 10 pmol/L (normal 10-20). He reports feeling tired but has no other symptoms. What is the most appropriate next step in management?

A. Start atorvastatin for dyslipidaemia
B. Start levothyroxine replacement therapy
C. Repeat thyroid function tests in 3 months
D. Check thyroid peroxidase antibodies and start levothyroxine if positive (Correct Answer)
E. Reassure and recheck thyroid function tests in 12 months

Explanation: ***Check thyroid peroxidase antibodies and start levothyroxine if positive*** - The patient has **type 1 diabetes**, a strong risk factor for **autoimmune thyroid disease** (Hashimoto's thyroiditis), and presents with **symptoms of fatigue** along with **elevated TSH** and **low-normal free T4**, indicating symptomatic subclinical hypothyroidism. - Confirming the presence of **thyroid peroxidase (TPO) antibodies** will establish the autoimmune etiology, justifying the initiation of **levothyroxine replacement therapy** to alleviate symptoms and prevent progression to overt hypothyroidism. *Start atorvastatin for dyslipidaemia* - The patient's **dyslipidaemia** could be secondary to both **poor glycemic control** (HbA1c 8.4%) and the newly identified **subclinical hypothyroidism**. - It is more appropriate to first optimize **glycemic control** and treat the **hypothyroidism**, as these interventions may resolve the dyslipidaemia, reducing the need for **statin therapy** in a young patient. *Start levothyroxine replacement therapy* - While treatment with **levothyroxine** is likely indicated given the symptoms and lab results, it is best practice to first confirm the **autoimmune nature** of the thyroid dysfunction. - Testing for **TPO antibodies** before initiating lifelong therapy provides a more complete diagnosis and helps guide long-term management decisions, particularly in patients with **type 1 diabetes**. *Repeat thyroid function tests in 3 months* - This patient is **symptomatic** (fatigue) and has **type 1 diabetes**, putting him at high risk for autoimmune thyroiditis, making a watchful waiting approach inappropriate. - Delaying further investigation for 3 months would postpone a definitive diagnosis and the potential benefits of early treatment for his **subclinical hypothyroidism**. *Reassure and recheck thyroid function tests in 12 months* - **Reassurance** is not appropriate as the patient is experiencing **fatigue** and has clear biochemical evidence of **thyroid dysfunction** (elevated TSH, low-normal free T4). - Waiting **12 months** for a recheck is too long; his symptoms and test results warrant more immediate investigation and potential management, especially given his underlying **type 1 diabetes**.

Question 97: A 6-year-old boy with a history of febrile seizures at age 18 months presents with his first afebrile seizure. The episode lasted 20 seconds and consisted of right arm jerking followed by head turning to the right, with preserved awareness throughout. EEG shows focal epileptiform discharges in the left centrotemporal region. Brain MRI is normal. What is the most likely diagnosis?

A. Juvenile myoclonic epilepsy
B. Benign epilepsy with centrotemporal spikes (BECTS) (Correct Answer)
C. Childhood absence epilepsy
D. Temporal lobe epilepsy
E. Lennox-Gastaut syndrome

Explanation: ***Benign epilepsy with centrotemporal spikes (BECTS)*** - The clinical presentation of a school-aged child with focal motor seizures (right arm jerking, head turning) and **preserved awareness** is classic for BECTS, also known as **Benign Rolandic Epilepsy**. - The diagnosis is confirmed by the characteristic EEG finding of **centrotemporal spikes** and a **normal brain MRI**, with an excellent prognosis for remission by adolescence. *Juvenile myoclonic epilepsy* - This syndrome typically presents later in **adolescence** (ages 12-18) with a triad of **myoclonic jerks**, generalized tonic-clonic seizures, and absence seizures. - The EEG in JME shows **generalized 4-6 Hz polyspike-and-wave** discharges rather than focal centrotemporal spikes. *Childhood absence epilepsy* - Characterized by brief **staring spells** with sudden impairment of consciousness, usually lasting only seconds without a postictal state. - The diagnostic hallmark on EEG is a **generalized 3-Hz spike-and-wave** pattern, which differs from the focal discharges seen in this patient. *Temporal lobe epilepsy* - Often involves **impaired awareness** (complex partial seizures) and is frequently associated with **automatisms** (e.g., lip-smacking) or an aura. - While it can cause focal discharges, it is more likely to show abnormalities on **brain MRI** (such as hippocampal sclerosis) and has a less favorable prognosis than BECTS. *Lennox-Gastaut syndrome* - This is a severe childhood epilepsy characterized by **multiple seizure types** (atonic, tonic, atypical absence) and **intellectual disability**. - The EEG typically shows a **slow spike-wave pattern** (<2.5 Hz) and the condition is associated with significant developmental delay.

Question 98: A 9-year-old girl with type 1 diabetes mellitus presents to the diabetes clinic. She has been using a basal-bolus insulin regimen for 3 years. Her parents report that she frequently develops hypoglycaemia in the late afternoon after school sports. Blood glucose readings show values of 2.5-3.0 mmol/L at 4 PM on multiple occasions. Morning fasting glucose and pre-lunch readings are well controlled. Which adjustment to her insulin regimen is most appropriate?

A. Increase the morning rapid-acting insulin dose
B. Reduce the morning long-acting insulin dose (Correct Answer)
C. Increase the lunchtime rapid-acting insulin dose
D. Reduce the evening long-acting insulin dose
E. Add an additional snack before breakfast

Explanation: ***Reduce the morning long-acting insulin dose*** - Late afternoon **hypoglycaemia** (4 PM) following physical activity suggests that the **basal insulin** levels are too high during the period of increased insulin sensitivity induced by exercise. - Reducing the **morning long-acting insulin** (e.g., Glargine or Detemir) lowers the background insulin concentration specifically during the day, preventing drops when activity levels are highest. *Increase the morning rapid-acting insulin dose* - This would lead to **hypoglycaemia** before or during lunch, as the peak action of **bolus insulin** occurs 1–3 hours after administration. - It does not address the late afternoon issue and would likely worsen the patient's overall **glycaemic control** by causing earlier lows. *Increase the lunchtime rapid-acting insulin dose* - Increasing the **prandial dose** at lunch would cause significant **hypoglycaemia** in the immediate post-prandial period (1–3 hours after lunch). - It would exacerbate the existing low glucose readings at 4 PM rather than preventing them. *Reduce the evening long-acting insulin dose* - The **evening basal insulin** dose primarily regulates hepatic glucose production **overnight** and determines the **fasting morning glucose**. - Since the morning fasting readings are already well controlled, reducing this dose might lead to **hyperglycaemia** upon waking. *Add an additional snack before breakfast* - A snack before breakfast would be ineffective for **hypoglycaemia** occurring in the late afternoon, as the caloric intake would be metabolized long before the 4 PM drop. - While a **pre-exercise snack** might help, the medical adjustment focus should be on addressing the excessive **basal insulin** dose relative to the child's activity level.

Question 99: A 8-year-old girl presents with episodes of sudden loss of muscle tone causing her to drop objects or fall to the ground. The episodes last 1-2 seconds, occur multiple times daily, and there is no loss of consciousness. She has mild learning difficulties. Her neurologist suspects Lennox-Gastaut syndrome. An EEG shows slow spike-wave complexes. Considering the specific seizure type and syndrome, which anti-epileptic medication would be most appropriate as first-line therapy?

A. Carbamazepine
B. Sodium valproate (Correct Answer)
C. Ethosuximide
D. Phenytoin
E. Gabapentin

Explanation: ***Sodium valproate*** - **Sodium valproate** is the broad-spectrum first-line treatment for **Lennox-Gastaut syndrome** as it effectively targets multiple seizure types including **atonic (drop attacks)**, tonic, and atypical absence seizures. - It is the preferred initial choice for generalized epilepsy syndromes with a multi-focal nature and characteristic **slow spike-wave EEG** patterns. *Carbamazepine* - Primarily used for focal seizures, **carbamazepine** is known to **exacerbate** atonic, myoclonic, and absence seizures. - It is generally contraindicated in cases of **Lennox-Gastaut syndrome** as it can worsen the frequency of drop attacks. *Ethosuximide* - This medication is the gold standard for **typical absence seizures** but lacks efficacy in managing **atonic** or tonic seizures. - It does not address the broad range of seizure semiologies found in **Lennox-Gastaut syndrome**. *Phenytoin* - Similar to carbamazepine, **phenytoin** can aggravate certain generalized seizure types and is not a first-line agent for complex pediatric epilepsy syndromes. - Its side effect profile and narrow therapeutic window make it unsuitable for the long-term management of **childhood encephalopathic epilepsies**. *Gabapentin* - **Gabapentin** has a narrow spectrum of activity focused on focal seizures and is largely **ineffective** for the generalized seizures seen in this patient. - It is not recommended for the treatment of **Lennox-Gastaut syndrome** or typical **drop attacks**.

Question 100: A 15-year-old boy with type 1 diabetes for 8 years presents to clinic with concerns about his future. He asks about life expectancy and long-term outcomes. His HbA1c has averaged 58 mmol/mol over the past 5 years, he has no microvascular complications on screening, and he is generally adherent to treatment. His parents are present and supportive. What is the most appropriate response regarding long-term prognosis?

A. Life expectancy is significantly reduced regardless of glycaemic control
B. With good glycaemic control from an early age, life expectancy approaches that of the general population (Correct Answer)
C. Life expectancy is normal but quality of life is substantially impaired by complications
D. Prognosis discussion should be deferred until after transition to adult services
E. Outcomes are unpredictable and discussing prognosis is not helpful

Explanation: ***With good glycaemic control from an early age, life expectancy approaches that of the general population*** - Evidence from major trials like **DCCT/EDIC** shows that intensive **glycaemic control** (HbA1c <58 mmol/mol) significantly reduces the risk of **microvascular** and **macrovascular** complications. - Maintaining excellent control from a young age can close the gap in mortality, allowing patients to have a life expectancy nearly equal to those without **Type 1 Diabetes**. *Life expectancy is significantly reduced regardless of glycaemic control* - This statement is outdated and overly pessimistic, failing to account for modern **insulin analogues** and **continuous glucose monitoring**. - Modern management focuses on the fact that clinical outcomes and longevity are directly correlated with **metabolic control**. *Life expectancy is normal but quality of life is substantially impaired by complications* - **Complications** such as retinopathy or nephropathy are not inevitable if **glycaemic targets** and **blood pressure** are consistently managed. - Many patients with well-controlled diabetes lead highly active, high-quality lives without significant **morbidity** from long-term sequelae. *Prognosis discussion should be deferred until after transition to adult services* - High-quality diabetes care requires **open communication** and **empowerment** of the adolescent during the transition phase. - Delaying these discussions can lead to **anxiety** and disengagement from treatment at a time when the patient is taking more personal responsibility. *Outcomes are unpredictable and discussing prognosis is not helpful* - Prognosis is largely predictable based on **long-term glycaemic trends** and the presence or absence of early **microalbuminuria**. - Providing positive, evidence-based prognostic information serves as a powerful **motivator** for treatment adherence and self-care.

Question 101: An 11-year-old boy with epilepsy controlled on carbamazepine is seen in clinic. His mother mentions that he has been experiencing double vision intermittently over the past month. Examination reveals horizontal diplopia on lateral gaze bilaterally. Serum carbamazepine level is reported as 14 mg/L (therapeutic range 4-12 mg/L). Full blood count and liver function tests are normal. Understanding the relationship between carbamazepine dosing and its side effects, what is the most appropriate management?

A. Reduce carbamazepine dose and monitor symptoms (Correct Answer)
B. Continue current dose as diplopia often resolves spontaneously
C. Switch immediately to sodium valproate
D. Arrange urgent MRI brain to exclude structural pathology
E. Add pyridoxine supplementation to reduce toxicity

Explanation: ***Reduce carbamazepine dose and monitor symptoms*** - The patient presents with **diplopia** and a serum level of **14 mg/L**, which exceeds the standard **therapeutic range (4-12 mg/L)**, indicating dose-dependent neurotoxicity.- Reducing the dose is the most logical next step to resolve symptoms like **nystagmus**, **ataxia**, and **diplopia** while maintaining the drug's antiepileptic efficacy.*Continue current dose as diplopia often resolves spontaneously*- Dose-dependent side effects of **carbamazepine** do not typically resolve spontaneously if the serum concentration remains in the **toxic range**.- Maintaining the current dose risks further toxicity and persistent neurological symptoms that can interfere with daily activities.*Switch immediately to sodium valproate*- Switching medications is unnecessary when seizures are well-controlled and the side effects are **dose-related** rather than an **idiosyncratic reaction** (like a severe rash).- A rapid switch also carries risks of **seizure breakthrough** or adverse reactions to the new agent before attempting a simple dose adjustment.*Arrange urgent MRI brain to exclude structural pathology*- While new neurological symptoms can warrant imaging, the **temporal relationship** with elevated drug levels makes medication toxicity the most likely cause.- An **MRI brain** should only be considered if symptoms persist after the serum carbamazepine level has been returned to the **therapeutic range**.*Add pyridoxine supplementation to reduce toxicity*- **Pyridoxine (Vitamin B6)** supplementation has no clinical role in managing or reversing **carbamazepine toxicity**.- It is primarily used to prevent peripheral neuropathy associated with **isoniazid** or in specific cases of neonatal **pyridoxine-dependent epilepsy**.

Question 102: A 16-year-old girl with type 1 diabetes for 10 years attends for her annual complications screening. Retinal photography reveals several microaneurysms and small dot haemorrhages in both eyes but no cotton wool spots, venous changes, or new vessel formation. Visual acuity is 6/6 bilaterally and she is asymptomatic. Her HbA1c is 64 mmol/mol. What grade of diabetic retinopathy is present and what is the most appropriate management?

A. Background retinopathy; continue annual screening
B. Pre-proliferative retinopathy; refer to ophthalmology within 2 weeks
C. Mild non-proliferative retinopathy; arrange ophthalmology review within 13 weeks (Correct Answer)
D. Background retinopathy; arrange ophthalmology review within 6 weeks
E. Maculopathy; refer urgently to ophthalmology

Explanation: ***Mild non-proliferative retinopathy; arrange ophthalmology review within 13 weeks*** - This patient exhibits **microaneurysms** and **dot hemorrhages**, which are the hallmark features of **mild non-proliferative retinopathy** (formerly known as background retinopathy). - According to current guidelines for pediatrics and adults, the presence of these changes requires a routine **ophthalmology referral** typically completed within **13 weeks** to monitor for progression. *Background retinopathy; continue annual screening* - Annual screening is only appropriate if there is **no retinopathy** (R0) detected during the photography session. - Once **microaneurysms** or hemorrhages are present, the patient must be moved from screening into an **ophthalmology review** pathway. *Pre-proliferative retinopathy; refer to ophthalmology within 2 weeks* - **Pre-proliferative retinopathy** is characterized by more severe features such as **cotton wool spots**, **venous beading**, or intraretinal microvascular abnormalities (IRMA). - This patient lacks these high-risk features and **asymptomatic 6/6 vision**, making a 2-week urgent referral unnecessary at this stage. *Background retinopathy; arrange ophthalmology review within 6 weeks* - While the features described match the definition of **background retinopathy**, a **6-week timeframe** is generally reserved for more concerning findings or specific monitoring protocols. - Routine follow-up for mild, non-sight-threatening changes is standardized to the **13-week** window in most referral pathways. *Maculopathy; refer urgently to ophthalmology* - **Maculopathy** is diagnosed when there are **hard exudates**, hemorrhages, or thickening within one disc diameter of the **fovea**. - There is no evidence of macular involvement or **reduced visual acuity** in this patient to justify an urgent referral for maculopathy.

Question 103: A 4-year-old boy presents to the emergency department with a first afebrile seizure lasting 3 minutes. It was generalized tonic-clonic in nature and self-terminated. He has now fully recovered with no neurological deficit. His development has been normal and there is no family history of epilepsy. Examination is unremarkable. What is the most appropriate initial management?

A. Arrange urgent MRI brain and EEG, discharge with safety advice (Correct Answer)
B. Commence levetiracetam and arrange outpatient neurology review
C. Arrange routine paediatric neurology outpatient appointment
D. Admit for 24-hour observation and commence anti-epileptic medication
E. Perform lumbar puncture to exclude CNS infection

Explanation: ***Arrange urgent MRI brain and EEG, discharge with safety advice*** - In a child with a **first afebrile seizure** that has self-terminated and led to full recovery, it is crucial to arrange **urgent investigations** like an **MRI brain** to rule out structural causes and an **EEG** to assess the risk of recurrence and identify potential epilepsy syndromes. - Given the child has fully recovered with no neurological deficits and normal development, discharge with clear **safety advice** (e.g., avoiding unsupervised swimming, bathing, or climbing) is appropriate while awaiting specialist review and investigation results. *Commence levetiracetam and arrange outpatient neurology review* - **Anti-epileptic drugs (AEDs)** are generally not initiated after a single unprovoked seizure, especially in a child with no high-risk features for recurrence, as many children will not have another seizure. - Starting **levetiracetam** prophylactically would expose the child to potential side effects without a clear benefit at this initial stage. *Arrange routine paediatric neurology outpatient appointment* - While follow-up with neurology is necessary, a **routine outpatient appointment** is insufficient as the initial management for a first unprovoked seizure. - **Urgent investigations** (EEG, MRI) are typically recommended to identify the cause and risk factors promptly, which might be delayed by a routine appointment. *Admit for 24-hour observation and commence anti-epileptic medication* - Admission for **24-hour observation** is not usually indicated for a child who has fully recovered from a brief, self-terminated seizure and has no ongoing neurological compromise. - Commencing **anti-epileptic medication** after a single unprovoked seizure is generally not recommended unless there are clear indications for high recurrence risk, which are absent here. *Perform lumbar puncture to exclude CNS infection* - A **lumbar puncture** is not indicated in this case because the child is **afebrile**, has no signs of meningism (e.g., neck stiffness, photophobia), and has returned to baseline neurological function. - There are no clinical features suggestive of a **central nervous system infection** (meningitis or encephalitis) that would warrant an invasive procedure.

Question 104: A 13-year-old girl with type 1 diabetes for 5 years presents to the diabetes clinic. She has recently started menstruating and her HbA1c has risen from 58 mmol/mol to 71 mmol/mol over the past 6 months despite no changes to her insulin regimen. She is on a basal-bolus regimen with insulin glargine once daily and insulin aspart with meals. Her mother reports she has been compliant with insulin administration. Blood glucose monitoring shows elevated readings particularly in the mornings and before lunch. What is the most likely explanation for her deteriorating glycaemic control?

A. Reduced physical activity due to menstruation
B. Surreptitious consumption of high-carbohydrate foods
C. Insulin resistance associated with puberty and increased sex hormone production (Correct Answer)
D. Development of insulin antibodies reducing insulin efficacy
E. Gastroparesis causing erratic carbohydrate absorption

Explanation: ***Insulin resistance associated with puberty and increased sex hormone production***- During **puberty**, surges in **growth hormone** and **sex hormones** (estrogen, progesterone) lead to significant physiological **insulin resistance**, often requiring a substantial increase in insulin doses.- The recent onset of **menstruation** (menarche) is a clear indicator of puberty, directly correlating with the 6-month rise in **HbA1c** and consistent elevated morning and pre-lunch glucose readings despite reported compliance.*Reduced physical activity due to menstruation*- While physical activity impacts glucose, a temporary reduction during menstruation would typically not cause such a sustained and significant 6-month rise in **HbA1c** (from 58 to 71 mmol/mol).- The deterioration is more consistently explained by **hormonal shifts** associated with puberty rather than a minor, intermittent lifestyle change.*Surreptitious consumption of high-carbohydrate foods*- Although dietary non-compliance can lead to hyperglycemia, the clinical picture strongly points to the recent onset of **puberty** and **menstruation** as the primary triggers for deteriorating control.- The pattern of consistently **elevated morning** and pre-lunch readings is more characteristic of physiological insulin resistance rather than random surreptitious eating.*Development of insulin antibodies reducing insulin efficacy*- The development of **insulin antibodies** is exceedingly rare with modern **recombinant human insulin analogs** like glargine and aspart, which are engineered to minimize immunogenicity.- If present, it would typically result in more unpredictable and severe glucose fluctuations, not a steady upward trend synchronized with **pubertal milestones**.*Gastroparesis causing erratic carbohydrate absorption*- **Diabetic gastroparesis** is a severe, late complication of long-standing, poorly controlled diabetes and is highly improbable in a 13-year-old with only a 5-year history of type 1 diabetes.- Gastroparesis typically causes **delayed gastric emptying**, leading to erratic glucose levels and often **postprandial hypoglycemia** due to mismatched insulin action, not consistent morning and pre-lunch hyperglycemia.

Question 105: A 10-year-old boy with juvenile myoclonic epilepsy has been well-controlled on sodium valproate for 18 months. He presents with a 3-week history of a tremor affecting both hands, which is interfering with his schoolwork. His parents are concerned. Examination reveals a fine postural tremor but no other neurological signs. Sodium valproate level is within therapeutic range. What is the most appropriate management?

A. Add propranolol to control the tremor
B. Reduce the sodium valproate dose (Correct Answer)
C. Switch to levetiracetam
D. Reassure and continue current medication
E. Add pyridoxine supplementation

Explanation: ***Reduce the sodium valproate dose*** - **Fine postural tremor** is a well-recognized **dose-dependent side effect** of sodium valproate, occurring even when serum levels are within the **therapeutic range**. - Reducing the dose to the **minimum effective dose** often alleviates the tremor while maintaining seizure control in patients with **juvenile myoclonic epilepsy**. *Add propranolol to control the tremor* - While **beta-blockers** like propranolol can treat tremors, it is preferable to manage the **underlying cause** by adjusting the offending medication first. - Adding another drug increases the risk of **polypharmacy** and side effects in a pediatric patient who is otherwise well-controlled. *Switch to levetiracetam* - **Levetiracetam** is an alternative for juvenile myoclonic epilepsy, but switching medications is premature when the patient has been **well-controlled** for 18 months. - A complete switch carries a risk of **seizure recurrence** or development of new side effects, such as behavioral changes. *Reassure and continue current medication* - This approach is inappropriate because the tremor is **interfering with schoolwork** and daily functioning, necessitating medical intervention. - **Dose-dependent side effects** should be addressed if they negatively impact a patient's **quality of life**. *Add pyridoxine supplementation* - **Pyridoxine (Vitamin B6)** supplementation is used for specific metabolic conditions or to mitigate side effects of medications like **isoniazid**, but not for valproate-induced tremors. - There is no clinical **evidence base** supporting the use of pyridoxine to treat postural tremors caused by sodium valproate.

Question 106: A 7-year-old girl with type 1 diabetes for 2 years is admitted with her second episode of diabetic ketoacidosis in 6 months. Both episodes occurred when she was unwell with intercurrent infections. Her parents appear knowledgeable about diabetes management and the child is usually compliant. During admission, blood tests reveal: pH 7.18, bicarbonate 11 mmol/L, blood glucose 24.3 mmol/L, and ketones 4.8 mmol/L. What additional investigation would be most important to guide future management?

A. Measure C-peptide levels to assess residual beta-cell function
B. Test for anti-GAD antibodies to confirm autoimmune etiology
C. Screen for coeliac disease with tissue transglutaminase antibodies
D. Assess for psychosocial factors and perform home visit assessment (Correct Answer)
E. Check thyroid function tests for associated autoimmune thyroid disease

Explanation: ***Assess for psychosocial factors and perform home visit assessment***- Recurrent **Diabetic Ketoacidosis (DKA)** in a child with established Type 1 DM, despite seemingly knowledgeable parents and child compliance, strongly suggests underlying **psychosocial triggers** or barriers to implementing **sick-day rules**.- A **multidisciplinary assessment** and a **home visit** can uncover practical management challenges, family stress, or psychological factors that are not evident in a clinic setting but contribute to DKA recurrence.*Measure C-peptide levels to assess residual beta-cell function*- By 2 years post-diagnosis, most children with **Type 1 Diabetes** have very low or undetectable **C-peptide** levels, indicating minimal residual beta-cell function. This measurement would not significantly alter management.- Assessing residual insulin production does not address the immediate issue of recurrent DKA triggered by intercurrent infections, which points to a management or psychosocial gap.*Test for anti-GAD antibodies to confirm autoimmune etiology*- The diagnosis of **Type 1 Diabetes** is already established in this patient; therefore, re-testing for **anti-GAD antibodies** (a marker of autoimmune etiology) is not necessary for guiding future management of recurrent DKA.- This test helps confirm the initial diagnosis but provides no insight into the reasons for repeated metabolic decompensation in a child already diagnosed with and managing Type 1 DM.*Screen for coeliac disease with tissue transglutaminase antibodies*- While **Coeliac disease** is a common comorbidity with Type 1 Diabetes and routine screening is recommended, it typically presents with symptoms like malabsorption, growth faltering, or erratic blood glucose control, not recurrent DKA as its primary manifestation.- Screening for coeliac disease is part of comprehensive long-term care, but it is not the most immediate or crucial investigation to prevent further acute DKA episodes in this specific clinical scenario.*Check thyroid function tests for associated autoimmune thyroid disease*- **Autoimmune thyroid disease** (e.g., Hashimoto's thyroiditis) is frequently associated with Type 1 Diabetes (part of Polyglandular Autoimmune Syndrome), but thyroid dysfunction itself does not typically cause recurrent **DKA** during infections.- Like coeliac screening, checking thyroid function tests is important for **long-term surveillance** of comorbidities, but it is not the most important investigation to address the underlying cause of repeated DKA in this context.

Question 107: A 14-year-old boy with refractory epilepsy presents to clinic. He has failed to achieve adequate seizure control despite trials of three appropriate anti-epileptic medications at therapeutic doses, including sodium valproate, levetiracetam, and lamotrigine. His seizures consist of focal episodes with impaired awareness, sometimes progressing to bilateral tonic-clonic seizures. MRI brain shows a discrete area of cortical dysplasia in the right temporal lobe. What is the most appropriate next step in management?

A. Trial of a fourth anti-epileptic drug (topiramate)
B. Referral to a tertiary epilepsy surgery centre for evaluation (Correct Answer)
C. Commence ketogenic diet
D. Add clobazam as adjunctive therapy
E. Increase lamotrigine to supra-therapeutic levels

Explanation: ***Referral to a tertiary epilepsy surgery centre for evaluation***- This patient meets the criteria for **drug-resistant epilepsy**, having failed trials of three appropriate **anti-epileptic drugs (AEDs)**.- The presence of a **discrete structural lesion** (cortical dysplasia in the right temporal lobe) that correlates with the **focal seizure semiology** makes him an ideal candidate for **epilepsy surgery**, which offers the best chance for seizure freedom.*Trial of a fourth anti-epileptic drug (topiramate)*- The likelihood of achieving sustained **seizure freedom** with a fourth or subsequent AED after failing two or more is very low, typically **less than 5%**.- Further medical trials delay definitive treatment, especially when a **surgically remediable lesion** has been identified.*Commence ketogenic diet*- The **ketogenic diet** is an effective non-pharmacological treatment for **refractory epilepsy**, particularly in children, but it is generally considered when surgery is not an option or has failed.- For **lesional focal epilepsy**, **surgical resection** is usually the first-line advanced treatment due to its potential for cure.*Add clobazam as adjunctive therapy*- **Clobazam** is a benzodiazepine often used as an **adjunctive therapy** to reduce seizure frequency, but it is rarely curative for **drug-resistant epilepsy**.- Its use would represent continued **palliative pharmacotherapy** rather than addressing the underlying resectable **epileptogenic focus**.*Increase lamotrigine to supra-therapeutic levels*- Increasing **lamotrigine** to **supra-therapeutic levels** carries a high risk of **adverse effects**, such as rash, dizziness, and ataxia, without a significant increase in efficacy for **drug-resistant epilepsy**.- This approach does not address the underlying **structural cause** of the seizures and is not standard practice.

Question 108: A 5-year-old girl with type 1 diabetes is brought to the GP surgery by her mother who is concerned about repeated episodes of unusual behaviour in the mornings before breakfast. The child becomes pale, sweaty, and irritable, and on one occasion had a brief period of confusion. The mother checks blood glucose during an episode and finds it to be 2.2 mmol/L. She is currently on twice-daily mixed insulin. What is the most appropriate adjustment to her insulin regimen?

A. Increase the morning short-acting insulin dose
B. Reduce the evening long-acting insulin component (Correct Answer)
C. Add a bedtime snack with complex carbohydrates
D. Switch to a basal-bolus regimen with glargine at bedtime
E. Increase the evening short-acting insulin dose

Explanation: ***Reduce the evening long-acting insulin component***- The child's episodes of paleness, sweating, irritability, confusion, and a blood glucose of **2.2 mmol/L** in the mornings before breakfast are classic signs of **nocturnal or fasting hypoglycemia**.- In a twice-daily mixed insulin regimen, the **long-acting component** of the evening dose provides basal insulin coverage overnight. If this component is excessive, it will cause glucose levels to drop too low by morning.*Increase the morning short-acting insulin dose*- Increasing the morning short-acting insulin would primarily affect **post-breakfast blood glucose levels** and would not address the pre-breakfast hypoglycemia.- This action would be inappropriate and potentially dangerous as the child is already experiencing morning hypoglycemia.*Add a bedtime snack with complex carbohydrates*- While a bedtime snack can temporarily mitigate nocturnal hypoglycemia, it is a supportive measure rather than a definitive solution for an **overdosed insulin regimen**.- The primary goal should be to adjust the insulin dose to physiological needs, not to compensate for excess insulin with extra food intake.*Switch to a basal-bolus regimen with glargine at bedtime*- A **basal-bolus regimen** offers greater flexibility and often better control for type 1 diabetes, but it is a major regimen change rather than the most immediate and appropriate adjustment for correcting an existing insulin overdose.- This complex switch would require new dose titration and does not directly solve the current acute problem of excessive evening long-acting insulin.*Increase the evening short-acting insulin dose*- Increasing the **short-acting component** of the evening mixed insulin dose would lower blood glucose primarily in the period **immediately after dinner**.- This would likely cause early nocturnal hypoglycemia and would not resolve or could even worsen the pre-breakfast hypoglycemia observed.

Question 109: What is the first-line anti-epileptic drug recommended by NICE for newly diagnosed generalized tonic-clonic seizures in children aged 12 years and above?

A. Levetiracetam
B. Lamotrigine
C. Carbamazepine
D. Sodium valproate (Correct Answer)
E. Topiramate

Explanation: ***Sodium valproate*** - **Sodium valproate** is the recommended **first-line** treatment by NICE for newly diagnosed **generalized tonic-clonic seizures** due to its broad-spectrum efficacy. - Although highly effective, it carries significant **teratogenic risks** and potential neurodevelopmental issues, requiring careful consideration in females of childbearing potential. *Levetiracetam* - It is typically considered a **second-line** option or an alternative when first-line medications are unsuitable or not tolerated. - While effective for **generalized seizures**, it is not the initial first-line recommendation for newly diagnosed cases by NICE. *Lamotrigine* - Often used as an add-on therapy or second-line for generalized seizures, it can sometimes **exacerbate** certain generalized seizure types, such as myoclonic jerks. - It requires a slow **titration period** to minimize the risk of serious skin reactions like **Stevens-Johnson syndrome**. *Carbamazepine* - This drug is primarily used as **first-line therapy** for **focal seizures**, not for generalized seizures. - It is contraindicated in generalized epilepsies because it can **exacerbate generalized tonic-clonic**, absence, or myoclonic seizures. *Topiramate* - Recommended as an **adjunctive** treatment or a **second-line** option rather than a primary first-line choice for pediatric patients. - It carries a significant side-effect profile, including **cognitive slowing** and an increased risk of **renal stones**.

Question 110: A 12-year-old boy with type 1 diabetes for 4 years attends clinic. His HbA1c has been consistently 55-60 mmol/mol (7.2-7.6%) over the past 2 years. He is on a basal-bolus insulin regimen. Annual screening reveals microalbuminuria with an albumin:creatinine ratio of 4.5 mg/mmol on two separate occasions. Blood pressure is 118/72 mmHg (90th centile). What is the most appropriate initial management?

A. Start ACE inhibitor therapy
B. Intensify insulin therapy to reduce HbA1c to <48 mmol/mol (Correct Answer)
C. Start low-dose aspirin therapy
D. Refer urgently to paediatric nephrology
E. Review in 12 months with repeat albumin:creatinine ratio

Explanation: ***Intensify insulin therapy to reduce HbA1c to <48 mmol/mol*** - The first-line management for early **diabetic nephropathy** in children is optimizing **glycaemic control**, as improving blood glucose levels can reverse persistent **microalbuminuria**. - This patient's **HbA1c** (55-60 mmol/mol) exceeds the NICE-recommended target of **<48 mmol/mol** (6.5%), suggesting significant room for improvement in metabolic management. *Start ACE inhibitor therapy* - **ACE inhibitors** are typically reserved for patients who have persistent microalbuminuria despite **optimized glycaemic control** or those with frank **hypertension**. - While his blood pressure is at the **90th centile**, the diagnosis of hypertension requires higher values or repeated elevated readings, making insulin adjustment a more appropriate initial step. *Start low-dose aspirin therapy* - There is currently no clinical indication for **low-dose aspirin** in the routine management of **paediatric diabetic nephropathy**. - Aspirin is generally used for secondary prevention of **cardiovascular disease**, which is not the immediate concern for this 12-year-old child. *Refer urgently to paediatric nephrology* - Early-stage microalbuminuria is typically managed within **paediatric diabetes clinics** through lifestyle and medical optimization. - An **urgent nephrology referral** is premature and only indicated for rapid decline in **GFR**, nephrotic-range proteinuria, or resistant hypertension. *Review in 12 months with repeat albumin:creatinine ratio* - Doing nothing for a year is inappropriate given that **persistent microalbuminuria** (confirmed on two occasions) is a marker of early **organ damage**. - Delaying intervention increases the risk of progression to **macroalbuminuria** and irreversible **chronic kidney disease**.

Question 111: A 9-year-old girl with epilepsy has been taking phenytoin for focal seizures with impaired awareness. She presents to clinic for routine review. Her mother reports that her seizures are well-controlled but she has noticed coarsening of her daughter's facial features and excessive gum growth. Blood tests show therapeutic phenytoin levels. Which medication change would be most appropriate to address these adverse effects while maintaining seizure control?

A. Switch to carbamazepine
B. Switch to lamotrigine (Correct Answer)
C. Add sodium valproate to phenytoin
D. Reduce phenytoin dose by 50%
E. Switch to levetiracetam

Explanation: ***Switch to lamotrigine*** - **Lamotrigine** is an effective anti-epileptic drug for **focal seizures** and is particularly suitable here as it does not cause the **cosmetic side effects** like gingival hyperplasia or facial coarsening seen with phenytoin. - It offers good **tolerability** and is a preferred choice for long-term management in children, avoiding the fibroblast stimulation responsible for **gum growth**. *Switch to carbamazepine* - While effective for **focal seizures**, **carbamazepine** is known for its own set of significant side effects, including a risk of **Stevens-Johnson syndrome** and **hyponatremia**. - It is also an **enzyme inducer** and may not be the ideal choice to switch to when the primary goal is to improve cosmetic side effects without introducing new significant risks. *Add sodium valproate to phenytoin* - This approach would involve **polytherapy**, increasing the risk of **drug-drug interactions** and potential side effects from sodium valproate itself, such as **weight gain** or **hepatic dysfunction**. - It does not directly address the **phenytoin-induced adverse effects** (gingival hyperplasia, facial coarsening) which are the main concern. *Reduce phenytoin dose by 50%* - Reducing the phenytoin dose significantly would likely lead to **subtherapeutic levels**, resulting in a **loss of seizure control** which is unacceptable given the seizures are currently well-controlled. - The cosmetic side effects like **gingival hypertrophy** are often dose-independent and require a change of medication rather than just a dose reduction, especially when levels are already therapeutic. *Switch to levetiracetam* - **Levetiracetam** is an effective broad-spectrum anti-epileptic drug for focal seizures and does not cause cosmetic side effects. - However, it is frequently associated with **behavioral side effects** like **irritability**, **aggression**, and **mood changes** in children, which might be a concern in a 9-year-old girl.

Question 112: A 6-year-old boy with type 1 diabetes mellitus is brought to the emergency department with a 24-hour history of vomiting and abdominal pain. His mother reports that he has been drinking excessively. On examination, he appears dehydrated with capillary refill time of 4 seconds. His respiratory rate is 32 breaths per minute with deep sighing respirations. Capillary blood glucose is 28.5 mmol/L and capillary ketones are 5.2 mmol/L. What is the most appropriate initial fluid resuscitation?

A. 0.9% sodium chloride 10 mL/kg bolus over 1 hour (Correct Answer)
B. 0.45% sodium chloride with 5% dextrose 10 mL/kg bolus over 1 hour
C. 0.9% sodium chloride with potassium chloride 10 mL/kg bolus over 1 hour
D. Hartmann's solution 20 mL/kg bolus over 15 minutes
E. 0.9% sodium chloride 20 mL/kg bolus with insulin infusion

Explanation: ***0.9% sodium chloride 10 mL/kg bolus over 1 hour***- This patient is in **diabetic ketoacidosis (DKA)** with signs of shock (prolonged **capillary refill time of 4 seconds**), necessitating a cautious fluid bolus of **isotonic saline** (0.9% NaCl).- Current **BSPED guidelines** recommend an initial bolus of **10 mL/kg over 1 hour** to restore circulatory volume while minimizing the risk of **cerebral oedema**.*0.45% sodium chloride with 5% dextrose 10 mL/kg bolus over 1 hour*- **Hypotonic fluids** are never used for initial volume resuscitation in DKA as they can trigger a rapid shift of water into brain cells, causing **cerebral oedema**.- Dextrose should only be added to maintenance fluids once blood glucose levels drop, not during the **initial resuscitation** phase.*0.9% sodium chloride with potassium chloride 10 mL/kg bolus over 1 hour*- **Potassium** should not be included in the initial fluid bolus; it is added later to the **maintenance and deficit replacement** fluids after confirming renal function.- Adding potassium too early or during rapid boluses can lead to dangerous **cardiac arrhythmias** if there is underlying renal impairment or rapid electrolyte shifts.*Hartmann's solution 20 mL/kg bolus over 15 minutes*- While Hartmann's is a balanced crystalloid, the volume of **20 mL/kg** and the rapid delivery over **15 minutes** is too aggressive for a child in DKA and increases the risk of **cerebral swelling**.- Resuscitation in paediatric DKA should be more gradual (typically **10 mL/kg**) unless the patient is in profound, life-threatening **uncompensated shock**.*0.9% sodium chloride 20 mL/kg bolus with insulin infusion*- **Insulin therapy** should never be started at the same time as initial fluid resuscitation; it must be delayed for at least **one hour** after fluids have commenced.- Starting insulin too early can cause a precipitous drop in **plasma osmolality**, which significantly raises the risk of **cerebral oedema**.

Question 113: A 16-year-old boy with drug-resistant focal epilepsy undergoes video-EEG telemetry to characterize his seizures before possible epilepsy surgery. The recordings show that his seizures consistently originate from the left temporal lobe, and neuropsychological testing confirms left hemisphere language dominance. MRI reveals left mesial temporal sclerosis. What is the most significant risk associated with left temporal lobe resection in this patient?

A. Contralateral hemiparesis
B. Visual field defect
C. Verbal memory impairment (Correct Answer)
D. Non-verbal memory impairment
E. Personality change

Explanation: ***Verbal memory impairment***- In patients with **left hemisphere language dominance**, the **left temporal lobe**, specifically the **hippocampus**, is critical for **verbal memory** processing.- Resection of the **dominant mesial temporal lobe** carries a high risk of postoperative decline in the ability to learn and recall new verbal information, making it the most significant risk in this context.*Contralateral hemiparesis*- This complication arises from damage to the **primary motor cortex** or the **corticospinal tract**, which are located in the frontal lobe and brainstem, areas generally preserved during a temporal lobe resection.- Standard **temporal lobe surgery** focuses on anterior and mesial structures, positioned distant from the **motor pathways**.*Visual field defect*- While a **superior quadrantanopia** (pie-in-the-sky defect) can occur due to injury to **Meyer's loop** (optic radiation) in the temporal lobe, it is often less functionally debilitating than severe memory loss.- Though a known surgical risk, it is usually not considered the *most significant* long-term neuropsychological consequence compared to language-related memory deficits in the dominant hemisphere.*Non-verbal memory impairment*- **Non-verbal memory**, such as visuospatial and facial recognition, is predominantly mediated by the **non-dominant (typically right)** temporal lobe.- Since this patient has **left hemisphere language dominance** and **left temporal lobe pathology**, the risk of **non-verbal memory impairment** is substantially lower than that for verbal memory.*Personality change*- Significant shifts in **personality**, social conduct, and executive functions are more commonly linked to damage or resection of the **frontal lobes**.- While temporal lobe epilepsy can have associated behavioral changes, direct surgical removal of the **mesial temporal lobe** itself typically does not result in global personality alterations.

Question 114: A 4-year-old boy with newly diagnosed type 1 diabetes is being discharged from hospital. His parents are being educated about sick day management. Which of the following statements about sick day rules is correct?

A. Insulin doses should be reduced by 50% during illness to prevent hypoglycaemia
B. Insulin should never be stopped, even if the child is not eating (Correct Answer)
C. Blood glucose monitoring can be reduced to twice daily during illness
D. Ketone testing is only necessary if blood glucose exceeds 20 mmol/L
E. Carbohydrate intake should be restricted to prevent hyperglycaemia

Explanation: ***Insulin should never be stopped, even if the child is not eating*** - During illness, **stress hormones** like cortisol and adrenaline increase **insulin resistance** and glucose production, necessitating continuous insulin therapy. - Stopping insulin is a primary trigger for **diabetic ketoacidosis (DKA)**, as the body requires at least basal insulin to suppress lipolysis. *Insulin doses should be reduced by 50% during illness to prevent hypoglycaemia* - Reducing insulin arbitrarily is dangerous because illness typically increases **metabolic demands** and hyperglycemic risk. - While mealtime insulin might be adjusted based on intake, **basal insulin** usually needs to be maintained or even increased to prevent ketosis. *Blood glucose monitoring can be reduced to twice daily during illness* - Monitoring frequency should be **increased** to every 2–4 hours (or more frequently) during sick days to track rapid changes in glucose levels. - Frequent checks allow for timely **correction boluses** and help identify the early onset of dehydration or DKA. *Ketone testing is only necessary if blood glucose exceeds 20 mmol/L* - Current guidelines recommend checking for **ketones** if the child is unwell or if blood glucose levels rise above **14 mmol/L**. - Ketones indicate how much fat is being metabolized for energy, acting as an early warning sign of impending **ketoacidosis** regardless of the specific glucose level. *Carbohydrate intake should be restricted to prevent hyperglycaemia* - Adequate **carbohydrate intake** must be maintained (using clear fluids or sugary drinks if solids aren't tolerated) to provide energy and prevent starvation ketosis. - Restricting carbohydrates while the body is under stress can lead to **hypoglycemia** or further promote ketone production.

Question 115: A 15-year-old girl with juvenile myoclonic epilepsy is well-controlled on sodium valproate. She is sexually active and requests contraceptive advice. She is counselled about the teratogenic risks of valproate. After discussion, she wishes to continue valproate as she has failed multiple other antiepileptic drugs and had frequent seizures. What is the most appropriate contraceptive management?

A. Combined oral contraceptive pill as first-line choice
B. Progesterone-only pill due to enzyme induction concerns
C. Copper intrauterine device (IUD) as most reliable option (Correct Answer)
D. Contraceptive implant with additional barrier methods
E. Depot medroxyprogesterone acetate injection (DMPA)

Explanation: ***Copper intrauterine device (IUD) as most reliable option*** - The **copper IUD** is a **long-acting reversible contraceptive (LARC)** with a failure rate of <1%, making it the most reliable choice to prevent pregnancy while on highly **teratogenic sodium valproate**. - Unlike hormonal methods, it has no metabolic interactions with **antiepileptic drugs** and avoids any potential (though small) risks of hormonal influence on seizure thresholds. *Combined oral contraceptive pill as first-line choice* - The **combined oral contraceptive pill (COCP)** has a higher typical-use failure rate due to **compliance issues**, which is unacceptable given the risk of **fetal valproate syndrome**. - Although sodium valproate is not an **enzyme-inducer**, the risk of user error makes the COCP an inferior choice compared to LARCs in this high-risk scenario. *Progesterone-only pill due to enzyme induction concerns* - The **progesterone-only pill (POP)** requires strict daily adherence, and its high **failure rate** makes it unsuitable for patients needing to avoid pregnancy for medical/safety reasons. - The premise of the option is incorrect as **sodium valproate is not an enzyme-inducing drug**, unlike phenytoin or carbamazepine. *Contraceptive implant with additional barrier methods* - While the **progestogen implant** is a LARC, it is generally considered less preferred than the IUD in some guidelines when maximal reliability is required for **teratogenic drug** users. - Relying on **barrier methods** as a primary addition is poor practice compared to selecting a single method with the highest baseline efficacy like an **intrauterine device**. *Depot medroxyprogesterone acetate injection (DMPA)* - **DMPA injections** are effective but carry concerns regarding a reversible reduction in **bone mineral density**, which is a significant consideration in a **15-year-old** adolescent. - It requires repeated visits every 12-13 weeks, which introduces a higher risk of **missed doses** compared to the "set and forget" nature of the **Copper IUD**.

Question 116: A 11-year-old boy with type 1 diabetes for 4 years presents to clinic. His insulin doses have remained stable over the past 6 months despite normal growth velocity. His HbA1c has improved from 72 mmol/mol to 54 mmol/mol. His mother reports he has had no hypoglycaemic episodes. On examination, he appears well with normal vital signs. Urinalysis shows glucose +++. What is the most likely explanation for his improved HbA1c?

A. Honeymoon phase with partial pancreatic beta-cell recovery
B. Improved compliance with diabetes management
C. Development of renal glucosuria reducing blood glucose
D. Omission of insulin doses with fabrication of blood glucose records (Correct Answer)
E. Reduced insulin requirements due to improved dietary control

Explanation: ***Omission of insulin doses with fabrication of blood glucose records*** - The combination of an **improved HbA1c** (suggesting better control) with **stable insulin doses** despite growth, and significant **+++ glucosuria** (indicating persistent hyperglycemia) is highly suspicious for insulin omission. - Adolescents with diabetes may **fabricate blood glucose records** to avoid parental or clinical scrutiny, leading to this paradoxical presentation of 'good' HbA1c but evidence of hyperglycemia. *Honeymoon phase with partial pancreatic beta-cell recovery* - The **honeymoon phase** typically occurs in the initial months after Type 1 Diabetes diagnosis, not **four years** into the disease. - While it reduces insulin requirements, the patient's insulin doses have been stable, and a significant improvement in HbA1c would usually require adjustment, not stable doses, particularly with growth. *Improved compliance with diabetes management* - Genuine **improved compliance** leading to a better HbA1c would generally require an *increase* in insulin doses to match an 11-year-old's growth, not stable doses. - The presence of **glucose +++** on urinalysis strongly contradicts the notion of truly improved and sustained glycemic control. *Development of renal glucosuria reducing blood glucose* - **Renal glucosuria** is characterized by glucose in the urine despite normal or near-normal blood glucose levels and would not significantly lower the **HbA1c** in a Type 1 Diabetic. - This rare condition does not explain the discrepancy of stable insulin doses, normal growth, improved HbA1c, and simultaneously high urinary glucose in a patient with Type 1 Diabetes. *Reduced insulin requirements due to improved dietary control* - While **dietary control** is crucial, it is unlikely to lead to stable insulin doses and a significant HbA1c improvement in a growing child with Type 1 Diabetes without any dose adjustments. - Effective dietary control, leading to lower blood glucose, would result in negative or trace **glucosuria**, not **+++ glucosuria**.

Question 117: A 8-year-old girl presents with episodes where she suddenly stops activity, drops objects from her hands, and appears briefly dazed for about 10 seconds before resuming normal activity with no recollection of the event. These occur multiple times daily. Her teacher reports she seems to be daydreaming frequently. An EEG is performed during hyperventilation. What is the most likely EEG finding?

A. 3 Hz spike-and-wave discharges (Correct Answer)
B. Hypsarrhythmia
C. Focal sharp waves in the temporal region
D. 4-6 Hz polyspike-and-wave complexes
E. Centrotemporal spikes

Explanation: ***3 Hz spike-and-wave discharges***- This presentation is classic for **childhood absence epilepsy**, characterized by brief staring spells, abrupt impairment of consciousness, and immediate recovery without postictal confusion.- The pathognomonic EEG finding is generalized **3 Hz spike-and-wave discharges**, which are frequently provoked by **hyperventilation**.*Hypsarrhythmia*- This disorganized, high-amplitude EEG pattern is the hallmark of **West syndrome** (infantile spasms), not absence seizures.- It is typically seen in infants aged 3 to 12 months and is associated with **flexor or extensor spasms**.*Focal sharp waves in the temporal region*- These findings indicate **focal epilepsy** originating in the temporal lobe, which often presents with **complex partial seizures**.- Unlike absence seizures, focal impaired awareness seizures usually last longer and are often followed by a **postictal state**.*4-6 Hz polyspike-and-wave complexes*- This EEG pattern is highly suggestive of **Juvenile Myoclonic Epilepsy (JME)**, which typically presents in adolescence.- JME is characterized by **myoclonic jerks** occurring shortly after awakening, rather than brief staring spells.*Centrotemporal spikes*- These are characteristic of **Self-limited Epilepsy with Centrotemporal Spikes** (formerly Benign Rolandic Epilepsy).- This condition typically presents with nocturnal seizures involving **orofacial muscles** and drooling, usually occurring during sleep or upon awakening.

Question 118: A 13-year-old boy with type 1 diabetes presents with a 4-week history of persistent tingling and numbness in both feet, which is worse at night. On examination, he has reduced sensation to light touch and pinprick in a stocking distribution, and absent ankle reflexes. His recent HbA1c is 89 mmol/mol. What is the most likely diagnosis?

A. Diabetic peripheral neuropathy (Correct Answer)
B. Guillain-Barré syndrome
C. Chronic inflammatory demyelinating polyneuropathy (CIDP)
D. Vitamin B12 deficiency neuropathy
E. Charcot-Marie-Tooth disease

Explanation: ***Diabetic peripheral neuropathy*** - This patient presents with classic features of **distal symmetric polyneuropathy**, including **persistent tingling and numbness** in both feet, which is worse at night, **reduced sensation in a stocking distribution**, and **absent ankle reflexes**. - The strong association with **type 1 diabetes** and a highly elevated **HbA1c of 89 mmol/mol** indicates poor glycemic control, the primary driver of this complication, even in adolescents. *Guillain-Barré syndrome* - Typically presents as an **acute, rapidly progressive** ascending paralysis or weakness, often following an infection. - While it features absent reflexes, it is primarily a **motor-dominant** condition, and the chronicity (4 weeks) and sensory-predominant presentation do not fit. *Chronic inflammatory demyelinating polyneuropathy (CIDP)* - Requires a symptom duration of at least **8 weeks** for diagnosis, whereas this patient has only had symptoms for 4 weeks. - Usually involves significant **proximal and distal muscle weakness** in addition to sensory symptoms, which is not the primary presentation here. *Vitamin B12 deficiency neuropathy* - Often presents with **subacute combined degeneration** of the spinal cord, leading to loss of **vibration and proprioception**, and can cause paresthesia. - While a cause of neuropathy, it is not directly linked to **poor glycemic control** and does not explain the specific stocking distribution of sensory loss in the context of diabetes. *Charcot-Marie-Tooth disease* - This is a group of **hereditary neuropathies** characterized by **slowly progressive distal muscle weakness** and sensory loss, often with **foot deformities** (e.g., pes cavus). - Its presentation is typically lifelong and gradually progressive, not acutely related to recent glycemic control, and lacks the typical rapid onset of symptoms described.

Question 119: A 7-year-old boy with focal epilepsy has been seizure-free for 18 months on lamotrigine monotherapy. His parents enquire about stopping the medication. His EEG 6 months ago showed persistent focal epileptiform discharges. His neurological examination is normal and he has no learning difficulties. What advice should be given regarding antiepileptic drug withdrawal?

A. Withdraw medication immediately as he has been seizure-free for over 1 year
B. Continue medication for at least 2 years seizure-freedom before considering withdrawal (Correct Answer)
C. The abnormal EEG is an absolute contraindication to drug withdrawal
D. Withdraw medication only if a repeat EEG is normal
E. Continue medication indefinitely as focal epilepsy always requires lifelong treatment

Explanation: ***Continue medication for at least 2 years seizure-freedom before considering withdrawal*** - Current guidelines generally recommend a minimum period of **2 years of seizure freedom** before attempting to taper antiepileptic drugs in children. - Although this child has been seizure-free for 18 months, premature withdrawal increases the risk of **seizure recurrence**, especially with persistent EEG abnormalities. *Withdraw medication immediately as he has been seizure-free for over 1 year* - Immediate withdrawal is unsafe; medications must be **tapered gradually** over several months to prevent withdrawal seizures. - The recommended clinical milestone for withdrawal in the pediatric population is **24 months**, not 12 months. *The abnormal EEG is an absolute contraindication to drug withdrawal* - While persistent **focal epileptiform discharges** represent a higher risk for recurrence, they are not an **absolute contraindication** to withdrawal. - Clinical decision-making balances the **EEG findings** with the child's seizure-free duration and the parents' preferences. *Withdraw medication only if a repeat EEG is normal* - A **normal EEG** is a favorable prognostic marker but is not a mandatory prerequisite for attempting medication withdrawal. - Management should be individualized, as some children remain seizure-free even if **interictal abnormalities** persist on EEG. *Continue medication indefinitely as focal epilepsy always requires lifelong treatment* - Many forms of **pediatric focal epilepsy** have a good prognosis and may resolve as the brain matures. - The decision to stop treatment is based on the **seizure-free interval** rather than the initial epilepsy classification alone.

Question 120: A 10-year-old girl with type 1 diabetes mellitus is found to have an albumin:creatinine ratio (ACR) of 3.8 mg/mmol on routine screening. A repeat sample 3 months later shows ACR of 4.2 mg/mmol, and a third sample confirms ACR of 4.5 mg/mmol. Her blood pressure is on the 60th centile for age. Her HbA1c is 68 mmol/mol. What is the most appropriate management?

A. Commence ACE inhibitor therapy immediately
B. Optimize glycaemic control and recheck ACR in 6 months (Correct Answer)
C. Refer to paediatric nephrology for renal biopsy
D. Commence angiotensin receptor blocker therapy
E. Commence statin therapy for cardiovascular protection

Explanation: ***Optimize glycaemic control and recheck ACR in 6 months***- The patient has confirmed **microalbuminuria** (ACR 3–30 mg/mmol), but her **HbA1c** is elevated, indicating that optimizing metabolic management is the first-line intervention.- In pediatric patients, microalbuminuria can be **transient** or reversible with improved glucose control, especially when **blood pressure** remains within the normal range (60th centile).*Commence ACE inhibitor therapy immediately*- **ACE inhibitors** are typically reserved for children who remain microalbuminuric after optimizing glycaemic control or those with **hypertension**.- Initiating medication is premature here as the patient is **normotensive** and has clear room for improvement in diabetes management.*Refer to paediatric nephrology for renal biopsy*- A **renal biopsy** is not indicated for isolated microalbuminuria in the context of Type 1 Diabetes; it is typically reserved for atypical presentations like **macroscopic hematuria**.- The diagnosis of early **diabetic nephropathy** is clinical and does not require histological confirmation at this stage.*Commence angiotensin receptor blocker therapy*- **ARBs** function similarly to ACE inhibitors in protecting the kidneys, but they are not the first-line choice for a **normotensive** child with poor glycaemic control.- Conservative management focusing on **HbA1c reduction** should be prioritized before identifying a permanent need for renin-angiotensin system blockade.*Commence statin therapy for cardiovascular protection*- **Statins** are not indicated based solely on microalbuminuria in a 10-year-old; they are considered for older adolescents or those with **dyslipidemia**.- While diabetes increases cardiovascular risk, the immediate priority for managing kidney health in this child is **glycaemic optimization**.

Question 121: A 5-year-old boy presents to the emergency department with a prolonged tonic-clonic seizure that has lasted 25 minutes despite receiving two doses of buccal midazolam (one from parents, one from paramedics). IV access has just been established. What is the most appropriate next management step?

A. IV lorazepam 0.1 mg/kg (Correct Answer)
B. IV phenytoin 20 mg/kg loading dose
C. IV diazepam 0.25 mg/kg
D. Rectal paraldehyde
E. IV phenobarbital 20 mg/kg loading dose

Explanation: ***IV lorazepam 0.1 mg/kg*** - According to established protocols for **status epilepticus**, if seizures continue after two doses of **non-IV benzodiazepines** (like buccal midazolam), the next step once IV access is obtained is **IV lorazepam**. - **Lorazepam** is preferred in the emergency setting due to its rapid onset and long duration of action within the brain, helping to stabilize the patient before moving to second-line antiepileptics. *IV phenytoin 20 mg/kg loading dose* - This is considered a **second-line** anticonvulsant and should only be initiated if the seizure persists after adequate **benzodiazepine** therapy has failed. - Starting this immediately skips the vital third step of the emergency algorithm, which is to attempt termination with a **titrated IV benzodiazepine** dose. *IV diazepam 0.25 mg/kg* - While a benzodiazepine, **IV diazepam** is less preferred than **lorazepam** because it is highly lipid-soluble and redistributes rapidly out of the brain, leading to a shorter duration of anticonvulsant effect. - Current guidelines prioritize **lorazepam** due to its superior efficacy in terminating seizures and lower risk of **respiratory depression** compared to repeated diazepam doses. *Rectal paraldehyde* - This is an alternative therapy used primarily when **intravenous or intraosseous access** cannot be established in a hospital setting. - Since **IV access** has already been secured in this scenario, rectal administration is no longer the most efficient or appropriate route of delivery. *IV phenobarbital 20 mg/kg loading dose* - Similar to phenytoin, **phenobarbital** is an antiepileptic drug reserved for refractory cases after **benzodiazepine** failure. - It is often utilized more frequently in **neonatal seizures** but remains a later-stage intervention in an older child's emergency seizure algorithm.

Question 122: A 14-year-old girl with type 1 diabetes for 6 years presents to clinic with her parents. Her HbA1c has risen from 58 mmol/mol to 76 mmol/mol over the past year. She admits to occasionally missing insulin doses and not checking her blood glucose regularly. She appears withdrawn and her mother reports she has been spending more time alone in her room. What is the most appropriate initial approach?

A. Arrange urgent psychiatric assessment for depression
B. Switch to an insulin pump to improve compliance
C. Speak to the young person alone to explore psychosocial factors and provide support (Correct Answer)
D. Increase the frequency of clinic appointments to weekly reviews
E. Refer to social services for safeguarding concerns

Explanation: ***Speak to the young person alone to explore psychosocial factors and provide support***- Adolescence is a critical period where **diabetes distress**, peer pressure, and body image issues often lead to **poor compliance**; speaking alone fosters trust and honest communication.- Establishing a **supportive, non-judgmental environment** is the first step according to NICE guidelines to identify underlying barriers before escalating to formal mental health or medical interventions.*Arrange urgent psychiatric assessment for depression*- While the patient shows signs of being **withdrawn**, an initial exploratory assessment by her usual diabetes team is required before declaring a **psychiatric emergency**.- Deteriorating glucose control in isolation does not qualify for **urgent psychiatric referral** unless there is immediate risk of self-harm or severe clinical depression.*Switch to an insulin pump to improve compliance*- Transitioning to an **insulin pump (CSII)** requires a high level of patient engagement and regular **blood glucose monitoring**, which this patient is currently failing to maintain.- Escalating technology without addressing the **psychosocial foundation** is unlikely to succeed and may increase the risk of **diabetic ketoacidosis** if the device is neglected.*Increase the frequency of clinic appointments to weekly reviews*- Overloading an adolescent with clinical visits can be **counterproductive**, increasing the sense of being controlled and potentially causing the patient to **disengage** further.- The priority is the **quality of the consultation** and the therapeutic relationship rather than the mere frequency of appointments.*Refer to social services for safeguarding concerns*- There is no evidence of **abuse or neglect** in the clinical history; the parents are actively involved and brought the child to the clinic for help.- Deteriorating chronic disease management in adolescence is common and should be managed as a **clinical and psychosocial challenge** rather than a legal safeguarding issue.

Question 123: What is the typical age range for onset of childhood absence epilepsy?

A. 2-4 years
B. 4-8 years (Correct Answer)
C. 6-12 years
D. 10-16 years
E. 12-18 years

Explanation: ***4-8 years*** - **Childhood absence epilepsy (CAE)** typically presents in school-aged children with a peak incidence between **5-7 years** of age. - It is characterized by frequent **brief episodes of impaired consciousness** and a classic **3 Hz spike-and-wave** pattern on EEG. *2-4 years* - Onset at this age is considered **unusually early** for CAE and would necessitate consideration of other early-childhood epilepsy syndromes. - Seizures appearing in this range are more likely to be associated with **Glucose transporter type 1 (GLUT1) deficiency** or other metabolic etiologies. *6-12 years* - While there is some overlap, the **peak onset** for CAE starts earlier than 6 years, typically around age 4 or 5. - This range leans more towards the transition into **Juvenile Absence Epilepsy (JAE)**, which is distinguished by a later age of onset. *10-16 years* - This age range is characteristic of **Juvenile Absence Epilepsy (JAE)** or **Juvenile Myoclonic Epilepsy (JME)**. - Patients in this group are less likely to experience the high frequency of daily absences seen in the **childhood form**. *12-18 years* - This encompasses the **adolescent period** where CAE typically reaches **remission** rather than initial onset. - Seizures appearing first in this age group are strongly indicative of **idiopathic generalized epilepsies** like JME, often featuring generalized tonic-clonic or myoclonic seizures.

Question 124: A 12-year-old boy with type 1 diabetes mellitus for 5 years has been experiencing recurrent early morning hyperglycaemia despite increasing his bedtime insulin dose. His continuous glucose monitor shows blood glucose dropping to 3.2 mmol/L at 02:00 hours before rising to 14.8 mmol/L by 07:00 hours. What is the most appropriate management adjustment?

A. Further increase the bedtime long-acting insulin dose
B. Add metformin to improve insulin sensitivity
C. Reduce the bedtime long-acting insulin dose (Correct Answer)
D. Give additional rapid-acting insulin at bedtime
E. Switch to an insulin pump therapy

Explanation: ***Reduce the bedtime long-acting insulin dose***- The patient is experiencing the **Somogyi phenomenon**, where nocturnal **hypoglycaemia** (3.2 mmol/L at 02:00) triggers the release of counter-regulatory hormones, leading to rebound morning **hyperglycaemia**.- Reducing the **bedtime insulin** prevents the initial drop in glucose levels, thereby stopping the subsequent hormonal surge and correcting the morning high.*Further increase the bedtime long-acting insulin dose*- Increasing the dose would exacerbate the **02:00 hours hypoglycaemia**, potentially making the rebound hyperglycaemia worse or causing severe nocturnal seizures.- This approach is only appropriate for the **Dawn phenomenon**, which lacks the preceding nocturnal hypoglycaemic dip.*Add metformin to improve insulin sensitivity*- **Metformin** is primarily used in **Type 2 DM** and is not the standard treatment for managing acute nocturnal glucose fluctuations in Type 1 DM.- It does not address the underlying issue of **insulin-induced** rebound hyperglycaemia described in this scenario.*Give additional rapid-acting insulin at bedtime*- Administering **rapid-acting insulin** at bedtime would cause an even sharper drop in blood glucose levels during the early night, increasing the risk of **life-threatening hypoglycaemia**.- This would further stimulate **counter-regulatory hormones** like glucagon and adrenaline, worsening the morning glucose profile.*Switch to an insulin pump therapy*- While **insulin pump therapy (CSII)** provides more precise basal rate delivery, the immediate clinical priority is to fix the current dose-related **nocturnal hypoglycaemia**.- Adjusting the **MDI (Multiple Daily Injection)** regimen is the first-line corrective step before considering a total change in delivery technology.

Question 125: A 9-year-old boy with recently diagnosed focal epilepsy is started on carbamazepine. Three weeks later, he develops a widespread erythematous rash with mucosal involvement, fever, and facial swelling. Blood tests show eosinophilia and deranged liver function tests. What is the most likely diagnosis?

A. Stevens-Johnson syndrome/toxic epidermal necrolysis (Correct Answer)
B. Simple viral exanthem
C. Urticaria secondary to carbamazepine allergy
D. Erythema multiforme minor
E. Scarlet fever

Explanation: ***Stevens-Johnson syndrome/toxic epidermal necrolysis*** - This is a severe cutaneous adverse reaction typically occurring 1-4 weeks after starting **carbamazepine**, characterized by **mucosal involvement**, systemic symptoms, and potential skin sloughing. - The presence of **fever**, **facial swelling**, **eosinophilia**, and **multiorgan involvement** (deranged LFTs) following high-risk medication exposure marks this as a medical emergency. *Simple viral exanthem* - Usually presents as a **morbilliform rash** following a prodromal viral illness, without the severe **mucosal involvement** or systemic organ dysfunction seen here. - **Eosinophilia** and deranged liver enzymes are not typical features of simple childhood viral infections. *Urticaria secondary to carbamazepine allergy* - Characterized by transient, itchy **wheals** that fluctuate in position and usually appear within hours of drug exposure rather than weeks. - Does not present with **fever**, **mucosal ulceration**, or laboratory abnormalities like **eosinophilia** and liver failure. *Erythema multiforme minor* - Typically presents with localized **target lesions** on the extremities and is most commonly triggered by **Herpes Simplex Virus (HSV)**. - It lacks the widespread distribution, **systemic toxicity**, and significant **mucosal involvement** associated with SJS/TEN. *Scarlet fever* - Caused by **Group A Streptococcus** and presents with a distinctive **sandpaper-like rash**, strawberry tongue, and circumoral pallor. - While it involves fever, it is treated with antibiotics and does not cause **eosinophilia** or liver dysfunction related to anticonvulsant therapy.

Question 126: A 6-year-old girl with type 1 diabetes mellitus attends the emergency department with a 2-day history of vomiting and abdominal pain. Her mother reports she has been unwell with a viral illness. On examination, she is lethargic, has deep sighing respirations, and appears dehydrated. Capillary blood glucose is 24.3 mmol/L. Blood gas shows pH 7.18, bicarbonate 9 mmol/L, and base excess -18. What is the most appropriate initial fluid resuscitation strategy?

A. 0.9% sodium chloride 10 mL/kg bolus over 1 hour, then maintenance fluids with added insulin (Correct Answer)
B. 0.9% sodium chloride 20 mL/kg bolus over 30 minutes, then reassess
C. 0.45% sodium chloride with 5% dextrose at twice maintenance rate
D. 0.9% sodium chloride at 1.5 times maintenance rate without initial bolus
E. Colloid bolus 20 mL/kg followed by 0.9% sodium chloride maintenance

Explanation: ***0.9% sodium chloride 10 mL/kg bolus over 1 hour, then maintenance fluids with added insulin*** - This patient presents with **Diabetic Ketoacidosis (DKA)**, indicated by hyperglycemia, metabolic acidosis, and ketosis. Current guidelines recommend a cautious **10 mL/kg bolus of 0.9% sodium chloride** over 30-60 minutes to manage initial dehydration and restore perfusion without rapid osmotic shifts that could precipitate **cerebral edema**. - Following the initial bolus and reassessment, the next steps involve calculating fluid deficit, providing maintenance fluids (usually 0.9% NaCl initially, then adjusting), and initiating a fixed-rate **insulin infusion** (0.05-0.1 units/kg/hour) to suppress ketogenesis and lower glucose gradually. *0.9% sodium chloride 20 mL/kg bolus over 30 minutes, then reassess* - While a **20 mL/kg bolus** is common for general pediatric shock or severe dehydration, in **DKA**, such a rapid and large volume of fluid is associated with an increased risk of **cerebral edema**, particularly in children. - The primary goal in DKA fluid resuscitation is slow, careful rehydration to prevent rapid changes in **serum osmolality**, which can lead to shifts of water into brain cells. *0.45% sodium chloride with 5% dextrose at twice maintenance rate* - Hypotonic solutions like **0.45% sodium chloride** are contraindicated for initial resuscitation in DKA as they can rapidly lower **serum osmolality**, exacerbating the risk of **cerebral edema**. - **Dextrose** should only be added to IV fluids once the blood glucose level falls to around **14-17 mmol/L** (250-300 mg/dL) to prevent hypoglycemia while continuing the insulin infusion. *0.9% sodium chloride at 1.5 times maintenance rate without initial bolus* - This patient exhibits clinical signs of significant **dehydration** (lethargy, deep sighing respirations) and metabolic derangement, necessitating an initial fluid bolus to restore **circulating volume** and improve perfusion. - Delaying an initial bolus in a dehydrated DKA patient can lead to inadequate tissue perfusion, worsen **acidosis**, and potentially contribute to further clinical deterioration or **acute kidney injury**. *Colloid bolus 20 mL/kg followed by 0.9% sodium chloride maintenance* - **Crystalloids** (0.9% NaCl) are the recommended first-line fluids for resuscitation in DKA due to their effectiveness and safety profile; **colloids** offer no proven advantage and are not typically part of standard DKA management protocols. - Large volumes of colloid can interfere with laboratory monitoring and do not specifically address the complex **osmotic and electrolyte imbalances** inherent in DKA.

Question 127: A 13-year-old girl with type 1 diabetes for 4 years presents with unexplained recurrent severe hypoglycaemic episodes requiring paramedic attendance. Her HbA1c has dropped from 65 mmol/mol to 42 mmol/mol over 6 months. Parents report finding hidden glucose testing strips showing readings of 2-3 mmol/L at various times. She is reluctant to discuss her diabetes management and appears distressed. What is the most likely underlying cause?

A. Undiagnosed Addison's disease causing adrenal insufficiency
B. Coeliac disease with malabsorption affecting carbohydrate absorption
C. Factitious hypoglycaemia from insulin manipulation (Correct Answer)
D. Unrecognized nocturnal hypoglycaemia with autonomic neuropathy
E. Excessive exercise without appropriate carbohydrate adjustment

Explanation: ***Factitious hypoglycaemia from insulin manipulation***- The rapid improvement in **HbA1c**, discovery of hidden glucose strips, and **psychological distress** strongly suggest deliberate insulin overdosing rather than an organic medical cause.- This condition is often seen in adolescents as a manifestation of **psychological distress**, eating disorders, or a desire for attention, requiring **multidisciplinary support** involving psychology or CAMHS.*Undiagnosed Addison's disease causing adrenal insufficiency*- While **adrenal insufficiency** can cause hypoglycaemia in type 1 diabetes, it is typically accompanied by **hyperpigmentation**, hypotension, and salt craving.- It would not explain the patient's **secretive behavior** or the discovery of hidden testing strips with low readings.*Coeliac disease with malabsorption affecting carbohydrate absorption*- **Coeliac disease** is frequently associated with type 1 diabetes but usually presents with **growth failure**, bloating, or iron deficiency anemia.- Malabsorption generally leads to **unstable or high HbA1c** levels due to erratic absorption, rather than a dramatic, sustained drop in HbA1c.*Unrecognized nocturnal hypoglycaemia with autonomic neuropathy*- **Autonomic neuropathy** is exceedingly rare in the pediatric population, typically requiring over **10 years of poor glycemic control** to develop.- While nocturnal hypoglycemia can occur, it would not account for the **recurrent daytime paramedic attendances** or the psychological components described.*Excessive exercise without appropriate carbohydrate adjustment*- **Exercise-induced hypoglycaemia** follows physical activity and is usually managed easily once the pattern is identified and insulin/carbs are adjusted.- This diagnosis does not explain the **distress, reluctance to discuss management**, or the dramatic shift in overall **glycaemic control (HbA1c)**.

Question 128: A 6-year-old boy with focal epilepsy controlled on levetiracetam for 2 years presents with increasing behavioural problems over 6 months. His parents report marked irritability, aggression, and emotional lability. Seizures remain well controlled. School reports deteriorating behaviour and peer relationships. What is the most appropriate management?

A. Add behavioural therapy and continue current medication
B. Switch from levetiracetam to an alternative anti-epileptic drug (Correct Answer)
C. Increase levetiracetam dose to improve seizure control
D. Add risperidone for behavioural management
E. Request child psychiatry assessment

Explanation: ***Switch from levetiracetam to an alternative anti-epileptic drug*** - **Levetiracetam** is well-known for causing **neuropsychiatric adverse effects** such as irritability, aggression, and emotional lability, particularly in pediatric patients, which aligns with the observed symptoms. - When significant **behavioral side effects** develop and impact a child's quality of life while seizures remain controlled, the most appropriate management is to switch to an alternative **anti-epileptic drug (AED)**. *Add behavioural therapy and continue current medication* - **Behavioral therapy** may be a supportive measure, but it will not address the primary cause of the behavioral problems, which is likely a medication side effect. - Continuing the **offending medication** while only adding therapy risks prolonging the child's distress and further exacerbating their social and academic difficulties. *Increase levetiracetam dose to improve seizure control* - The question explicitly states that the boy's **seizures remain well controlled**, meaning there is no clinical indication to increase the medication dose. - Increasing the dose of **levetiracetam** would likely worsen the already present **dose-dependent neuropsychiatric side effects** such as irritability and aggression. *Add risperidone for behavioural management* - Adding a **second-generation antipsychotic** like risperidone introduces additional medications and potential side effects to treat a condition that is likely **iatrogenic**. - The standard approach is to remove or replace the suspected **causative medication** before resorting to polypharmacy for drug-induced symptoms. *Request child psychiatry assessment* - While a child psychiatry assessment could be useful for complex behavioral issues, the clear **temporal association** between levetiracetam use and the onset of behavioral problems strongly suggests a drug side effect. - The initial and most direct intervention is for the prescribing **neurologist or pediatrician** to manage the anti-epileptic drug regimen, prior to specialized psychiatric referral.

Question 129: A 15-year-old boy with type 1 diabetes for 9 years presents for annual screening. Urinalysis shows microalbuminuria on two separate occasions (albumin:creatinine ratio 3.5 mg/mmol and 4.2 mg/mmol). Blood pressure is 128/78 mmHg (95th centile for age/height). HbA1c is 68 mmol/mol. Retinal screening shows no retinopathy. What is the most appropriate initial management?

A. Reassure and repeat screening in 12 months
B. Start ACE inhibitor therapy immediately
C. Optimize glycaemic control and repeat albumin:creatinine ratio in 3 months (Correct Answer)
D. Refer to paediatric nephrology for renal biopsy
E. Start angiotensin receptor blocker and low-protein diet

Explanation: ***Optimize glycaemic control and repeat albumin:creatinine ratio in 3 months*** - Persistent **microalbuminuria** (ACR 3-30 mg/mmol) in type 1 diabetes, especially with an elevated **HbA1c** of 68 mmol/mol, initially warrants optimization of **glycaemic control**. - Improved glucose control can reverse early **hyperfiltration** and albumin leakage, necessitating a repeat **albumin:creatinine ratio** in 3 months to assess response before considering pharmacological intervention. *Reassure and repeat screening in 12 months* - Two consecutive abnormal **albumin:creatinine ratio** results indicate **persistent microalbuminuria**, a sign of early **diabetic nephropathy**, which is not a benign finding requiring reassurance. - Delaying re-evaluation for 12 months is inappropriate as prompt intervention, especially **glycaemic optimization**, is crucial to prevent progression of renal damage. *Start ACE inhibitor therapy immediately* - **ACE inhibitors** are typically initiated for persistent microalbuminuria or hypertension that doesn't resolve with **glycaemic control**, or if **blood pressure** is consistently above the 95th centile. - Given the poor **HbA1c**, the immediate priority is to first attempt **glycaemic optimization** to see if this reverses the early albuminuria. *Refer to paediatric nephrology for renal biopsy* - **Renal biopsy** is not typically indicated for the diagnosis of early **diabetic nephropathy** with isolated microalbuminuria in a patient with long-standing type 1 diabetes. - Biopsy is usually reserved for atypical presentations, such as rapid decline in renal function, absence of **retinopathy**, or active urinary sediment, which are not present here. *Start angiotensin receptor blocker and low-protein diet* - **Angiotensin receptor blockers (ARBs)** are often reserved for patients who cannot tolerate ACE inhibitors, and like ACE inhibitors, are not the immediate first step before **glycaemic optimization**. - A **low-protein diet** is generally not recommended in children with early **diabetic nephropathy** due to potential negative impacts on growth and limited evidence for benefit at this stage.

Question 130: A 10-year-old girl experiences her first seizure consisting of jerking movements of the right arm that remain localized, with preserved consciousness throughout the 90-second episode. She has no past medical history and developmental milestones were normal. Examination reveals no focal neurological deficit. What is the most appropriate next investigation?

A. MRI brain with contrast (Correct Answer)
B. EEG only
C. CT head without contrast
D. Lumbar puncture
E. No investigation required, observe only

Explanation: ***MRI brain with contrast***- A **focal aware seizure** (motor features localized to the right arm) in a child necessitates neuroimaging to rule out **structural brain lesions** such as tumors, cortical dysplasia, or vascular malformations.- **MRI** is the gold standard as it provides superior resolution of **cortical architecture** and the addition of **contrast** helps in identifying inflammatory or neoplastic processes.*EEG only*- While an **EEG** is vital to classify the seizure type and identify specific **epilepsy syndromes**, it cannot exclude structural abnormalities.- In the context of a **focal seizure**, imaging is prioritized to ensure there is no macroscopic lesion requiring surgical or specific medical intervention.*CT head without contrast*- **CT scans** are generally reserved for **acute emergencies** to look for hemorrhage or large masses when MRI is not immediately available.- It is less sensitive than MRI for detecting the subtle **structural pathologies** (like small tubers or focal cortical dysplasia) often associated with focal childhood seizures.*Lumbar puncture*- This invasive procedure is indicated only if there is a clinical suspicion of **meningitis or encephalitis**, usually presenting with fever or altered mental status.- The patient is currently afebrile with **normal developmental milestones** and no signs of meningism, making a CNS infection unlikely.*No investigation required, observe only*- While some single generalized seizures may be observed, a **focal seizure** is a red flag that requires investigation to exclude an underlying cause.- Failing to investigate a focal onset seizure risks missing **treatable structural lesions** or progressive neurological conditions.

Question 131: A 7-year-old boy with newly diagnosed type 1 diabetes and his family are being educated about sick day management. During intercurrent illness, which of the following statements about insulin management is correct?

A. Insulin doses should be reduced by 50% to prevent hypoglycaemia
B. Insulin should be stopped if the child is not eating normally
C. Insulin requirements typically increase and doses should never be stopped (Correct Answer)
D. Only basal insulin should be continued, with bolus insulin omitted
E. Insulin dose adjustments are not necessary if blood glucose remains in target range

Explanation: ***Insulin requirements typically increase and doses should never be stopped***- During illness, **stress hormones** like cortisol and adrenaline cause **insulin resistance** and glycogenolysis, which typically raises blood glucose levels.- Insulin must **never be stopped**, even if the child is not eating, because basal insulin is essential to suppress **ketogenesis** and prevent **diabetic ketoacidosis (DKA)**.*Insulin doses should be reduced by 50% to prevent hypoglycaemia*- Reducing insulin arbitrarily is dangerous because the **metabolic stress** of infection usually necessitates a **20-50% increase** in dose rather than a reduction.- Dose adjustments should be based on frequent **blood glucose and ketone monitoring** every 2-4 hours during sick days.*Insulin should be stopped if the child is not eating normally*- Stopping insulin is the leading cause of **illness-precipitated DKA**; the body requires insulin to manage the counter-regulatory hormone surge regardless of oral intake.- If oral intake is poor, the focus should be on maintaining **hydration** and providing **carbohydrate-containing fluids** to allow continued insulin administration.*Only basal insulin should be continued, with bolus insulin omitted*- **Bolus insulin** is often still required to correct **hyperglycemia** and manage the glucose produced by the liver during the stress response.- Omitting bolus doses when blood glucose or **ketone levels** are elevated increases the risk of rapid clinical deterioration.*Insulin dose adjustments are not necessary if blood glucose remains in target range*- Even if glucose is stable, frequent monitoring of **blood ketones** is vital as ketosis can develop despite relatively normal glucose levels (**euglycemic DKA**).- Management must be **dynamic**; requirements can change rapidly as the illness progresses or resolves, requiring proactive adjustments.

Question 132: What is the minimum concentration of blood glucose that defines hypoglycaemia requiring treatment in a child with type 1 diabetes?

A. Less than 3.0 mmol/L
B. Less than 3.5 mmol/L
C. Less than 4.0 mmol/L (Correct Answer)
D. Less than 4.5 mmol/L
E. Less than 5.0 mmol/L

Explanation: ***Less than 4.0 mmol/L***- According to **NICE** and **ISPAD** guidelines, hypoglycaemia in children with **type 1 diabetes** is clinically defined as a blood glucose level below **4.0 mmol/L**.- This threshold is chosen because **counter-regulatory hormones** are typically triggered at this level, and treating here prevents progression to severe neuroglycopenia.*Less than 3.0 mmol/L*- This level represents a more **severe physiological state** and is significantly below the recognized diagnostic threshold for initiating treatment in diabetic children.- Waiting for glucose to drop this low increases the risk of **seizures** or **loss of consciousness** before intervention occurs.*Less than 3.5 mmol/L*- While technically a low glucose level, this value is lower than the **standardized 4.0 mmol/L** threshold for initiating treatment in children with type 1 diabetes.- The **4.0 mmol/L** threshold is established to allow for timely intervention and prevent more significant symptoms.*Less than 4.5 mmol/L*- A blood glucose level of 4.5 mmol/L is generally considered within the **normal or acceptable range** for blood glucose, even for individuals with type 1 diabetes, and does not typically indicate hypoglycaemia requiring immediate treatment.- The aim is to maintain glucose levels above **4.0 mmol/L** to prevent symptomatic hypoglycaemia.*Less than 5.0 mmol/L*- Similar to 4.5 mmol/L, a blood glucose level of 5.0 mmol/L is well within the **normal physiological range** and would not be considered hypoglycaemia requiring treatment.- This value is a target for **normoglycaemia**, not a threshold for hypoglycaemia.

Question 133: A 16-year-old girl with juvenile myoclonic epilepsy controlled on valproate presents requesting to switch medication as she is now sexually active. She has been seizure-free for 18 months. Which alternative medication would be most appropriate considering efficacy and her reproductive health?

A. Lamotrigine (Correct Answer)
B. Carbamazepine
C. Phenytoin
D. Topiramate
E. Phenobarbital

Explanation: ***Lamotrigine***- It is the preferred alternative for **valproate** in females of childbearing age due to its significantly lower risk of **teratogenicity** and major congenital malformations.- It provides broad-spectrum coverage for **generalized epilepsies** like JME, though it must be titrated slowly to avoid **Stevens-Johnson syndrome**.*Carbamazepine*- This sodium channel blocker is known to **exacerbate myoclonic jerks** and absence seizures in patients with **Juvenile Myoclonic Epilepsy (JME)**.- It is primarily used for **focal seizures** and is inappropriate for the generalized seizure types seen in this patient.*Phenytoin*- Similar to carbamazepine, it can **worsen myoclonic seizures** and is not considered a first-line or appropriate treatment for JME.- Long-term use is associated with significant side effects like **gingival hyperplasia**, coarsening of facial features, and **osteomalacia**.*Topiramate*- While it has broad-spectrum activity, it carries a higher risk of **teratogenicity**, specifically **cleft lip and palate**, compared to lamotrigine.- It is also associated with significant cognitive side effects often referred to as "**word-finding difficulties**" or "brain fog."*Phenobarbital*- This medication is rarely used as first-line due to its high risk of **congenital malformations** and adverse effects on **neurodevelopment** in the fetus.- It also causes significant **sedation**, cognitive impairment, and has a long half-life that makes management difficult in young patients.

Question 134: A 12-year-old girl with type 1 diabetes presents to clinic. Her insulin pump shows frequent high glucose readings (15-22 mmol/L) at 3 AM over the past 2 weeks, followed by normal pre-breakfast readings (5-7 mmol/L). She reports no symptoms during the night. Her basal insulin rate was recently increased. What is the most likely explanation?

A. Dawn phenomenon
B. Somogyi effect (rebound hyperglycaemia) (Correct Answer)
C. Dietary non-compliance with bedtime snacks
D. Insulin pump malfunction
E. Intercurrent illness

Explanation: ***Somogyi effect (rebound hyperglycaemia)***- The **Somogyi effect** occurs when nocturnal **hypoglycaemia**, often unrecognised and caused by excessive insulin (e.g., increased basal rate), triggers the release of **counter-regulatory hormones** like glucagon, cortisol, and growth hormone.- This hormonal surge leads to a subsequent rebound **hyperglycaemia** (high glucose at 3 AM), which then corrects to normal levels by pre-breakfast, as seen with the normal 5-7 mmol/L readings.*Dawn phenomenon*- This phenomenon is characterized by an early morning increase in glucose levels (typically between 4 AM and 8 AM) due to the normal physiological release of **growth hormone** and **cortisol**.- Unlike the Somogyi effect, the dawn phenomenon does not involve an preceding drop in glucose and typically results in **high pre-breakfast glucose readings**, not the normalization observed in this patient.*Dietary non-compliance with bedtime snacks*- Consuming excessive carbohydrates before bed would usually lead to elevated glucose readings **earlier in the night** and would likely persist, resulting in high pre-breakfast levels.- This scenario does not explain the initial high 3 AM reading followed by a **spontaneous normalization** to target range by breakfast.*Insulin pump malfunction*- An insulin pump malfunction, such as an occlusion or dislodgement, typically leads to **persistent and uncontrolled hyperglycaemia** due to lack of insulin delivery.- This would generally result in continuously high glucose levels and potentially **diabetic ketoacidosis**, rather than glucose values normalizing by breakfast.*Intercurrent illness*- An intercurrent illness (e.g., infection) causes physiological stress, leading to the release of **stress hormones** that increase insulin resistance and raise blood glucose levels.- This would result in **sustained hyperglycaemia** throughout the night and into the morning, not a temporary elevation at 3 AM that normalizes by breakfast, and would likely be accompanied by other symptoms.

Question 135: A 9-year-old boy with refractory epilepsy is being considered for ketogenic diet therapy. His seizures are poorly controlled despite trials of three anti-epileptic drugs. Which of the following seizure types would be the LEAST suitable indication for ketogenic diet?

A. Infantile spasms (West syndrome)
B. Dravet syndrome
C. Myoclonic-astatic epilepsy (Doose syndrome)
D. Lennox-Gastaut syndrome
E. Benign rolandic epilepsy (Correct Answer)

Explanation: ***Benign rolandic epilepsy*** - This is a **self-limiting** focal epilepsy of childhood that typically responds well to standard medications or may not require treatment at all due to **spontaneous remission** by adolescence. - The **ketogenic diet** is highly restrictive and inappropriate for a benign condition that lacks a **refractory** nature or a specific metabolic indication. *Infantile spasms (West syndrome)* - The ketogenic diet is a recognized and effective treatment for **refractory infantile spasms**, often used when hormonal therapy or vigabatrin fails. - It helps in achieving significant **seizure reduction** and may improve developmental outcomes in these infants. *Dravet syndrome* - This is a severe, **pharmacoresistant** epilepsy where the ketogenic diet is considered a **first-line non-pharmacological** intervention. - Clinical studies show that it is particularly effective in reducing the frequency of **convulsive seizures** in these patients. *Myoclonic-astatic epilepsy (Doose syndrome)* - The ketogenic diet is often the **treatment of choice** for this syndrome, sometimes even before traditional anti-epileptic drugs. - It frequently results in rapid and dramatic improvement in **myoclonic** and **atonic** seizure types. *Lennox-Gastaut syndrome* - This syndrome involves multiple seizure types and **cognitive impairment**, making it highly difficult to manage with drugs alone. - The ketogenic diet is a well-established therapy for **Lennox-Gastaut**, with a high percentage of patients achieving greater than 50% seizure control.

Question 136: A 14-year-old girl with type 1 diabetes for 7 years is admitted with severe DKA (pH 7.05, glucose 28 mmol/L, ketones 5.8 mmol/L). During initial treatment with IV fluids and insulin infusion, she becomes increasingly drowsy with bradycardia and develops a fixed dilated right pupil. What is the most appropriate immediate management?

A. Immediate CT head scan
B. Increase insulin infusion rate
C. Administer IV mannitol 0.5-1 g/kg or hypertonic saline 2.7% (Correct Answer)
D. Rapid IV fluid bolus 20 mL/kg
E. Reduce insulin infusion and increase glucose supplementation

Explanation: ***Administer IV mannitol 0.5-1 g/kg or hypertonic saline 2.7%*** - The sudden neurological deterioration, including increasing drowsiness, **bradycardia**, and a **fixed dilated pupil**, are classic signs of **cerebral edema** and impending uncal herniation, a life-threatening complication of DKA treatment. - Immediate administration of **osmotic agents** like **IV mannitol** or **hypertonic saline** is crucial to rapidly reduce intracranial pressure and prevent further brain injury or death, without delaying for neuroimaging. *Immediate CT head scan* - While a **CT head scan** is important for confirming **cerebral edema**, it must not delay life-saving treatment with osmotic agents. - Clinical suspicion necessitates immediate intervention; imaging should only be performed once the patient is stabilized and intracranial pressure is being addressed. *Increase insulin infusion rate* - Increasing the **insulin infusion** does not address the acute intracranial emergency and might even contribute to fluid shifts that exacerbate **cerebral edema**. - The immediate priority is managing intracranial pressure, not accelerating the metabolic correction of DKA. *Rapid IV fluid bolus 20 mL/kg* - A rapid **IV fluid bolus** is contraindicated as aggressive fluid administration is a recognized risk factor for developing or worsening **cerebral edema** in DKA patients, particularly children. - Fluid management should be carefully controlled and may need to be restricted upon suspicion of **cerebral edema**. *Reduce insulin infusion and increase glucose supplementation* - Although hypoglycemia can cause altered mental status, the combination of **bradycardia** and a **fixed dilated pupil** points strongly to increased intracranial pressure and **brainstem compression**, not hypoglycemia. - This intervention would address hypoglycemia, but it fails to treat the critical and immediate problem of **cerebral edema**.

Question 137: A 8-year-old boy experiences sudden episodes where he stops talking mid-sentence, stares blankly for 5-10 seconds with subtle eye fluttering, then immediately resumes normal activity with no post-ictal confusion. Episodes occur 10-15 times daily. EEG shows 3 Hz spike-and-wave discharges during hyperventilation. What is the most appropriate first-line treatment?

A. Sodium valproate (Correct Answer)
B. Carbamazepine
C. Levetiracetam
D. Lamotrigine
E. Phenytoin

Explanation: ***Sodium valproate*** - This drug is a highly effective first-line treatment for **Childhood Absence Epilepsy (CAE)**, offering coverage if the patient also develops **generalized tonic-clonic seizures**. - The clinical triad of **brief staring spells**, lack of a **post-ictal state**, and **3 Hz spike-and-wave discharges** on EEG confirms the diagnosis and indicates the need for this broad-spectrum anticonvulsant. *Carbamazepine* - This medication is a narrow-spectrum agent primarily used for **focal seizures** and can paradoxically **exacerbate absence seizures**. - Its use is strictly contraindicated when the EEG shows characteristic **generalized 3 Hz spike-waves**. *Levetiracetam* - While it is a broad-spectrum antiepileptic, it is considered a **second-line treatment** for absence seizures due to lower efficacy compared to valproate or ethosuximide. - It is generally preferred for **myoclonic seizures** or as adjunctive therapy rather than primary management for classic CAE. *Lamotrigine* - This is an alternative treatment option but is typically less effective than first-line agents and requires **slow titration** to avoid serious side effects like **Stevens-Johnson syndrome**. - It may be considered if first-line drugs are poorly tolerated, but it is not the initial treatment of choice in a typical pediatric presentation. *Phenytoin* - Similar to carbamazepine, this sodium channel blocker is **ineffective** against absence seizures and may increase the frequency of the episodes. - It is primarily indicated for **status epilepticus** and focal-to-bilateral tonic-clonic seizures, not for primary generalized absence patterns.

Question 138: A 11-year-old girl with type 1 diabetes for 5 years attends for routine retinal screening. Fundoscopy reveals microaneurysms and occasional dot haemorrhages in both eyes, but no cotton wool spots or new vessels. Visual acuity is normal. Her recent HbA1c is 72 mmol/mol. What stage of diabetic retinopathy is present?

A. No retinopathy
B. Background (mild non-proliferative) diabetic retinopathy (Correct Answer)
C. Pre-proliferative diabetic retinopathy
D. Proliferative diabetic retinopathy
E. Diabetic maculopathy

Explanation: ***Background (mild non-proliferative) diabetic retinopathy*** - This stage is characterized by the presence of **microaneurysms** and occasional **dot haemorrhages**, which are precisely what is described in the fundoscopy findings. - The patient's long duration of type 1 diabetes (5 years) and suboptimal glycemic control (**HbA1c 72 mmol/mol**) support the development of early diabetic retinopathy. *No retinopathy* - This diagnosis requires a **completely normal fundoscopic examination** with no signs of vascular damage. - The presence of **microaneurysms** and **dot haemorrhages** in this patient explicitly indicates the presence of retinopathy, ruling out this option. *Pre-proliferative diabetic retinopathy* - This stage involves more severe signs of retinal ischemia, such as **cotton wool spots**, **venous beading**, and intraretinal microvascular abnormalities (IRMA). - The question explicitly states there are **no cotton wool spots**, meaning the disease has not progressed to this more advanced stage. *Proliferative diabetic retinopathy* - This is the most severe stage, defined by the presence of **neovascularization** (new blood vessel formation) on the optic disc or elsewhere. - The scenario clearly mentions there are **no new vessels**, thus excluding proliferative diabetic retinopathy. *Diabetic maculopathy* - This condition involves changes in the **macula**, often leading to macular edema or hard exudates that typically impair **central visual acuity**. - This patient has **normal visual acuity**, and there is no specific mention of macular edema or lesions directly affecting the macula's function.

Question 139: A 5-year-old girl with newly diagnosed focal epilepsy is commenced on carbamazepine. After 10 days, she develops fever, facial swelling, cervical lymphadenopathy, and a widespread maculopapular rash. Blood tests reveal eosinophilia and deranged liver function tests with ALT 450 U/L. What is the most likely diagnosis?

A. Stevens-Johnson syndrome
B. Drug reaction with eosinophilia and systemic symptoms (DRESS) (Correct Answer)
C. Acute viral exanthem with coincidental hepatitis
D. Serum sickness
E. Kawasaki disease

Explanation: ***Drug reaction with eosinophilia and systemic symptoms (DRESS)***- DRESS syndrome is a severe hypersensitivity reaction characterized by **fever**, **generalized lymphadenopathy**, **facial swelling**, and a **maculopapular rash**, typically occurring 2–8 weeks after starting a drug like **carbamazepine**.- The presence of significant **eosinophilia** and **internal organ involvement** (specifically **hepatitis** with elevated ALT) is a hallmark of this condition compared to other cutaneous drug reactions.*Stevens-Johnson syndrome*- While triggered by **carbamazepine**, SJS is primarily characterized by **mucosal involvement** (e.g., mouth, eyes) and **epidermal necrolysis/skin detachment**, which are absent here.- SJS does not typically present with the prominent **eosinophilia** or significant **lymphadenopathy** seen in DRESS syndrome.*Acute viral exanthem with coincidental hepatitis*- Viral exanthems may cause fever and rash, but they are unlikely to cause the combination of **facial edema** and the severe **ALT elevation (450 U/L)** seen in this patient.- **Blood eosinophilia** is not a feature of most viral infections; it strongly points toward a **hypersensitivity reaction** to the recently introduced medication.*Serum sickness*- Serum sickness is a Type III hypersensitivity reaction causing fever, rash, and **arthralgia**, typically occurring 1–3 weeks after drug exposure (often antibiotics or foreign proteins).- It lacks the characteristic **eosinophilia** and **severe hepatic dysfunction** (hepatitis) that define DRESS syndrome.*Kawasaki disease*- Kawasaki disease presents with prolonged fever and rash, but requires features like **conjunctival injection**, **strawberry tongue**, or **extremity changes** for diagnosis.- It does not typically cause **eosinophilia**, and the temporal relationship with **carbamazepine** initiation makes a drug reaction far more likely.

Question 140: A 13-year-old boy with type 1 diabetes mellitus for 6 years presents for annual review. His growth chart shows progressive deceleration in height velocity over the past 18 months, now below the 2nd centile. His weight is appropriate for height. He reports intermittent abdominal discomfort and occasional loose stools. Blood tests show HbA1c 58 mmol/mol, thyroid function normal. What is the most appropriate initial investigation?

A. Tissue transglutaminase antibodies (anti-TTG) (Correct Answer)
B. Short Synacthen test
C. Insulin-like growth factor 1 (IGF-1) level
D. Coeliac genetic testing (HLA-DQ2/DQ8)
E. 72-hour faecal fat collection

Explanation: ***Tissue transglutaminase antibodies (anti-TTG)*** - There is a high association between **Type 1 Diabetes Mellitus (T1DM)** and **Coeliac disease** (shared HLA-DQ2/DQ8), and **anti-TTG IgA** is the first-line screening investigation. - The clinical triad of **growth deceleration**, **abdominal discomfort**, and **loose stools** in a patient with T1DM is highly suspicious for malabsorption due to Coeliac disease. *Short Synacthen test* - This is used to diagnose **Addison is disease** (adrenal insufficiency), which may co-occur with T1DM but usually presents with **hypoglycemia** or hyperpigmentation. - It does not typically explain intermittent loose stools or growth failure while maintaining appropriate weight-for-height. *Insulin-like growth factor 1 (IGF-1) level* - While used to screen for **Growth Hormone deficiency**, it is less likely here as growth failure in GH deficiency often involves **increased subcutaneous fat**. - Primary malabsorption from Coeliac disease is a much more common cause of growth failure in the context of T1DM than isolated pituitary pathology. *Coeliac genetic testing (HLA-DQ2/DQ8)* - These tests have a high **negative predictive value** and are used to rule out Coeliac disease, but they cannot confirm an active diagnosis. - Serological testing with **anti-TTG** is the preferred initial step to detect active autoimmune response to gluten. *72-hour faecal fat collection* - This is an **outdated** and cumbersome method for assessing for **steatorrhea** and does not provide a specific diagnosis. - It has been largely replaced by specific serology and **faecal elastase** for investigating malabsorption or pancreatic insufficiency.

Question 141: A 7-year-old boy with Dravet syndrome (severe myoclonic epilepsy of infancy) continues to have frequent seizures despite trials of multiple antiepileptic medications. His current medications include sodium valproate and clobazam. Which additional treatment has the strongest evidence base for effectiveness in Dravet syndrome?

A. Ethosuximide
B. Cannabidiol (CBD) (Correct Answer)
C. Carbamazepine
D. Phenytoin
E. Vigabatrin

Explanation: ***Cannabidiol (CBD)*** - Randomized controlled trials have demonstrated that **adjunctive cannabidiol** significantly reduces seizure frequency in patients with **Dravet syndrome** who are refractory to standard treatments. - It is specifically licensed for use alongside other anti-epileptic drugs like **clobazam** and **valproate** in children two years of age and older. *Ethosuximide* - This medication is the first-line treatment specifically for **absence seizures** and does not have a role in managing the mixed seizure types of Dravet syndrome. - It lacks evidence of effectiveness for the **generalized tonic-clonic** or myoclonic seizures that characterize this developmental encephalopathy. *Carbamazepine* - This drug acts as a **sodium channel blocker**, which is strictly **contraindicated** in Dravet syndrome because it can paradoxically worsen seizures. - Since Dravet syndrome is usually caused by a loss-of-function mutation in the **SCN1A gene** (sodium channel), blocking remaining channels exacerbates the condition. *Phenytoin* - Similar to carbamazepine, phenytoin is a **sodium channel blocker** that should be **avoided** in patients with Dravet syndrome. - Use of this medication can lead to a significant increase in **seizure frequency** and may worsen the patient's clinical status. *Vigabatrin* - This agent is primarily indicated as the first-line treatment for **infantile spasms** (West syndrome) or focal seizures. - It is not an evidence-based treatment for Dravet syndrome and carries a risk of permanent **visual field defects**.

Question 142: A 15-year-old girl with epilepsy presents requesting contraceptive advice. She takes carbamazepine 400mg twice daily for focal epilepsy and has been seizure-free for 18 months. She is in a stable relationship and considering starting the combined oral contraceptive pill. What is the most appropriate advice regarding contraception?

A. Standard dose combined oral contraceptive pill is safe and effective with carbamazepine
B. She must stop carbamazepine before starting any hormonal contraception
C. Switch to levetiracetam first, then start standard contraception after 3 months
D. Use double dose combined oral contraceptive pill to overcome drug interaction
E. Carbamazepine reduces effectiveness of combined oral contraceptive; recommend barrier methods, intrauterine device, or depot medroxyprogesterone (Correct Answer)

Explanation: ***Carbamazepine reduces effectiveness of combined oral contraceptive; recommend barrier methods, intrauterine device, or depot medroxyprogesterone***- **Carbamazepine** is a potent **hepatic enzyme inducer**, which increases the metabolism of the **estrogen** and **progestogen** components of the combined oral contraceptive pill (COCP), making it unreliable.- Therefore, non-hormonal methods, **intrauterine devices (IUDs)**, **intrauterine systems (IUSs)**, or **depot medroxyprogesterone acetate** are recommended as they are not affected by hepatic enzyme induction.*Standard dose combined oral contraceptive pill is safe and effective with carbamazepine*- This is incorrect as **carbamazepine** is a strong **enzyme inducer** that accelerates the breakdown of contraceptive hormones.- Using a standard dose COCP with carbamazepine significantly **reduces its efficacy** and increases the risk of an unplanned pregnancy.*She must stop carbamazepine before starting any hormonal contraception*- **Abruptly discontinuing carbamazepine** in a patient with well-controlled epilepsy poses a high risk of **seizure recurrence** or **status epilepticus**.- It is medically inappropriate to stop an effective anti-epileptic drug solely for contraceptive choice when other safe and effective options exist.*Switch to levetiracetam first, then start standard contraception after 3 months*- While **levetiracetam** is not an enzyme inducer, switching a stable patient's anti-epileptic medication solely for contraception is not recommended as it carries risks of **seizure breakthrough** during transition.- Such a change would require careful titration and may delay immediate contraceptive needs, which is not ideal when effective non-oral options are available.*Use double dose combined oral contraceptive pill to overcome drug interaction*- Doubling the dose of the COCP is **not reliably effective** in overcoming the enzyme-inducing effects of carbamazepine and increases the risk of **hormone-related side effects**.- Current guidelines advise against this approach, favoring **long-acting reversible contraceptives (LARCs)** that are not affected by hepatic enzyme induction for patients on enzyme-inducing anti-epileptic drugs.

Question 143: A 8-year-old boy with type 1 diabetes for 2 years develops microalbuminuria on screening. His HbA1c is 72 mmol/mol and blood pressure is on the 95th centile for age. Apart from optimizing glycaemic control, what is the most appropriate next step in management?

A. Increase blood glucose monitoring frequency to 8 times daily
B. Start an ACE inhibitor after confirming persistent microalbuminuria on repeat testing (Correct Answer)
C. Arrange urgent renal biopsy to assess for diabetic nephropathy
D. Commence statin therapy for cardiovascular protection
E. Restrict dietary protein to 0.8g/kg/day

Explanation: ***Start an ACE inhibitor after confirming persistent microalbuminuria on repeat testing***- **ACE inhibitors** are the first-line treatment for **diabetic nephropathy** as they provide renoprotection by reducing glomerular capillary pressure and decreasing **microalbuminuria**. They also help manage the elevated **blood pressure**.- It is crucial to confirm **persistent microalbuminuria** (typically 2 out of 3 positive samples over 3-6 months) before initiating ACE inhibitors, as a single measurement can be transiently elevated due to factors like exercise or infection.*Increase blood glucose monitoring frequency to 8 times daily*- While optimizing **glycaemic control** is crucial to slow disease progression, simply increasing monitoring frequency does not directly address the established **microalbuminuria** and **hypertension**. - These complications require active therapeutic intervention with medications in addition to improved glucose management strategies.*Arrange urgent renal biopsy to assess for diabetic nephropathy*- A **renal biopsy** is generally not indicated in children when the clinical presentation (long-standing diabetes, microalbuminuria, hypertension) is highly suggestive of **diabetic nephropathy**.- Biopsy is reserved for atypical presentations, such as rapid decline in renal function, sudden onset **nephrotic syndrome**, or the absence of typical diabetic retinopathy, none of which are present here.*Commence statin therapy for cardiovascular protection*- **Statin therapy** is not the most appropriate immediate next step for an 8-year-old. The primary focus for cardiovascular protection at this age is aggressive control of **blood pressure** and **glycaemia**.- Cardiovascular risk management in pediatric diabetes primarily involves lifestyle modifications and targeted management of **hypertension** and **microalbuminuria** before considering statins.*Restrict dietary protein to 0.8g/kg/day*- Strict **protein restriction** in growing children can negatively impact **growth and development** and is generally not recommended in pediatric diabetic kidney disease.- Current guidelines emphasize pharmacological interventions like **ACE inhibitors** and optimized **glycaemic and blood pressure control** over severe dietary protein restriction.

Question 144: A 10-year-old girl with juvenile myoclonic epilepsy (JME) has been seizure-free for 18 months on sodium valproate. Her parents ask about her long-term prognosis and whether she will outgrow her epilepsy. What is the most accurate information to provide?

A. JME typically requires lifelong treatment as seizures usually recur if medication is withdrawn (Correct Answer)
B. Most children with JME can stop medication after 2 years seizure freedom with low recurrence risk
C. JME spontaneously remits in most cases by age 18 years
D. Seizure freedom for 18 months indicates cure and medication can be withdrawn
E. JME will definitely persist into adulthood and treatment withdrawal should never be attempted

Explanation: ***JME typically requires lifelong treatment as seizures usually recur if medication is withdrawn*** - **Juvenile Myoclonic Epilepsy (JME)** is characterized by an extremely high recurrence rate (80-90%) if **antiepileptic drugs** are discontinued, even after long periods of seizure freedom. - While the response to medications like **sodium valproate** is excellent, the condition is a **lifelong genetic generalized epilepsy** that rarely undergoes spontaneous remission. *Most children with JME can stop medication after 2 years seizure freedom with low recurrence risk* - This rule generally applies to several pediatric focal or absence epilepsies, but **JME** is a notable exception due to its **lifelong nature**. - Withdrawing medication in JME patients after only two years carries a very high risk of **relapse**, often presenting as generalized tonic-clonic seizures. *JME spontaneously remits in most cases by age 18 years* - Unlike **childhood absence epilepsy**, JME typically begins in adolescence and persists throughout adulthood. - It does not follow a **self-limiting course**, and patients remain symptomatic or at risk of seizures long after they reach 18 years of age. *Seizure freedom for 18 months indicates cure and medication can be withdrawn* - **Seizure freedom** indicates that the medication is effective at controlling the neural hyperexcitability, not that the underlying **epileptic tendency** is cured. - In JME, 18 months is an insufficient period to consider **treatment withdrawal**, and even then, withdrawal is rarely successful. *JME will definitely persist into adulthood and treatment withdrawal should never be attempted* - While it persists into adulthood, the word "never" is too absolute; some patients may attempt **supervised withdrawal** for specific reasons (e.g., pregnancy planning or side effects). - However, the standard clinical guidance emphasizes that **lifelong therapy** is the norm and most suitable approach for maintaining a seizure-free life.

Question 145: A 12-year-old boy with type 1 diabetes is admitted with DKA. Initial investigations show pH 7.08, glucose 32 mmol/L, potassium 3.2 mmol/L, sodium 148 mmol/L. He is commenced on 0.9% saline with added potassium and fixed-rate insulin infusion. After 6 hours of treatment, repeat electrolytes show potassium 2.9 mmol/L despite potassium supplementation. What is the most likely explanation for the persistent hypokalaemia?

A. Insulin-driven intracellular shift of potassium compounded by ongoing urinary losses (Correct Answer)
B. Inadequate initial potassium supplementation rate
C. Concurrent primary hyperaldosteronism
D. Laboratory error in potassium measurement
E. Renal tubular acidosis

Explanation: ***Insulin-driven intracellular shift of potassium compounded by ongoing urinary losses***- In **Diabetic Ketoacidosis (DKA)**, insulin therapy rapidly moves potassium into the intracellular compartment as the **acidosis** resolves, causing a sharp drop in serum levels.- Total body potassium is already depleted due to **osmotic diuresis** and vomiting; starting insulin when potassium is low (initially 3.2 mmol/L) worsens this deficit, compounded by continued urinary losses.*Inadequate initial potassium supplementation rate*- While the replacement rate might require adjustment, it is the underlying **physiological shift** driven by insulin that primarily causes the persistent drop.- Even with appropriate supplementation, the rapid cellular uptake of potassium can transiently lower serum levels, requiring close monitoring and adjustments.*Concurrent primary hyperaldosteronism*- This is a chronic endocrine disorder causing **hypertension** and hypokalemia, which does not fit the acute presentation of **Type 1 Diabetes** and DKA.- There is no clinical evidence provided, such as persistent hypertension or suppressed renin, to support this unrelated diagnosis in an acutely unwell child.*Laboratory error in potassium measurement*- While errors like **hemolysis** can occur, a repeat value of 2.9 mmol/L after 6 hours suggests a consistent downward trend rather than a random lab mistake.- Clinical management should always prioritize the expected **pathophysiological process** (insulin-induced shift) over assuming laboratory error, especially in DKA.*Renal tubular acidosis*- **Renal Tubular Acidosis (RTA)** can cause hypokalemia and metabolic acidosis, but it does not cause the **marked hyperglycemia** seen in this patient.- The context of known **Type 1 Diabetes** and severe hyperglycemia (32 mmol/L) confirms DKA as the primary cause of the electrolyte imbalance, rather than RTA.

Question 146: What is the minimum duration of seizure freedom required before considering withdrawal of antiepileptic medication in a child with epilepsy who has been seizure-free on treatment?

A. At least 2 years seizure freedom (Correct Answer)
B. At least 1 year seizure freedom
C. At least 3 years seizure freedom
D. At least 6 months seizure freedom
E. At least 5 years seizure freedom

Explanation: ***At least 2 years seizure freedom*** - According to **NICE guidelines** and standard pediatric neurology practice, antiepileptic drug (AED) withdrawal is generally considered after a child has been seizure-free for a minimum of **2 years**. - This period balances the benefit of stopping medication against the **risk of recurrence**, which is estimated to be approximately **40%** overall. *At least 1 year seizure freedom* - A **1-year** period is considered insufficient for most epilepsy syndromes as the risk of relapse remains significantly high. - Guidelines emphasize a longer duration to ensure **neurological stability** before tapering doses. *At least 3 years seizure freedom* - While some high-risk syndromes may require longer monitoring, **3 years** is not the standard minimum requirement for general pediatric epilepsy. - Delaying withdrawal unnecessarily can increase the risk of **dose-related side effects** and long-term toxicity. *At least 6 months seizure freedom* - A **6-month** interval is far too short and carries an **unacceptable risk** of immediate seizure recurrence. - Most clinical protocols require a more sustained period of **cortical stability** before altering the treatment regimen. *At least 5 years seizure freedom* - Requiring **5 years** of seizure freedom is unnecessarily prolonged for the majority of children. - Extended use of AEDs can lead to **cognitive or behavioral** side effects that could be avoided with a timely trial of withdrawal.

Question 147: A 4-year-old boy with newly diagnosed epilepsy has been started on levetiracetam. Two weeks later, his parents report he has become increasingly irritable, has frequent aggressive outbursts, and is having difficulty sleeping. His seizures are well controlled. What is the most appropriate management?

A. Switch to an alternative antiepileptic medication (Correct Answer)
B. Add a short course of melatonin for sleep
C. Reduce the dose of levetiracetam
D. Continue current treatment and review in 6 weeks
E. Add risperidone for behavioural control

Explanation: ***Switch to an alternative antiepileptic medication***- **Levetiracetam** is well-known for causing **behavioral side effects**, including irritability, aggression, and hyperactivity (often termed "Leva-rage"), particularly in children.- When behavioral changes are clinically significant or distressing, the standard management is to **discontinue the drug** and switch to an alternative like **sodium valproate** or **lamotrigine**.*Add a short course of melatonin for sleep*- This addresses the **insomnia** but fails to manage the primary issue of **aggression and irritability** caused by the medication.- Adding more drugs increases the risk of **polypharmacy** and drug interactions instead of removing the causative agent.*Reduce the dose of levetiracetam*- While dose reduction may sometimes mitigate side effects, it often fails to resolve **idiosyncratic behavioral reactions** and risks **breakthrough seizures**.- Switching to another drug is a safer long-term strategy for maintaining both **seizure control** and a stable mood.*Continue current treatment and review in 6 weeks*- Behavioral side effects of levetiracetam often persist or worsen over time and rarely show **tachyphylaxis** (the body adjusting to the drug).- Delaying action for 6 weeks is inappropriate given the risk of **physical aggression** and the impact on the child's quality of life.*Add risperidone for behavioural control*- Using an **antipsychotic** to treat a drug-induced behavioral side effect is poor practice and exposes the child to **metabolic** and **extrapyramidal** risks.- The most logical step is to remove the **offending stimulus** (levetiracetam) rather than adding a potent psychotropic medication.

Question 148: A 14-year-old girl with type 1 diabetes presents with a 6-month history of worsening glycaemic control. Her HbA1c has risen from 58 mmol/mol to 89 mmol/mol. She reports abdominal pain after meals and has lost 3kg in weight. Blood glucose readings show unexplained hyperglycaemia despite apparently appropriate insulin doses. Coeliac serology is negative. What is the most likely explanation for her deteriorating control?

A. Insulin omission and disordered eating behaviour (Correct Answer)
B. Thyroid dysfunction
C. Mauriac syndrome
D. Dawn phenomenon
E. Lipohypertrophy at injection sites

Explanation: ***Insulin omission and disordered eating behaviour***- Often termed **diabulimia**, this involves intentionally skipping insulin to induce **glucosuria** and weight loss, typically seen in adolescent females.- The combination of **unexplained hyperglycaemia**, significant **weight loss**, and abdominal pain (due to recurrent **ketosis**) is highly characteristic of this dangerous behavior.*Thyroid dysfunction*- While **Autoimmune Thyroid Disease** is associated with Type 1 Diabetes, hyperthyroidism usually presents with a **goitre** or palpitations rather than pure glycaemic instability.- Screening is performed annually, but it does not typically explain the discrepancy between **reported insulin doses** and high glucose levels seen here.*Mauriac syndrome*- This is a rare complication of chronic poor glycaemic control characterized by **hepatomegaly**, **growth failure**, and **delayed puberty**.- While it involves poor control, it presents with a **cushingoid appearance** rather than acute weight loss in a previously well-growing adolescent.*Dawn phenomenon*- This refers to a physiological rise in blood glucose in the **early morning hours** (usually 4 am to 8 am) due to the surge of **counter-regulatory hormones** like growth hormone.- It would not explain **weight loss**, abdominal pain, or consistently elevated **HbA1c** levels throughout the entire day.*Lipohypertrophy at injection sites*- This occurs due to repeated injections in the same site, leading to **erratic insulin absorption** and unpredictable blood glucose fluctuations.- While it causes poor control, it would not explain the intentional **weight loss** and systemic symptoms like chronic abdominal pain.

Question 149: A 6-year-old boy experiences his first unprovoked generalized tonic-clonic seizure lasting 3 minutes with full recovery. His developmental history is normal, neurological examination is unremarkable, and MRI brain shows no abnormalities. His EEG demonstrates generalized 3Hz spike-wave discharges. What is the most appropriate next step in management?

A. Commence sodium valproate and discuss risk-benefit ratio with parents (Correct Answer)
B. Reassure parents that no treatment is needed after a single seizure
C. Start levetiracetam immediately
D. Arrange genetic testing for channelopathies
E. Commence carbamazepine for seizure prophylaxis

Explanation: ***Commence sodium valproate and discuss risk-benefit ratio with parents*** - The presence of **generalized 3Hz spike-wave discharges** on EEG in a child with a generalized tonic-clonic seizure is pathognomonic for a **Genetic Generalized Epilepsy (GGE)** syndrome, necessitating treatment even after a first seizure due to high recurrence risk. - **Sodium valproate** is a first-line, broad-spectrum antiepileptic drug for males with generalized epilepsy syndromes, effectively managing both tonic-clonic and potential absence seizures, with a crucial **risk-benefit discussion** regarding its side effects. *Reassure parents that no treatment is needed after a single seizure* - While observation can be an option for an isolated seizure with a normal EEG, the definitive **epileptiform activity (3Hz spike-wave)** indicates a high risk of future seizures and warrants intervention. - Current guidelines recommend initiating treatment after a first seizure if there is clear evidence of an underlying **epileptic syndrome**, as seen with this characteristic EEG finding. *Start levetiracetam immediately* - Although **levetiracetam** is an effective broad-spectrum antiepileptic, **sodium valproate** is often preferred as a first-line agent in classic **primary generalized epilepsies** due to its established efficacy against various seizure types within these syndromes. - Starting any antiepileptic drug requires a thorough **discussion** with parents about the diagnosis, chronic nature of treatment, and potential side effects, which

Question 150: A 9-year-old girl with type 1 diabetes for 4 years has an HbA1c consistently between 75-85 mmol/mol despite multiple clinic visits. Her parents report she often forgets her lunchtime insulin at school and sometimes refuses injections. She has begun expressing that she wants to be 'normal like her friends'. What is the most appropriate initial approach to improve her diabetes management?

A. Arrange formal psychological assessment and family therapy (Correct Answer)
B. Switch to an insulin pump to reduce injection burden
C. Increase insulin doses to compensate for missed injections
D. Implement a behaviour reward chart with prizes for compliance
E. Refer to social services for safeguarding assessment

Explanation: ***Arrange formal psychological assessment and family therapy*** - The patient's behaviors, such as forgetting insulin and refusing injections, coupled with expressing a desire to be 'normal like her friends', strongly indicate **diabetes distress** and underlying **psychological resistance** to managing her chronic condition. - Formal psychological assessment will identify specific emotional burdens or coping difficulties, while **family therapy** can address family dynamics, communication, and support systems critical for long-term adherence and well-being in pediatric diabetes. *Switch to an insulin pump to reduce injection burden* - While an insulin pump can reduce the frequency of injections, it demands significant **patient and family engagement** and adherence to thrive; without addressing the underlying **psychological barriers**, the patient may still struggle with pump management or refusal. - Introducing advanced technology without first resolving the **emotional distress** and non-adherence issues may lead to frustration and further disengagement rather than improved control. *Increase insulin doses to compensate for missed injections* - Increasing insulin doses without ensuring consistent administration is a **dangerous approach** that significantly increases the risk of **severe hypoglycemia** if the child eventually takes the full, adjusted dose. - This strategy does not address the root cause of missed doses and can lead to **unpredictable glycemic control** and greater health risks. *Implement a behaviour reward chart with prizes for compliance* - For a 9-year-old experiencing significant **identity-related distress** and resistance to lifelong treatment, a simple reward chart is often insufficient to address the complex emotional and psychological challenges. - This approach focuses on external motivators rather than exploring and resolving the **internal conflict** and distress, which is crucial for sustainable self-management in chronic conditions. *Refer to social services for safeguarding assessment* - A safeguarding referral is **premature** as the parents are actively reporting the issues and seeking help, indicating concern rather than neglect; the primary issue appears to be the child's struggle with coping and adherence. - The initial and most appropriate step is to provide **multidisciplinary support** and psychological intervention to the child and family, as this is a common challenge in managing pediatric chronic illnesses.

Question 151: An 11-year-old boy with refractory focal epilepsy is being considered for epilepsy surgery. His seizures originate from the left temporal lobe according to video-EEG telemetry. Which of the following investigations is most essential in the pre-surgical evaluation to assess language lateralization?

A. Functional MRI (Correct Answer)
B. Wada test (intracarotid amobarbital procedure)
C. Neuropsychological testing
D. High-resolution structural MRI
E. Magnetoencephalography

Explanation: ***Functional MRI***- **Functional MRI (fMRI)** is the standard non-invasive tool used to determine **language lateralization** by measuring Blood Oxygen Level Dependent (BOLD) signals during linguistic tasks.- In pediatric patients, it has largely replaced more invasive procedures due to its safety profile and high reliability in identifying **hemispheric dominance**.*Wada test (intracarotid amobarbital procedure)*- Historically the gold standard, the **Wada test** is highly invasive, requiring **arterial catheterization** and sedation which carries higher risks for children.- It is currently reserved as a second-line investigation for cases where **fMRI results** are inconclusive or when patient cooperation is limited.*Neuropsychological testing*- This provides an essential baseline for **cognitive function**, memory, and IQ, but it cannot definitively **localize or lateralize** specific language centers.- While it helps predict surgical outcomes, it does not provide the **functional mapping** required to guide surgical boundaries.*High-resolution structural MRI*- **Structural MRI** is vital for identifying anatomical lesions like **hippocampal sclerosis** or cortical dysplasia that cause epilepsy.- It provides no information regarding **brain function** or the lateralization of language cortex.*Magnetoencephalography*- **Magnetoencephalography (MEG)** is primarily used to localize the **epileptogenic zone** and magnetic dipoles associated with interictal spikes.- While it can provide some functional data, it is significantly less specific and less commonly utilized for **language dominance** mapping compared to fMRI.

Question 152: A 5-year-old boy with type 1 diabetes is found to have a blood glucose of 2.8 mmol/L during a routine pre-lunch check at school. He is alert, able to swallow, and complaining of feeling 'wobbly'. According to current UK guidelines, what is the most appropriate immediate management?

A. Give 15g fast-acting carbohydrate orally followed by a long-acting carbohydrate snack (Correct Answer)
B. Administer intramuscular glucagon immediately
C. Give 150ml of fruit juice and recheck glucose in 30 minutes
D. Call emergency services and keep nil by mouth
E. Give a chocolate bar and continue with normal activities

Explanation: ***Give 15g fast-acting carbohydrate orally followed by a long-acting carbohydrate snack*** - For a conscious child with **hypoglycaemia** (glucose <4 mmol/L) who is able to swallow, **15g of fast-acting carbohydrate** is the first-line treatment to rapidly raise blood glucose. - Following this with a **long-acting carbohydrate snack** (like a cereal bar or bread) is necessary to maintain stable glucose levels and prevent a secondary drop. *Administer intramuscular glucagon immediately* - **Intramuscular glucagon** is reserved for **severe hypoglycaemia** where the patient is unconscious, fitting, or unable to swallow safely. - This patient is alert and **able to swallow**, making oral treatment the safer and more appropriate initial step. *Give 150ml of fruit juice and recheck glucose in 30 minutes* - While fruit juice is a good fast-acting source, the glucose should be rechecked in **10–15 minutes**, not 30 minutes, to ensure levels are rising. - Waiting **30 minutes** is too long and risks the patient's condition deteriorating if the initial treatment was insufficient. *Call emergency services and keep nil by mouth* - **Emergency services** are generally not required for mild, manageable hypoglycaemia that responds to oral glucose in a school setting. - Keeping the patient **nil by mouth** is contraindicated when they are conscious and need oral sugar to correct a dangerously low glucose level. *Give a chocolate bar and continue with normal activities* - **Chocolate** is inappropriate for acute management because its high **fat content** slows down the absorption of sugar into the bloodstream. - Activities should be paused until the blood glucose is confirmed to be **above 4 mmol/L** and the child feels well again.

Question 153: A 7-year-old girl with epilepsy is started on carbamazepine for focal seizures with impaired awareness. Her mother asks about potential side effects. Which of the following is the most common dose-related side effect of carbamazepine in children?

A. Ataxia and drowsiness (Correct Answer)
B. Hyponatraemia
C. Aplastic anaemia
D. Stevens-Johnson syndrome
E. Hepatotoxicity

Explanation: ***Ataxia and drowsiness*** - These are the most frequent **dose-related** adverse effects of carbamazepine, often occurring during the **initiation phase** or when titrating the dose upward. - These symptoms typically resolve with a reduction in dosage or by establishing a slower **titration schedule** to reach the maintenance dose. *Hyponatraemia* - This occurs due to the **SIADH** (Syndrome of Inappropriate Antidiuretic Hormone) effect of carbamazepine, but it is less common in children than in the elderly. - When it does occur, it is often **asymptomatic** and is detected incidentally on routine electrolyte panels. *Aplastic anaemia* - This is a rare, **idiosyncratic** reaction rather than a dose-dependent side effect, requiring immediate cessation of the drug. - While mild **leukopenia** is common and benign, true aplastic anemia is extremely infrequent but life-threatening. *Stevens-Johnson syndrome* - This is a severe, life-threatening **cutaneous hypersensitivity** reaction that is not related to the drug dosage. - Risk is significantly increased in patients matching the **HLA-B*1502 allele**, particularly in those of East Asian and South Asian descent. *Hepatotoxicity* - This is an **idiosyncratic reaction** that can range from a mild increase in liver enzymes to acute liver failure. - It is not a common dose-related effect; monitoring **liver function tests** is recommended primarily to catch early signs of hypersensitivity.

Question 154: A 13-year-old boy with type 1 diabetes mellitus presents to the emergency department with a 24-hour history of vomiting, abdominal pain, and increasing confusion. His blood glucose is 28 mmol/L, pH 7.15, bicarbonate 10 mmol/L, and urinary ketones are 4+. He is commenced on an intravenous insulin infusion and fluid resuscitation. Four hours into treatment, he suddenly develops a severe headache and becomes bradycardic with decreasing level of consciousness. What is the most likely complication that has occurred?

A. Cerebral oedema (Correct Answer)
B. Hypoglycaemia
C. Intracerebral haemorrhage
D. Meningitis
E. Posterior reversible encephalopathy syndrome

Explanation: ***Cerebral oedema***- The sudden onset of **severe headache**, **bradycardia**, and decreasing level of consciousness during DKA treatment are classic signs of **increased intracranial pressure**, highly indicative of **cerebral oedema**.- Rapid fluid resuscitation and insulin administration can lead to an abrupt fall in **serum osmolality**, causing water to shift into brain cells and result in brain swelling, particularly in children.*Hypoglycaemia*- While a potential complication of insulin therapy, **hypoglycaemia** typically manifests with symptoms like sweating, tremors, and **tachycardia**, not the signs of increased intracranial pressure (headache, bradycardia, altered consciousness) observed here.- The patient's initial blood glucose was extremely high (28 mmol/L), and although glucose will fall, these severe neurological symptoms with bradycardia point to a different, more acute complication.*Intracerebral haemorrhage*- **Intracerebral haemorrhage** usually presents with acute onset **focal neurological deficits** (e.g., hemiparesis, specific visual field loss), rather than the generalized signs of increasing intracranial pressure described.- Although DKA can be a **prothrombotic state**, haemorrhage is a significantly rarer complication in pediatric DKA management compared to cerebral oedema, and the clinical picture does not fit typical haemorrhage.*Meningitis*- **Meningitis** is an infectious process that would typically present with **fever**, **neck stiffness**, and often a characteristic rash, none of which are reported in this patient's history.- The acute deterioration occurring specifically 4 hours into DKA treatment strongly suggests a **treatment-related complication** rather than an underlying acute infection.*Posterior reversible encephalopathy syndrome*- **PRES** is characterized by symptoms such as headache, visual disturbances, seizures, and altered mental status, often associated with **severe hypertension** or renal disease.- While it involves oedema, its typical radiological findings are distinct (vasogenic oedema in posterior circulation), and the clinical context of DKA treatment makes cerebral oedema a far more common and direct complication.

Question 155: A 16-year-old girl with type 1 diabetes for 5 years presents for transition planning to adult services. Her current HbA1c is 72 mmol/mol, and she has background diabetic retinopathy detected at recent screening. She is on a basal-bolus insulin regimen. During the consultation, she discloses that she is sexually active and not using contraception. Her periods are regular. When counselling about pregnancy planning in type 1 diabetes, which target HbA1c should be achieved before conception to minimize the risk of congenital malformations?

A. Less than 36 mmol/mol (5.5%)
B. Less than 48 mmol/mol (6.5%) (Correct Answer)
C. Less than 53 mmol/mol (7.0%)
D. Less than 58 mmol/mol (7.5%)
E. Less than 64 mmol/mol (8.0%)

Explanation: ***Less than 48 mmol/mol (6.5%)*** - For women with pre-existing diabetes planning pregnancy, **NICE guidelines** recommend aiming for an HbA1c below **48 mmol/mol (6.5%)** to significantly reduce the risk of **congenital malformations**. - This target is specifically aimed at balancing optimal **glycaemic control** against the risk of **hypoglycaemia** during the critical period of **organogenesis** (weeks 5-8). *Less than 36 mmol/mol (5.5%)* - This target is excessively low and is not recommended as it carries an extremely high risk of **severe hypoglycaemia**. - Standard clinical goals focus on reaching the **lowest possible level** safely, typically not exceeding the 6.5% threshold. *Less than 53 mmol/mol (7.0%)* - While 7.0% is often a standard target for general diabetes management, it is **suboptimal** for the pre-conception period. - Research shows that an HbA1c above 6.5% correlates with an increased risk of **fetal abnormalities** and miscarriage. *Less than 58 mmol/mol (7.5%)* - This level indicates **inadequate control** for pregnancy planning and is associated with a 2-4 fold increase in the risk of **major malformations**. - Patients with this level are advised to use **effective contraception** until their glucose levels are brought closer to the 6.5% target. *Less than 64 mmol/mol (8.0%)* - An HbA1c of 8.0% or higher is considered high-risk and is strongly linked to **adverse pregnancy outcomes**. - Screening for and managing **diabetic retinopathy** is even more critical when HbA1c is high, as rapid tightening of control can temporarily worsen eye disease.

Question 156: An 8-year-old boy with a 3-year history of epilepsy controlled on sodium valproate presents with a 2-week history of increasing tremor, unsteady gait, and drowsiness. His seizures remain well controlled with no recent changes to his medication. Blood tests show: sodium 138 mmol/L, potassium 4.2 mmol/L, urea 5.2 mmol/L, creatinine 55 μmol/L, ammonia 145 μmol/L (normal <50), ALT 180 U/L, AST 165 U/L, and albumin 38 g/L. What is the most likely diagnosis?

A. Acute liver failure secondary to valproate hepatotoxicity
B. Progression of underlying neurometabolic disorder
C. Viral encephalitis with concurrent hepatitis
D. Valproate-induced hyperammonaemic encephalopathy (Correct Answer)
E. Phenytoin toxicity from drug interaction

Explanation: ***Valproate-induced hyperammonaemic encephalopathy***- This condition is characterized by neurological deterioration (tremor, unsteady gait, drowsiness) and significantly **elevated ammonia levels** in a patient on **sodium valproate**.- It can occur with **normal or mildly elevated transaminases** and often involves valproate's interference with the **urea cycle**, leading to ammonia accumulation without severe hepatocyte damage.*Acute liver failure secondary to valproate hepatotoxicity*- Acute liver failure would typically present with **markedly higher transaminases** (often >1000 U/L) and clear evidence of **synthetic hepatic dysfunction**, such as a coagulopathy or profound hypoalbuminemia.- In this case, the patient’s **albumin is normal** (38 g/L) and transaminases are only mildly raised, which does not support a diagnosis of acute liver failure.*Progression of underlying neurometabolic disorder*- While valproate can sometimes exacerbate underlying **urea cycle defects**, a sudden 2-week decline after 3 years of stability points more towards a drug-induced complication rather than a progressive disorder.- The immediate and strong association of **hyperammonemia** with **valproate therapy** makes it the more direct and likely cause for the acute symptoms.*Viral encephalitis with concurrent hepatitis*- Viral encephalitis typically presents with a more **acute onset**, often with **fever**, and distinct CSF findings not observed here.- While it can cause drowsiness and elevated liver enzymes, it would not specifically explain the **isolated and marked hyperammonemia** seen in this patient.*Phenytoin toxicity from drug interaction*- There is no mention of the patient taking **phenytoin**; he is on **sodium valproate** monotherapy, making phenytoin toxicity irrelevant.- **Phenytoin toxicity** primarily causes cerebellar symptoms like **nystagmus and ataxia** but does not lead to **hyperammonemia**.

Question 157: A 13-year-old girl with type 1 diabetes presents with an HbA1c of 82 mmol/mol despite good reported adherence to her insulin regimen. Review of her blood glucose diary shows consistently well-controlled readings between 4-8 mmol/L. Her download data from the glucose meter indicates readings were taken on only 15% of days in the last 3 months. She appears anxious during consultation. Her mother is present and very concerned about diabetes control. What is the most likely explanation for the discrepancy?

A. She has developed haemoglobinopathy affecting HbA1c measurement
B. Her insulin has been stored incorrectly and has lost potency
C. The HbA1c result is spurious and should be repeated
D. She is fabricating blood glucose results to avoid parental conflict (Correct Answer)
E. She has undiagnosed coeliac disease causing erratic glucose absorption

Explanation: ***She is fabricating blood glucose results to avoid parental conflict*** - The marked discrepancy between a high **HbA1c (82 mmol/mol)** and a "perfect" manual logbook (4-8 mmol/L), paired with a **glucose meter download** showing data for only 15% of days, confirms the diary is inaccurate. - This behavior, often seen in **adolescent patients**, is frequently a coping mechanism to manage **parental pressure** or anxiety regarding disease control without actual adherence.*She has developed haemoglobinopathy affecting HbA1c measurement* - **Haemoglobinopathies** can interfere with HbA1c readings, but they do not explain the lack of physical data on the **meter download** or the fabricated diary. - A false HbA1c due to haemoglobinopathy would typically occur in an asymptomatic patient with stable, non-discordant actual meter readings.*Her insulin has been stored incorrectly and has lost potency* - Loss of **insulin potency** would lead to persistently high blood glucose levels on the meter, matching the high HbA1c, contradicting the reported normal readings. - This explanation fails to account for the critical finding that the **glucose meter hardware** reflects minimal testing activity over the past three months.*The HbA1c result is spurious and should be repeated* - While lab errors can occur, the objective evidence from the **glucose meter download** (data for only 15% of days) strongly suggests that the reported blood glucose levels are not real. - The clinical context of **anxiety** and parental concern points more towards a behavioral issue rather than a laboratory error.*She has undiagnosed coeliac disease causing erratic glucose absorption* - **Coeliac disease**, while common in Type 1 Diabetes, typically causes **erratic blood sugars** (hypo- or hyperglycemia) due to malabsorption, not consistently

Question 158: Which of the following insulin types has the longest duration of action when used in paediatric type 1 diabetes management?

A. Insulin aspart
B. Insulin detemir
C. Insulin glargine U300 (Correct Answer)
D. Insulin lispro
E. Neutral protamine Hagedorn (NPH) insulin

Explanation: ***Insulin glargine U300*** - **Insulin glargine U300** is an ultra-long-acting basal insulin analogue with a duration of action typically extending up to **30-36 hours**. - Its more concentrated formulation allows for a **flatter pharmacological profile** and a longer duration compared to standard U100 basal insulins. *Insulin aspart* - This is a **rapid-acting insulin** analogue with a very short duration of action, typically only **3-5 hours**. - It is used for **prandial (mealtime)** bolus coverage rather than basal glucose control. *Insulin detemir* - This is a long-acting insulin with a duration of action ranging from **18-24 hours**, which is significantly shorter than U300 glargine. - In many children, its effective duration necessitates **twice-daily dosing** to maintain stable basal insulin levels. *Insulin lispro* - Like aspart, lispro is a **rapid-acting insulin** analogue used to manage postprandial glucose spikes with a duration of **3-5 hours**. - It lacks the sustained release mechanism required for **24-hour basal** management. *Neutral protamine Hagedorn (NPH) insulin* - This is an **intermediate-acting insulin** with a duration of action usually lasting between **12-18 hours**. - It has a distinct **peak of action**, making it less stable as a basal insulin than modern long-acting analogues.

Question 159: A 3-year-old boy is brought to the emergency department with a generalized tonic-clonic seizure that has lasted 25 minutes. He has received two doses of buccal midazolam (at 5 and 10 minutes) with no response. Intravenous access has been established and he has received intravenous lorazepam 0.1 mg/kg 5 minutes ago, but the seizure continues. He has no previous medical history. What is the most appropriate next management step?

A. Prepare for rapid sequence intubation and general anaesthesia
B. Give a second dose of intravenous lorazepam 0.1 mg/kg
C. Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes (Correct Answer)
D. Commence intravenous levetiracetam 40 mg/kg over 5 minutes
E. Give rectal paraldehyde 0.4 mL/kg

Explanation: ***Commence intravenous phenytoin infusion 20 mg/kg over 20 minutes***- This patient is in **convulsive status epilepticus** having failed two doses of benzodiazepines; current guidelines (APLS) dictate the administration of a second-line anticonvulsant like **phenytoin**.- A loading dose of **20 mg/kg** is standard for established status to achieve therapeutic levels rapidly and prevent recurrence.*Give a second dose of intravenous lorazepam 0.1 mg/kg*- While some protocols allow a second dose, this child has already received **three total doses** of benzodiazepines (two buccal, one IV) without resolution.- Continuing with benzodiazepines increases the risk of **respiratory depression** and delays the definitive management of refractory seizures.*Prepare for rapid sequence intubation and general anaesthesia*- This is the fourth stage of management reserved for **refractory status epilepticus** that fails to respond to second-line agents like phenytoin or levetiracetam.- Intubation is typically indicated if seizures persist beyond **40–60 minutes** or if there is critical airway compromise.*Commence intravenous levetiracetam 40 mg/kg over 5 minutes*- While **levetiracetam** is an acceptable second-line alternative, current traditional guidelines still prioritize **phenytoin** as the primary choice due to more robust long-term evidence.- If selected, a dose of **40-60 mg/kg** would be required, but it does not supersede phenytoin in the established hierarchy of most acute algorithms.*Give rectal paraldehyde 0.4 mL/kg*- Paraldehyde is an older treatment that is rarely used in modern practice where **intravenous access** is already available.- It is generally reserved for situations where further IV access is impossible and standard **second-line infusions** cannot be initiated.

Question 160: A 15-year-old boy with type 1 diabetes mellitus for 8 years attends for annual screening. His HbA1c is 68 mmol/mol. Urine albumin:creatinine ratio is 4.5 mg/mmol on two separate occasions. Blood pressure is 118/72 mmHg. Fundoscopy is normal. What is the most appropriate next step in management?

A. Reassure that this is normal and continue annual screening
B. Commence an ACE inhibitor (Correct Answer)
C. Repeat testing in 3 months before making any changes
D. Refer to paediatric nephrology urgently
E. Increase the frequency of screening to 6-monthly

Explanation: ***Commence an ACE inhibitor*** - This patient has **confirmed microalbuminuria**, defined by an **albumin:creatinine ratio (ACR) of 4.5 mg/mmol** on two separate occasions, indicating early **diabetic nephropathy**. - In Type 1 Diabetes, **ACE inhibitors** are the recommended first-line treatment for **microalbuminuria** to provide **renoprotection** and slow the progression of kidney disease, even with **normal blood pressure**. *Reassure that this is normal and continue annual screening* - An **ACR of 4.5 mg/mmol** falls within the range for **microalbuminuria (3-30 mg/mmol)**, which is an abnormal finding and a marker of early kidney damage in diabetes. - Reassurance would be inappropriate as it delays necessary intervention to prevent further **renal deterioration**. *Repeat testing in 3 months before making any changes* - The diagnosis of **microalbuminuria** requires an elevated ACR on **two out of three samples** within a 3-6 month period, which has already been met in this case by

Question 161: A 6-year-old girl with newly diagnosed childhood absence epilepsy requires anti-epileptic drug therapy. She has typical absence seizures occurring 10-20 times daily with 3 Hz spike-and-wave activity on EEG. Her mother had similar seizures as a child. There is no history of learning difficulties. Which anti-epileptic medication is first-line treatment?

A. Sodium valproate
B. Ethosuximide (Correct Answer)
C. Lamotrigine
D. Levetiracetam
E. Carbamazepine

Explanation: ***Ethosuximide***- **Ethosuximide** is the first-line treatment for **childhood absence epilepsy** (CAE) when absence seizures are the only seizure type due to its high efficacy and favorable safety profile.- It specifically targets **T-type calcium channels** in the thalamus, which are responsible for the characteristic **3 Hz spike-and-wave** discharges seen on EEG.*Sodium valproate*- While highly effective, it is no longer first-line for females of childbearing potential due to significant risks of **teratogenicity** and neurodevelopmental delays, making ethosuximide a safer initial choice.- It is generally reserved for cases where ethosuximide is ineffective or if there are concurrent **generalized tonic-clonic seizures**.*Lamotrigine*- This is considered a **second-line** option if ethosuximide or sodium valproate are either not tolerated or fail to control seizures.- It carries a risk of **Stevens-Johnson syndrome** and is generally less effective than ethosuximide for controlling absence seizures.*Levetiracetam*- Although widely used for focal and generalized seizures, it is not established as first-line therapy for **isolated absence epilepsy**.- Clinical trials have shown it to be less effective than ethosuximide and valproate in maintaining **seizure freedom** for this specific syndrome.*Carbamazepine*- This medication is **contraindicated** in generalized epilepsies such as CAE because it can worsen or precipitate **absence seizures** and myoclonus.- Its mechanism of action on **sodium channels** is effective for focal seizures but exacerbates the thalamocortical rhythms of absence epilepsy.

Question 162: A 10-year-old boy with type 1 diabetes presents with a 3-day history of polyuria, polydipsia, and weight loss of 2 kg. Blood tests show: glucose 25 mmol/L, pH 7.38, bicarbonate 22 mmol/L, ketones 1.5 mmol/L. He is alert and well-perfused. Which condition best describes his presentation?

A. Diabetic ketoacidosis
B. Hyperglycaemic hyperosmolar state
C. Hyperglycaemia with ketonaemia (Correct Answer)
D. Hyperosmolar hyperglycaemic state with ketosis
E. Compensated metabolic acidosis

Explanation: ***Hyperglycaemia with ketonaemia*** - The patient exhibits **hyperglycaemia** (25 mmol/L) and elevated **blood ketones** (1.5 mmol/L) but lacks the biochemical criteria for **diabetic ketoacidosis** (DKA). - Since the **pH** is normal (7.38) and the **bicarbonate** is within the reference range (22 mmol/L), the patient is in a state of metabolic decompensation that has not yet progressed to acidosis. *Diabetic ketoacidosis* - DKA requires a triad of hyperglycaemia, ketonaemia (**>3.0 mmol/L**), and **acidosis** defined by a **pH <7.3** or **bicarbonate <15 mmol/L**. - This patient is alert and well-perfused with a normal pH, failing to meet the mandatory **acidotic criteria** for this diagnosis. *Hyperglycaemic hyperosmolar state* - This condition is rare in **Type 1 Diabetes** and typically presents with extreme hyperglycaemia (often **>30 mmol/L**) and profound dehydration. - It is characterized by high **serum osmolality** and a lack of significant ketonaemia, which contradicts the presence of ketones in this boy. *Hyperosmolar hyperglycaemic state with ketosis* - This is a mixed presentation usually seen in Type 2 Diabetes where **hyperosmolarity** is the dominant feature alongside modest ketone production. - The clinical picture here is a straightforward insulin deficiency in **Type 1 Diabetes**, lacking the extreme glucose levels and dehydration associated with hyperosmolar states. *Compensated metabolic acidosis* - Compensated metabolic acidosis would present with a **low bicarbonate** and a low **pCO2** to maintain a near-normal pH. - In this case, the **bicarbonate** is completely normal (22 mmol/L), indicating that no significant metabolic acid load has been generated yet.

Question 163: A 4-year-old girl has a 2-minute episode of blank staring with lip-smacking movements. She is unresponsive during the episode and afterwards appears confused for 3 minutes. Her developmental history is normal. Which type of seizure has she most likely experienced?

A. Absence seizure
B. Focal seizure with impaired awareness (Correct Answer)
C. Atonic seizure
D. Focal aware seizure
E. Myoclonic seizure

Explanation: ***Focal seizure with impaired awareness*** - The duration of **2 minutes**, coupled with **blank staring**, **lip-smacking automatisms**, and **unresponsiveness** during the episode, are classic features of a focal seizure with impaired awareness (formerly complex partial seizure). - The subsequent **3 minutes of confusion** (post-ictal confusion) is a key indicator, as it commonly follows this type of seizure, reflecting the brain's recovery phase. *Absence seizure* - Absence seizures are typically very brief (**5-20 seconds**), involve staring, but usually lack prominent complex automatisms like lip-smacking and are not followed by significant **post-ictal confusion**. - The patient typically returns to full baseline awareness almost immediately after the episode, unlike the prolonged confusion described here. *Atonic seizure* - Atonic seizures are characterized by a sudden, brief **loss of muscle tone**, leading to **"drop attacks"** or head drops. - The clinical presentation does not describe a loss of muscle tone or falling, making this diagnosis unlikely. *Focal aware seizure* - In a focal aware seizure (formerly simple partial seizure), the individual retains **full consciousness** and awareness throughout the event and can typically recall what happened. - The patient's **unresponsiveness** during the episode and subsequent **confusion** clearly rule out a focal aware seizure. *Myoclonic seizure* - Myoclonic seizures present as sudden, **brief, shock-like muscle jerks** without loss of consciousness or a significant post-ictal state. - The described symptoms of prolonged staring, lip-smacking, unresponsiveness, and post-ictal confusion are inconsistent with a myoclonic seizure.

Question 164: A 14-year-old boy with type 1 diabetes is admitted with his third episode of diabetic ketoacidosis in 6 months. Each admission has occurred when his parents were away. His HbA1c is 95 mmol/mol. During the admission, the nursing staff note that he disconnects his insulin pump for prolonged periods and appears disinterested in his diabetes management. He lives with his parents and younger sister. What is the most important immediate action?

A. Refer to child and adolescent mental health services for assessment of depression
B. Arrange a safeguarding meeting to assess risk of neglect (Correct Answer)
C. Switch from insulin pump therapy to multiple daily injections
D. Refer to the diabetes psychology team for assessment and support
E. Arrange for district nursing support for insulin administration

Explanation: ***Arrange a safeguarding meeting to assess risk of neglect*** - Recurrent **diabetic ketoacidosis (DKA)**, especially when associated with parental absence, intentional non-adherence (disconnecting insulin pump), and poor glycemic control (**HbA1c 95 mmol/mol**), are major **red flags** for medical neglect. - A **safeguarding meeting** is the most important immediate action to protect the child from further harm and formally evaluate whether the lack of supervision or engagement constitutes a **child protection** concern. *Refer to child and adolescent mental health services for assessment of depression* - While **depression** can contribute to poor self-care in adolescents with chronic conditions, the immediate concern here is the life-threatening physical risk posed by recurrent **DKA**. - Assessment for depression, though important, should follow once the **immediate safety** and safeguarding protocols have been initiated to prevent acute medical emergencies. *Switch from insulin pump therapy to multiple daily injections* - Changing the **insulin delivery method** does not address the underlying issue of intentional non-adherence or the suspected **medical neglect** and lack of parental supervision. - If the child is deliberately disconnecting the pump, they are likely to continue poor adherence with multiple daily injections, keeping them at high risk for **DKA**. *Refer to the diabetes psychology team for assessment and support* - Psychology input is crucial for long-term management of **chronic conditions** and adherence issues, but it is not the immediate priority when a **safeguarding** concern involving life-threatening events is identified. - Formal safeguarding processes must take precedence to ensure the patient's immediate **safety** and involve multi-agency oversight. *Arrange for district nursing support for insulin administration* - This approach might provide a temporary solution for insulin administration but fails to address the critical issues of **parental supervision**, the child's disinterest, and the potential **medical neglect**. - It shifts responsibility without addressing the root causes of non-adherence and the high risk for recurrent **DKA**.

Question 165: A 12-year-old girl with a 6-month history of absence seizures is commenced on ethosuximide. Her EEG shows typical 3 Hz spike-and-wave discharges. After 4 weeks of treatment at an appropriate dose, her mother reports that the absence seizures have stopped but she has now had two generalized tonic-clonic seizures. What is the most likely explanation for this development?

A. The absence seizures were misdiagnosed and she actually has juvenile myoclonic epilepsy
B. Ethosuximide has unmasked underlying generalized tonic-clonic seizures that were not previously apparent (Correct Answer)
C. The ethosuximide dose is too low and seizure control is inadequate
D. She has developed juvenile absence epilepsy which has naturally progressed
E. She has developed drug-induced seizures as a side effect of ethosuximide

Explanation: ***Ethosuximide has unmasked underlying generalized tonic-clonic seizures that were not previously apparent*** - **Ethosuximide** is highly effective for treating **absence seizures** but provides no protection against **generalized tonic-clonic seizures (GTCS)**. - Approximately 40% of patients with **childhood absence epilepsy** also have a predisposition to GTCS, which may only become clinically evident once the absence seizures are controlled. *The absence seizures were misdiagnosed and she actually has juvenile myoclonic epilepsy* - The **3 Hz spike-and-wave discharges** are pathognomonic for **childhood absence epilepsy**, whereas JME typically shows faster 4-6 Hz polyspike-and-wave patterns. - **Juvenile myoclonic epilepsy** usually presents in a slightly older age group and is characterized primarily by early morning **myoclonic jerks**. *The ethosuximide dose is too low and seizure control is inadequate* - The patient's **absence seizures have stopped**, which indicates that the ethosuximide dose is pharmacologically **adequate** for its intended target. - Increasing the dose of **ethosuximide** would not prevent GTCS, as the drug lacks the mechanism of action required to stabilize generalized motor seizures. *She has developed juvenile absence epilepsy which has naturally progressed* - While some patients with **juvenile absence epilepsy** develop GTCS, the prompt appearance of these seizures exactly at 4 weeks suggests **unmasking** rather than natural progression. - **Childhood absence epilepsy** (the likely diagnosis at age 12) and JAE are separate clinical syndromes; the timing here strongly correlates with the initiation of specific therapy. *She has developed drug-induced seizures as a side effect of ethosuximide* - **Ethosuximide** does not typically possess **pro-convulsant** properties that trigger new seizure types as a direct side effect. - The onset of GTCS is a reflection of the drug's **narrow spectrum** of activity rather than a toxic or idiosyncratic drug reaction.

Question 166: A 9-year-old boy with type 1 diabetes for 3 years attends clinic for routine review. His HbA1c has increased from 58 mmol/mol to 75 mmol/mol over the past 6 months. He is currently on a basal-bolus insulin regimen with insulin detemir twice daily and insulin aspart before meals. His total daily dose is 0.9 units/kg/day. Blood glucose monitoring shows fasting levels of 12-15 mmol/L and post-prandial levels of 8-12 mmol/L. What is the most appropriate adjustment to his insulin regimen?

A. Increase the insulin aspart doses by 10%
B. Increase the morning insulin detemir dose by 10%
C. Increase the evening insulin detemir dose by 10% (Correct Answer)
D. Switch from insulin detemir to insulin glargine
E. Add metformin to improve insulin sensitivity

Explanation: ***Increase the evening insulin detemir dose by 10%*** - The patient's **fasting blood glucose** levels (12-15 mmol/L) are significantly elevated, while post-prandial levels (8-12 mmol/L) are relatively closer to target, indicating inadequate **overnight basal insulin** coverage. - In a twice-daily insulin detemir regimen, the **evening dose** is responsible for controlling hepatic glucose production and maintaining stable glucose levels throughout the night, directly impacting the **fasting glucose** reading. *Increase the insulin aspart doses by 10%* - **Insulin aspart** is a rapid-acting insulin used to manage post-meal glucose excursions. The patient's **post-prandial levels** are relatively controlled (8-12 mmol/L). - Increasing rapid-acting insulin when post-prandial levels are not the main issue could lead to **hypoglycemia** after meals, without addressing the primary problem of **fasting hyperglycemia**. *Increase the morning insulin detemir dose by 10%* - The **morning dose of insulin detemir** provides basal insulin coverage for the daytime hours, primarily affecting glucose levels before lunch and dinner. - This adjustment would not effectively correct the **elevated fasting glucose** observed in the morning, which points to insufficient overnight basal support. *Switch from insulin detemir to insulin glargine* - Both **insulin detemir** and **insulin glargine** are long-acting basal insulins. There is no indication that detemir itself is ineffective, but rather that its current dose is suboptimal. - The initial approach should be to **titrate the current regimen** based on blood glucose patterns before considering a change in insulin type. *Add metformin to improve insulin sensitivity* - **Metformin** is primarily used in **Type 2 Diabetes** to reduce hepatic glucose production and improve insulin sensitivity. - It is not a standard treatment for **Type 1 Diabetes** in children, where the fundamental problem is absolute insulin deficiency requiring exogenous insulin replacement.

Question 167: A 5-year-old girl is witnessed having a generalized tonic-clonic seizure at school lasting 8 minutes. On arrival of the ambulance crew, the seizure continues. She has no previous history of seizures. Which medication should be administered first?

A. Intravenous lorazepam 0.1 mg/kg
B. Buccal midazolam 10 mg (Correct Answer)
C. Rectal diazepam 5 mg
D. Intravenous phenytoin 20 mg/kg
E. Intramuscular paraldehyde 0.4 mL/kg

Explanation: ***Buccal midazolam 10 mg***- In a **pre-hospital setting** or when **intravenous access** is not established, **buccal midazolam** is the first-line treatment for a prolonged seizure (status epilepticus).- It is preferred over other routes due to its ease of administration, rapid absorption through the **buccal mucosa**, and greater **social acceptability**.*Intravenous lorazepam 0.1 mg/kg*- While **IV lorazepam** is the gold standard for hospital-based management, it requires **intravenous access**, which is typically not available immediately upon the ambulance crew's arrival.- Establishing IV access in a convulsing child is technically difficult and can cause unnecessary delays in delivering **anti-epileptics**.*Rectal diazepam 5 mg*- **Rectal diazepam** was previously the standard pre-hospital treatment but has been largely replaced by **buccal midazolam** in clinical guidelines.- It has a slower onset of action compared to buccal routes and is considered less **socially acceptable** in public or school environments.*Intravenous phenytoin 20 mg/kg*- **Phenytoin** is a **second-line** agent used in the management of status epilepticus after the failure of two doses of **benzodiazepines**.- It requires cardiac monitoring during administration due to the risk of **arrhythmias** and hypotension, making it unsuitable as an initial treatment.*Intramuscular paraldehyde 0.4 mL/kg*- **Paraldehyde** is rarely used in modern emergency protocols and is generally reserved for refractory cases when other **benzodiazepines** have failed.- It must be administered using a **glass syringe** as it reacts with plastic, making it impractical for rapid first-line use by emergency crews.

Question 168: A 7-year-old boy with type 1 diabetes mellitus is brought to the emergency department with a 12-hour history of vomiting and abdominal pain. His mother reports he has been unwell with a cold for 2 days. On examination, he is drowsy but responsive to verbal commands. His temperature is 37.8°C, heart rate 130 bpm, respiratory rate 32/min with deep sighing respirations, blood pressure 95/60 mmHg, and capillary refill time 3 seconds. Blood glucose is 28 mmol/L. What is the most appropriate initial fluid resuscitation?

A. 0.9% sodium chloride 10 mL/kg over 1 hour (Correct Answer)
B. 0.9% sodium chloride 20 mL/kg bolus over 15 minutes
C. 0.45% sodium chloride with 5% dextrose 10 mL/kg over 1 hour
D. Hartmann's solution 20 mL/kg bolus over 15 minutes
E. 0.9% sodium chloride with 5% dextrose 10 mL/kg over 1 hour

Explanation: ***0.9% sodium chloride 10 mL/kg over 1 hour***- The patient presents with **diabetic ketoacidosis (DKA)** and signs of dehydration (tachycardia, reduced BP, prolonged CRT, drowsiness, Kussmaul respirations). Initial fluid resuscitation in pediatric DKA should be with **isotonic saline (0.9% sodium chloride)**.- Current guidelines (e.g., ISPAD) recommend a cautious bolus of **10 mL/kg over 1 hour** to gradually correct dehydration and reduce the risk of **cerebral edema**, a serious complication of rapid fluid shifts in DKA.*0.9% sodium chloride 20 mL/kg bolus over 15 minutes*- While 0.9% sodium chloride is the correct fluid, a rapid **20 mL/kg bolus over 15 minutes** is typically reserved for patients in profound **hypovolemic shock** or circulatory collapse, which is not indicated here.- In DKA, rapid fluid administration can significantly increase the risk of **cerebral edema** due to rapid changes in serum osmolality.*0.45% sodium chloride with 5% dextrose 10 mL/kg over 1 hour*- **Hypotonic solutions** like 0.45% sodium chloride are contraindicated for initial resuscitation in DKA as they can exacerbate fluid shifts into the intracellular space, increasing the risk of **cerebral edema**.- **Dextrose** should not be included in initial resuscitation fluids when blood glucose is as high as 28 mmol/L; it is added later when glucose levels fall to prevent hypoglycemia during insulin therapy.*Hartmann's solution 20 mL/kg bolus over 15 minutes*- Hartmann's solution (Lactated Ringer's) is a balanced crystalloid, which can be considered in some DKA protocols, but a **20 mL/kg bolus over 15 minutes** is still too aggressive for initial management unless the patient is in severe shock.- The **rapid administration rate** is a primary concern in pediatric DKA due to the risk of **cerebral edema**, favoring slower initial rehydration.*0.9% sodium chloride with 5% dextrose 10 mL/kg over 1 hour*- While 0.9% sodium chloride is the correct base fluid and 10 mL/kg over 1 hour is an appropriate rate, the inclusion of **5% dextrose** is inappropriate at this stage.- The patient's **blood glucose is 28 mmol/L**, and adding dextrose would worsen hyperglycemia, delaying the metabolic correction of DKA. Dextrose is only added once glucose levels drop significantly.

Practice by Chapter

Epilepsy in children

Practice Questions

Type 1 diabetes in children

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free

Chronic Paediatric Conditions — MCQs

Chronic Paediatric Conditions — MCQs

On this page